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The zoonotic parasite, Plasmodium knowlesi, is one of five human malaria species. P. 
knowlesi is geographically restricted to locations of the long-tailed and pig-tailed 
macaque, indigenous across South-East Asia (SEA). Initial research showed that P. 
knowlesi was present in the human population in Malaysian Borneo, with subsequent 
studies confirming P. knowlesi throughout SEA. P. knowlesi cases were shown to be 
both severe (10%) and lethal (2%), with hyperparasitaemia correlating with severe 
malaria. Recent work has identified a polymorphism in the essential P. knowlesi 
normocyte binding protein Xa (Pknbpxa) gene that associates with high parasitaemia. 
The aims of this study were firstly to enhance and standardise the isolation of parasite 
DNA from a Biobank of frozen clinical isolates. Alongside this we aimed to take P. 
knowlesi whole genome sequence data and identify further mutations in the Pknbpxa 
gene linked to severe disease and express these in an in vitro P. knowlesi experimental 
line.  
Detailed here is the optimisation of the Whatman-Plasmodipur method to purify P. 
knowlesi DNA from a Biobank of frozen clinical samples. This resulted in 13/22 
samples returning greater than 70% P. knowlesi DNA and within this, 8 samples were 
suitable for genome sequencing. Genome sequence data representing cluster type 2 was 
used to inform the synthesis and construction of a Pknbpxa synthetic gene representing 
clinical alleles. Single-crossover homologous recombination was used to replace the 
native Pknbpxa with this synthetic copy, containing polymorphisms associated with 
high parasitaemia. This was subsequently transfected into the P. knowlesi A.1-H.1 clone 
via nucleofection, resulting in an experimental line expressing clinically relevant 
mutations within the essential PkNBPXa invasion gene. The construction of this 
translational approach enables functional examination for mutation involvement in 
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1.1   Malaria General Information   
1.1.1   Malaria: An introduction 
Alarming statistics demonstrate malaria still remains one of the biggest global health 
issues in the world today. In 2016, there were over 3 billion people worldwide at risk of 
malaria, with an estimated 212 million cases and 429,000 deaths (WHO, 2016). 
Although the number of malaria cases has decreased over the last 16 years, there is still 
a large global burden with 91 malaria endemic countries, Figure 1.1 (WHO, 2016). As 
Figure 1.1 shows 90% of global malaria cases were in African regions, while only 7% 
of cases occurred in the South-East Asian region and the remaining 2% of cases 
reported in the Eastern Mediterranean region (WHO, 2016). When examining global 
malaria cases nine African countries feature in the top ten for percentage of global cases 
and Nigeria was estimated to have over 25% of global cases alone (WHO, 2016). It is 
reported that 70% of the global fatalities are of children under the age of 5 (WHO, 
2016). The mortalities alone are predicted to cost malaria endemic countries 3.6% of 
their combined gross domestic product, without taking into account the much higher 
non-fatal case numbers (WHO, 2016). Currently treatment is available for malaria, yet 
drug-resistance is a concern and still the underlying mechanisms of disease pathology 
and parasite biology are not fully understood highlighting the requirement for further 
research on this devastating disease. However, considering the worldwide scale of this 
disease it is likely that a combined approach from governments, medical professionals 
and researchers will be required to eradicate malaria. 
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1.1.2  A brief history of malaria 
One of the first descriptions of malaria came from an ancient Chinese medical textbook, 
the Nei Ching (Moss, 2008) which described periodic fever, a hallmark symptom of 
malaria (Cunha and Cunha, 2008, Cox, 2010). Fast-forwarding through time, further 
clinical observations were documented by Hippocrates in 400BC who recorded 
intermittent fever in combination with chills, sweating and enlargement of the spleen 
(Cox, 2010). The word malaria itself arose from the Romans who believed that poor air 
quality or “bad airs”, “mal’ aria” in Italian, around swamp and marsh land, was 
responsible for the characteristic fevers associated with malaria (Meshnick and Dobson, 
2001). Although incorrect, the Romans had inadvertently connected the importance of 
stagnant water, the mosquito breeding grounds, with contracting malaria. However, the 
link between stagnant water, mosquitoes and fever was not connected until the late 19
th
 
century when the mosquito was implicated in transmitting malaria (Cox, 2010). 
Following publication of Louis Pasteur’s germ theory, Charles Laveran, a French 
military doctor, discovered the presence of parasites in the blood of a malaria patient 
(Laveran, 1982). Following this breakthrough discovery, research intensified identifying 
different parasite forms based on regularity of fever. This causative parasitic agent of 
malaria was termed Plasmodium (Cox, 2010). 
 
  23 
 
Figure 1.1  Global distribution of malaria in 2016.  
A world map is shown highlighting the 91 countries in blue where malaria is endemic. Countries in green 
represent countries where malaria was endemic in 2000, but are no longer endemic in 2016. Countries 
with no colour were not endemic for malaria in 2000. No data is available for countries shaded in grey.  
Figure adapted from the World Malaria Report 2016 (WHO, 2016). 
 
1.1.3   Plasmodium the causative agent 
Malaria is caused by species of the genus Plasmodium, a member of the large 
Apicomplexan phylum. There are over 450 species of Anopheles mosquitoes (Cohuet et 
al., 2010), capable of transmitting Plasmodium parasites responsible for causing malaria 
in a range of mammals, birds and reptiles. Of these Anopheline mosquitoes, 
approximately 60 species are capable of transmitting Plasmodium parasites that cause 
malaria in humans (Cohuet et al., 2010). Currently 6 Plasmodium species have been 
reported in humans; Plasmodium falciparum, P. vivax, P. knowlesi, P. malariae and P. 
ovale, of which there are two subspecies, P. ovale wallikeri and P. ovale curtisi (Oguike 
et al., 2011). Phylogenetically, the latter 5 species cluster with Plasmodium species that 
infect monkeys, while P. falciparum clusters with ape Plasmodium species. P. 
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falciparum is responsible for causing almost all deaths (99%) caused by malaria (WHO, 
2016). In contrast, P. vivax is the second most common human malaria-causing species, 
and is responsible for only 0.7% of all malaria deaths (WHO, 2016). P. vivax is less 
likely to cause severe malaria as it is restricted to the invasion of reticulocytes, which 
comprise approximately 2% of all red blood cells. A naturally acquired human infection 
of the simian malaria P. knowlesi was reported but considered to be a rare event (Chin 
et al., 1968). However, an important study revealed that there was a large number of 
human P. knowlesi cases in Kapit, Malaysian Borneo that were being microscopically 
misdiagnosed as P. malariae  (Singh et al., 2004). Morphologically P. knowlesi is 
similar to the early life stages of P. falciparum and the later stages of P. malariae, and 
PCR was required for accurate identification. Recently, a naturally acquired P. 
cynomolgi infection was reported (Ta et al., 2014). This may suggest that P. cynomolgi 
is a zoonotic Plasmodium species. 
1.1.4   Global malaria distribution 
Over 3 billion people are at risk of malaria infection and transmission occurs in the 
tropical and sub-tropical belt (Figure 1.1, Table 1.1). Most of the reported cases (90%) 
occur in Sub-Saharan African countries and are caused by P. falciparum, the human 
malaria responsible for the highest prevalence of morbidity and mortality. P. vivax is 
distributed throughout the sub-tropical belt (Figure 1.1, Table 1.1), and contributes to 
approximately 41% of cases outside of Africa (WHO, 2016). P. vivax is rarely found in 
Africa as the majority of the African population lack the Duffy erythrocyte receptor 
required for P. vivax infection (Miller et al., 1976). However recently cases of P. vivax 
have been reported in regions of Africa, suggesting invasion can occur independent of 
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the Duffy erythrocyte receptor (Mendes et al., 2011, Ryan et al., 2006, Wurtz et al., 
2011). P. malariae has the same distribution as P. falciparum and P. ovale and is 
primarily found in Sub-Saharan Africa (Figure 1.1, Table 1.1). P. knowlesi, as a 
zoonosis, is only found across areas of South-East Asia (SEA) where the geographical 
distribution of the natural host, the long-tailed or pig-tailed macaques, overlaps with 
mosquitoes belonging to the group Anopheles leucosphyrus (Lee et al., 2011).  
  
 
1.1.5  Epidemiology of P. knowlesi 
P. knowlesi was previously believed to be a simian malaria that rarely infected humans, 
however, in 2004 it was identified that P. knowlesi malaria was being misdiagnosed as 
P. malariae (Singh et al., 2004). P. knowlesi is unique compared to the other human 
malarias as it is zoonotic, naturally infecting Macacca fascicularis (long-tailed) and 
Macacca nemestrina (pig-tailed) (Coatney et al., 1971, Garnham, 1966). The 
geographical distribution of these two macaque species can be seen in Figure 1.2 (Cox-
Singh, 2012). This distribution shows that the natural hosts of P. knowlesi are found in 
areas of SEA, and since the discovery of P. knowlesi as a pathogen causing malaria in 
humans cases of P. knowlesi malaria have been reported in almost all countries within 
the boundaries of the natural host (Figure 1.2). Research has shown P. knowlesi to be 
the main cause of malaria in Malaysian Borneo, with relatively few P. falciparum and 
P. vivax cases, and few cases of P. malariae (Cox-Singh et al., 2008, Singh et al., 
2004). Furthermore, the only country not to have reported human cases of P. knowlesi 
in SEA is Laos (Figtree et al., 2010, Jiang et al., 2010, Luchavez et al., 2008, Jeslyn et 
al., 2011, Jongwutiwes et al., 2011, Sermwittayawong et al., 2012, Khim et al., 2011, 
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Marchand et al., 2011, Maeno et al., 2016). A recent study carried out in North 
Sumatra, Indonesia (Figure 1.2) showed that P. knowlesi was present in 11.8% of 
patients tested, levels similar to P. vivax and P. falciparum in that region (Lubis et al., 
2017). This result suggests that within this geographical region, P. knowlesi is important 
and occurs as frequently as P. vivax and P. falciparum. This suggests that as monitoring 
P. knowlesi infected macaques and humans increases, and in combination with more 
sensitive diagnostics, the exact range and prevalence of P. knowlesi infections across 
SEA will become clear. 
 
1.1.6   P. knowlesi natural hosts and mosquito vectors 
The geographical restriction of P. knowlesi to SEA (Figure 1.2) is determined by both 
the anopheline vectors responsible for transmitting P. knowlesi, and presence of either 
the long-tailed macaques or pig-tailed macaques indigenous to SEA (Lee et al., 2011). 
Currently, transmission of P. knowlesi to humans is associated with entry or close 
proximity to the forest, the natural habitat of the macaques’ (Daneshvar et al., 2009). 
Human-to-human transmission of P. knowlesi has to date only been demonstrated under 
experimental transmission conditions (Chin et al., 1965, Chin et al., 1968). Only a small 
number of studies have been conducted to identify geographical locations in SEA where 
macaques are P. knowlesi positive. P. knowlesi infected long-tailed and pig-tailed 
macaques have been found in Singapore (Jeslyn et al., 2011), Peninsular Malaysia 
(Vythilingam et al., 2008), Malaysian Borneo (Lee et al., 2011), Thailand (Jongwutiwes 
et al., 2004), Palawan Island and the Philippines (Tsukamoto et al., 1978). 
The Anopheles leucosphyrus group of mosquitoes shows a similar distribution to that of 
the two macaque hosts (Figure 1.2). Both distributions overlap across the majority of 
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SEA with a few exceptions, such as southern regions of Indonesia (Figure 1.2). 
Presence of both the macaque hosts and the Anopheles leucosphyrus group of mosquito 
vectors are required for a geographical area to be classed as a potential P. knowlesi 
transmission area (Vythilingam and Hii, 2013). Within the leucosphyrus group of 
mosquitoes, there are a number of species reported to transmit P. knowlesi, including A. 
cracens (Jiram et al., 2012), A. dirus (Marchand et al., 2011, Maeno et al., 2016), A. 
balabacensis (Vythilingam, 2010, Collins et al., 1967), A. latens (Tan et al., 2008) and 
A. introlatus (Vythilingam et al., 2014). Interestingly, A. cracens was not observed in 
households, and feeding was exophagic, which in part might explain why human-to-
human transmission has not been reported (Jiram et al., 2012). Different members of the 
Anoepheles leucosphyrus group have been implicated in P. knowlesi transmission in 
different geographical locations. Although only a handful of studies have examined the 
vectors of P. knowlesi however the geographical distribution of those that have been 
identified suggest further regions of transmission across SEA (Figure 1.2). An important 
observation made by Daneshvar and colleagues was that 87% of P. knowlesi patients 
had recently been in close proximity to a forest setting (Daneshvar et al., 2009). This 
suggests that the primary transmission site is the forest setting, where both macaques 
and Anopheles mosquitoes are located (Lee et al., 2011).  
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Figure 1.2 Geographical distribution of the hosts and vectors of P. knowlesi.  
The map of SEA shows the countries that P. knowlesi vectors and macaque hosts are native to. The A. 
leucosphyrus group of mosquitoes (inside the black line) covers the majority of SEA, except some 
locations in Indonesia. The long-tailed macaques (orange dotted line) cover a similar range to the 
mosquito vector, although the range does not reach as far north, and the macaques are not found in India 
or Sri Lanka. The pig-tailed macaques (horizontal green lines) are less widespread, but are predominantly 
found in Borneo, Peninsular Malaysia, Thailand and Indonesia. Countries with cases of human P. knowlesi 
malaria reported before 2008 are shown by a blue square, while cases reported after 2008 are shown by 
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1.1.7 Treatment and prevention of malaria 
Traditionally the bark from the Chinchona tree, was used as a herbal remedy for 
treatment of malaria (Meshnick and Dobson, 2001). It was not until the early 19
th
 
century that quinine was identified as the active compound (Achan et al., 2011). 
Although quinine was effective it was costly and poorly tolerated, but is still used today 
to treat severe malaria (WHO, 2016, Meshnick and Dobson, 2001). In 1934, the 
antimalarial chloroquine was synthesised, and quickly became adopted as the primary 
treatment of malaria due to its cost effective production compared to the extraction of 
quinine, (Giadom et al., 1996). Chloroquine functions by inhibiting the formation of 
hemozoin in the parasite’s food vacuole, producing toxic haem intermediates causing 
parasite death (Sullivan et al., 1996). Chloroquine was primarily used as a monotherapy 
across the world for both uncomplicated and severe malaria (Achan et al., 2011). 
Although extremely effective, during the 1950s and 60s reports of chloroquine 
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resistance were arising (Eyles et al., 1963, Wellems and Plowe, 2001). The resistance to 
chloroquine spread to almost all worldwide transmission areas, with the guideline that 
suspected P. falciparum malaria in Africa no longer be treated with chloroquine (WHO, 
2016). Following the widespread resistance to chloroquine, two novel compounds, 
sulfadoxine and pyrimethamine, targeting the folate pathway inhibiting nuclear 
replication, were introduced in 1967 as a replacement for chrloroquine. However, 
resistance to sulfadoxine/pyrimethamine was detected in a refugee camp in Thailand 
(Hurwitz et al., 1981).  A similar story is seen with mefloquine. It was brought into use 
in the mid-1980s (Price et al., 2004) and again a pattern of resistance emerged as within 
6 years mefloquine-resistant P. falciparum was identified (Wongsrichanalai and 
Meshnick, 2008). 
The discovery of the compound artemisinin, isolated from the Chinese plant qinghaosu, 
merited the Nobel Prize in 2015 (White et al. 2015, Qinghaosu Antimalaria 
Coordinating Research Group 1979). This important new compound was not only found 
to have antimalarial properties, but also had better parasite clearance compared to 
previous antimalarials (White, 2011). Additionally, artemisinin has been reported as 
being well tolerated and fast acting (White et al., 2015). These drugs are currently being 
used as combination therapies with pre-existing drugs to delay the onset of drug 
resistance. However, recent studies in SEA have shown that resistance in P. falciparum 
is developing against these latest antimalarials (Ashley et al., 2014). New antimalarial 
compounds such as cipargamin, a spiroindolone targeting all stages of the erythrocytic 
cycle have undergone clinical testing with results suggesting cipargamin has a higher 
parasite clearance compared to artemisinin (Chavchich et al., 2016, White et al., 2014, 
Rottmann et al., 2010). The compound DDD107498 targets a broad spectrum of 
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parasite life stages, including liver stages, erythrocytic stages, gametocytes and the 
sexual stages to oocysts (Baragana et al., 2015). A primary concern will be over 
reliance on specific antimalarials, driving selection pressures and increases in resistance. 
 
 
1.1.8  Pathology and classification of disease severity 
Malaria can present as asymptomatic, uncomplicated or severe disease. Patients can be 
infected with Plasmodium spp. but are asymptomatic with no clinical symptoms 
(Laishram et al., 2012). Uncomplicated malaria is characterised by presence of any 
range of the following symptoms; fever, chills, nausea, diarrhea, headache, abdominal 
pain and malaise (Bartoloni and Zammarchi, 2012). Clinical presentation can include 
any number of these non-specific symptoms, which can result in misdiagnosis, 
especially if not in areas of high transmission (Mahdavi et al., 2014). Failure to 
diagnose these symptoms can lead to delayed treatment and an increased likelihood of 
progression to severe malaria and death (Rajahram et al., 2013, Allen et al., 2013). 
Severe malaria is characterised by convulsions, respiratory distress, circulatory shock, 
organ dysfunction, hyperparasitaemia and, in P. falciparum, coma (WHO, 2016, World 
Health Organisation, 2012). Children under the age of 5 are most at risk of severe 
malaria. Immunity in areas of high transmission is obtained through repeated infections 
and children under the age of 5 have not acquired this immunity yet, putting them at risk 
of severe disease (Doolan et al., 2009). Severe malaria can occur in adults who enter 
high transmission areas that are either from low areas of transmission or from non-
endemic areas. P. falciparum is the primary cause of severe malaria although both P. 
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vivax and P. knowlesi can cause severe malaria although only P. knowlesi can reach 
parasitaemias similar to those associated with severe P. falciparum infection (World 
Health Organisation, 2012, Rahimi et al., 2014, Naing et al., 2014, Daneshvar et al., 
2009).  
 
1.2   Plasmodium Life Cycle 
The Plasmodium life cycle is complex as it requires both a vertebrate and mosquito host 
(Bray and Garnham, 1982). Infection of the vertebrate host begins when a blood meal is 
taken by an infected female Anopheline mosquito from a susceptible vertebrate host 
(Coatney et al., 1971). Sporozoites residing in the salivary glands of the mosquito are 
injected into the host, (Figure 1.3) and migrate to the liver from the host dermis (Jin et 
al., 2007, Menard et al., 2013). The sporozoites are able to migrate by exhibiting a 
gliding motility from the dermis to the lymph nodes and blood stream with some 
remaining in the dermis (Sinnis and Zavala, 2012). In order to continue the life cycle the 
sporozoites exit the blood stream in the liver and invade hepatocytes via invagination 
creating a parasitophorous vacuole (PV) where they undergo asexual replication, 
forming thousands of merozoites capable of invading host erythrocytes, Figure 1.3 
(Stanway et al., 2011). In P. vivax and P. ovale rather than undergoing immediate 
asexual replication in the liver a portion of sporozoites differentiate into quiescent 
hypnozoites which can remain dormant for months or years before asexual replication 
begins, however the mechanisms controlling these conversions remain unknown (Wells 
et al., 2010, Markus, 2015, Hulden and Hulden, 2011). Following asexual replication 
and merozoite formation, breakdown of the PV releases the merozoites into the 
 
  33 
cytoplasm of the hepatocyte (Prudencio et al., 2006). Subsequently the merozoites bud 
off into the host’s blood stream in hepatocyte derived vesicles termed merosomes 
(Graewe et al., 2011, Tawk et al., 2013, Baer et al., 2007, Burda et al., 2017). 
Once in the blood stream, merozoites can attach to erythrocytes via their protein coat to 
initiate erythrocyte invasion, involving adhesive proteins secreted from merozoite apical 
organelles (detailed further in section 1.5). Interestingly some species of malaria have 
adapted to invade specific invasion susceptible erythrocytes. P. vivax and P. ovale are 
adapted to invade reticulocytes (immature red blood cells) while P. malariae is adapted 
to invade senescent (older) erythrocytes. Both P. falciparum and P. knowlesi can invade 
all erythrocyte ages (Moreno-Perez et al., 2013, Antinori et al., 2012), although some 
data suggests that reticulocytes are preferred by long standing experimental lines of P. 
knowlesi during in vitro culture (Lim et al., 2013, Moon et al., 2016). The early 
trophozoite/ring stage parasite exists within the PV and is named so because of the ring-
shaped morphology (Figure 1.3). As the parasite matures to a trophozoite, known as the 
feeding stage, the parasite digests host haemoglobin in the digestive vacuole (DV) using 
this as a nutrient source for energy metabolism and for incorporation into newly 
expressed parasite proteins (Francis et al., 1997). As further haemoglobin is digested the 
inert by-product hemozoin can be seen within the digestive vacuole (DV) (Dluzewski et 
al., 2008). During trophozoite stages the DV is dilated with hemozoin diffusely spread 
throughout the DV (Wunderlich et al., 2012). 
A trophozoite can have two fates; maturation to schizonts, where multiple copies of 
merozoites are produced asexually (8-12 copies P. knowlesi, 16-20 copies P. 
falciparum, (Coatney et al., 1971), or to enter the sexual life stage of the life cycle. The 
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most common trophozoite fate is to continue with asexual development producing 
multiple merozoites which can go on to infect further erythrocytes (Figure 1.3). As the 
trophozoite matures it develops into a schizont, characterised by rounds of mitotic 
division producing a multinucleated syncytium (Francia and Striepen, 2014). Upon the 
last mitotic division, the synchronous formation of individual daughter merozoites takes 
place which are released from the erythrocyte via a process termed egress (detailed 
further in section 1.6). The newly released merozoites are released into the blood stream 
allowing further erythrocytes to be invaded, creating a mounting parasitaemia producing 
the symptoms of malaria. The full erythrocytic cycle time varies depending on 
Plasmodium species (P. knowlesi 24 hours; P. falciparum, P. vivax, P. ovale 48 hours; 
P. malariae 72 hours). Alternatively, a small proportion of parasites develop into sexual 
parasite forms known as gametocytes (Josling and Llinas, 2015). These trophozoites are 
able to produce both male and female gametocytes which remain in the S phase of cell 
cycle development until taken up by a female mosquito during a blood meal (Bray and 
Garnham, 1982). In the mosquito mid-gut the male gametocyte undergoes exflagellation 
and fertilises the female gametocyte producing a zygote (Coatney et al., 1971). The 
zygote develops into a motile ookinete that traverses the mosquito’s midgut epithelium, 
permitting oocyst formation beneath the basal lamina in the subepithelial space (Carter 
et al., 2007). The oocyst cytoplasm  increases in size over 10-15 days whilst undergoing 
mitotic divisions producing a sporoblast from which thousands of sporozoites bud 
asynchronously (Prudencio et al., 2006, Nacer et al., 2008, Wang et al., 2005, Gerald et 
al., 2011). The sporozoites then migrate from the oocyst on the basal epithelial 
membrane to the salivary glands of the mosquito host (Coatney et al., 1971). Once at 
this stage of the life cycle, when a mosquito takes a blood meal the cycle can repeat. 
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Figure 1.3 Plasmodium life cycle. 
The asexual Plasmodium life cycle begins with inoculation of a human host by an Anopheline mosquito 
infected with Plasmodium sporozoites in the salivary glands (1). The sporozoites migrate to the liver via the 
blood stream and infect a liver cell (2), where multiple rounds of division produce thousands of merozoites 
contained within the liver cell (3). Rupture of the liver schizont (4) releases the merozoites into the blood 
stream (5) where they enter the erythrocytic cycle (B). Merozoites invade a susceptible RBC and are 
maintained in the asexual erythrocytic cycle where they digest host proteins using this as an energy 
source to grow and replicate producing anywhere between 8-30 merozoites depending on the Plasmodium 
species. Rupture of the schizont releases the merozoites which can remain in the erythrocytic cycle (B). 
Alternatively, newly invaded red blood cells (RBCs) can mature into male or female gametocytes (7), the 
early stage of sexual replication. The gametocytes are ingested by the mosquito (8) where the female 
gametocyte is fertilised by the male in the mosquito mid-gut (9). The zygote matures into an ookinete (10) 
which traversed the midgut epithelium and undergoes divisions beneath the basal lamina in the 
subepithelial space (11) creating an oocyst containing thousands of sporozoites. When the oocyst 
ruptures, the sporozoites migrate to the salivary glands where they can then be injected into a host upon 
the next blood meal (Centers for Disease, 2017). 
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1.2.1 Clinical presentation of P. knowlesi malarial in humans 
Unlike other human Plasmodium species, P. knowlesi has a 24-hr life cycle. This results 
in fever every 24 hours, and can progress to severe disease rapidly if misdiagnosed, or 
treatment is delayed (Rajahram et al., 2012). The majority of patients presenting with 
uncomplicated P. knowlesi malaria exhibit non-specific symptoms similar to 
uncomplicated P. falciparum malaria (Daneshvar et al., 2009). The most common 
symptoms reported were fever/chills, rigors, headache, malaise, muscle pain and poor 
appetite (Daneshvar et al., 2009). Laboratory results indicate that thrombocytopenia is a 
common feature of P. knowlesi malaria (Daneshvar et al., 2009). Complications 
associated with severe P. knowlesi are as seen with severe P. falciparum malaria, but 
without coma (Cox-Singh et al., 2010, Daneshvar et al., 2009, Willmann et al., 2012). 
The ranges on the proportion of P. knowlesi malaria cases that meet severe disease 
criteria varies drastically between study sites (9.5% - 39%) (Barber et al., 2013, 
Willmann et al., 2012, Cox-Singh et al., 2011, William et al., 2011). However, this is 
likely due to some study sites being based at referral hospitals (Barber et al., 2013, 
William et al., 2011). As with the reported disease severity rates, the fatality rates of P. 
knowlesi malaria vary between studies (1.8 - 10.7%) (Barber et al., 2013, Willmann et 
al., 2012, Cox-Singh et al., 2011, William et al., 2011, Daneshvar et al., 2009). 
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1.3 Severe Malaria Pathophysiology  
1.3.1 Features of severe malaria 
A common feature of severe P. falciparum malaria is the sequestration of late stage 
parasites in the microvasculature resulting in removal infected RBCs (iRBCs) from 
peripheral blood circulation. This process prevents infected RBCs passing through the 
spleen preventing removal of iRBCs (Del Portillo et al., 2012, White, 2017). 
Sequestration of iRBCs to different host tissues can result in different pathologies. For 
example sequestration and rosetting cause microvasculature obstruction in the brain that 
can produce cerebral malaria characterised by coma and death, while sequestration in 
the placenta of pregnant women can result in an increased risk of severe malaria, 
mortality and abortion (Kovacs et al., 2015, Wahlgren et al., 2017). The binding of 
iRBCs to microvasculature starves tissue of oxygen, resulting in increased lactate and a 
lower pH in the blood producing the symptoms of severe malaria discussed in section 
1.1.8 (Wahlgren et al., 2017). 
 
1.3.2 Sequestration in P. falciparum 
The PfEMP1 proteins are the primary cause of sequestration and are encoded by a 
multi-gene family termed the var genes. This antigenically variable gene family consists 
of approximately 60 copies (Gardner et al., 2002). During the erythrocyte life cycle the 
parasite silences the majority of the var genes, resulting in mutually exclusive 
expression (Brancucci et al., 2014, Perez-Toledo et al., 2009, Guizetti and Scherf, 
2013). The expressed var gene determines the cytoadherent properties of the iRBC as 
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the protein is anchored to knob structures on the erythrocyte surface enabling 
interactions with the endothelial cells to take place (Hviid and Jensen, 2015). 
Periodically a small number of parasites switch var gene expression, resulting in a 
PfEMP1 variant that has not been exposed to the immune system enabling immune 
evasion (Hviid and Jensen, 2015). The var genes that encode the PfEMP1 proteins can 
be grouped into 3 main groups (A-C) according to sequence similarity of the 5’ 
upstream promoter that drives var gene transcription (Lavstsen et al., 2003). Members 
of each group have a common chromosomal location, with group A encoded in the 
subtelomeric regions and group B are encoded in the telomeric regions while the group 
C var genes are located in central chromosomal regions (Tuikue Ndam et al., 2017). 
The PfEMP1 family consist of DBL domains, cysteine rich domain regions, 
transmembrane domains and an acidic terminal segment (Kraemer and Smith, 2006). 
Different domain combinations combined with variation within each domain enables 
variant PfEMP1 proteins to bind different endothelial surface receptors resulting in 
sequestration in different host tissues (Chakravorty et al., 2008). PfEMP1 
predominantly binds to the human CD36 receptor expressed across all endothelial cells 
except those in the brain (Kaestli et al., 2006). PfEMP1 variants specific for chondroitin 
sulfate A (CSA) are responsible sequestration of infected erythrocytes to the placenta 
(Beeson et al., 2002). The binding of PfEMP1 to intercellular adhesion molecule 1 
(ICAM-1) on brain endothelium was implicated as the cause of cerebral malaria 
(Newbold et al., 1999), however recent studies have implicated the presence of PfEMP1 
variants containing the cysteine rich interdomain region in binding to host endothelial 
protein C receptor (EPCR) (Turner et al., 2013). Additionally, an EPCR variant was 
identified to protect children in Thailand from severe malaria (Naka et al., 2014).  
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In addition to PfEMP1 both RIFIN and STEVOR have been proposed to contribute to 
sequestration of iRBCs to endothelial cells (Bachmann et al., 2009, Wahlgren et al., 
2017). The RIFIN proteins are encoded by a family of approximately 150 repetitive 
interspaced genes (rif) with 70% of these categorised as subgroup A (A-RIFIN) and 
remainder classified as subgroup B (B-RIFIN) (Goel et al., 2015). As with PfEMP1, 
RIFINs have an extracellular N-terminal domain enabling interactions with the host 
(Goel et al., 2015). Antibodies against A-RIFIN present in the FCR3S1.2 parasite clone 
were shown to disrupt rosettes specifically when cultured in blood group A RBCs (Goel 
et al., 2015). However, rosetting was unchanged when parasites were cultured in blood 
group O RBCs in the presence of the same antibody, suggesting the specific A-RIFIN in 
this clone only bound the blood group A antigen on the RBC surface (Goel et al., 2015). 
The rosetting as seen in parasites cultured with RBCs from blood group O has been 
attributed to the function of B-RIFIN binding glycophorin A on the erythrocyte surface 
(Goel et al., 2015). Microvasculature sequestration was observed when iRBCs matured 
in blood group A were injected into rodents (Goel et al., 2015, Wahlgren et al., 2017). 
Although implicated in sequestration RIFINs are also expressed in merozoites and 
gametocytes, suggesting they may have a broader function (Wahlgren et al., 2017). 
The stevor gene family contain approximately 30 gene copies encoding the STEVOR 
proteins which are structurally similar to RIFINs (Wahlgren et al., 2017). STEVORs 
bind to glycophorin C, similar to B-RIFINs that bind glycophorin A (Niang et al., 
2014). As with the RIFINs, STEVORs are expressed in merozoites and gametocyte 
stages, suggesting a wider ranging function (Wahlgren et al., 2017). This may be the 
case, as Niang et al., show that antibodies against STEVOR inhibited invasion by 
approximately 10-30%, and rosetting by approximately 50% (Niang et al., 2014). 
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1.3.3 Sequestration in P. knowlesi 
Although less thoroughly researched, P. knowlesi appears to exhibit cytoadhesion 
characteristics similar to those of P. falciparum infected erythrocytes. Sequestration has 
been documented in macaque infections (Miller et al., 1971) but importantly it has also 
been observed in fatal human infections (Cox-Singh et al., 2010). Post-mortem studies 
have shown that infected erythrocytes accumulated in the brain microvasculature in a 
patient that died of severe P. knowlesi malaria (Cox-Singh et al., 2010). The schizont 
infected cell agglutination variant (sicavar) gene family is present in the genome of P. 
knowlesi, which show homology to the var genes in P. falciparum (Korir and Galinski, 
2006) and homologues are not present in any other human malaria species (Galinski et 
al., 2017). Unlike the var genes the sicarvar genes have not been classified or grouped 
according to the 5’ upstream promoter region as in P. falciparum. Investigations into the 
functions of individual sicavar genes and SICA proteins may now accelerate with the 
annotations of the sicavar genes now complete (Lapp et al., 2017). As seen with the var 
genes in P. falciparum, switching of sicavar genes occurs periodically resulting in the 
expression of different SICA antigens (Brown and Brown, 1965). Investigations into 
SICA endothelial receptor interactions has only been tested by incubating ex vivo 
matured schizonts on dishes coated with recombinant protein (Fatih et al., 2012). 
Binding was variably to recombinant ICAM1 and vascular cell adhesion molecule 
(VCAM), but mature schizonts did not bind to CD36 (Fatih et al., 2012). Further 
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1.3.4 Hyperparasitaemia and severe malaria 
In P. falciparum, the most widely studied human malaria, hyperparasitaemia is a feature 
of severe malaria and primarily affects children in Sub-Saharan African countries 
(Trampuz et al., 2003, World Health Organisation, 2012). The laboratory marker for 
hyperparasitaemia is a parasitaemia greater than 100,000 para/µL for non-immune 
individuals, and greater than 250,000 para/µL for individuals residing in endemic 
countries (World Health Organisation, 2012). Recently, hyperparasitaemia was found to 
associate with an increased risk of progression to cerebral malaria in children under 5 
(Sowunmi et al., 2011). Severe complications of P. knowlesi malaria are also strongly 
linked with hyperparasitaemia (Daneshvar et al., 2009). Parasite counts can reach 
764,720 para/uL, densities similar to those seen in P. falciparum hyperparasitaemia 
(Cox-Singh et al., 2008, Daneshvar et al., 2009). The pathogenesis behind severe 
malaria in both P. knowlesi and P. falciparum remains unclear, although both host and 
parasite factors are thought to contribute to disease outcome (Cox-Singh et al., 2010). 
1.3.5 Parasite polymorphisms in severe malaria 
A recent study performed by Ahmed et al, (2014) identified an association between a 
single nucleotide polymorphism (913C) in the P.knowlesi invasion gene Pknbpxa and 
high parasitaemia (Ahmed et al., 2014). Pknbpxa is essential to invasion of human 
erythrocytes (discussed further in section 1.8.2) suggesting that non-synonymous 
mutations in genes essential to the invasion process may affect merozoite invasion 
efficiencies (Moon et al., 2016). Little research has been conducted on the contribution 
of parasite polymorphisms to severe malaria. However, polymorphisms were identified 
in the invasion genes EBA-140 and EBA-181 which affected the affinity of the protein 
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to erythrocytes (Maier et al., 2009). Additionally, a case control study examining 
associations between severe malaria and polymorphisms in 6 virulence genes identified 
polymorphisms in both Rh1 and EBA-175 as associating with severe malaria 
(Chokejindachai and Conway, 2009). This suggests that polymorphisms in merozoite 
invasion proteins can potentially contribute to severe malaria, likely by an altered 
invasion phenotype. In order to conduct experiments on the contribution of invasion 
efficiencies or erythrocyte selection to the pathology of severe malaria would require an 
appropriate research model. 
 
 
1.4  Models to Study Malaria Pathophysiology 
During the 20
th
 century, the tools and models available for malaria research have 
improved greatly and have become more accessible. One of the main developments was 
the ability to maintain the asexual erythrocytic stages in culture in vitro (Trager and 
Jensen, 1976, Haynes, 1976 #1312). Prior to this, studies were confined to in vivo and 
ex vivo work primarily using rodent and simian Plasmodium species (Brown et al., 
1968, Brown and Brown, 1965, Bannister et al., 1975). In vitro cultures of P. 
falciparum are an important part of malaria research as this is the most deadly form of 
the disease. However, studies on pathophysiology are difficult to perform in P. 
falciparum as there is no natural in vivo model, although P. falciparum is infectious to 
several Aotus monkey species (Egan et al., 2002, Herrera et al., 2002). Currently, 
results from P. falciparum pathophysiology studies conducted in vitro must be 
translated to a Plasmodium spp with an appropriate in vivo model which may not 
comprehensively mirror P. falciparum pathophysiology in humans. Alternatively a host 
that is experimentally susceptible to P. falciparum can be used to model human disease 
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however often key features of human severe malaria are not mirrored in the chosen host 
(Schmidt, 1973). Recently, novel mechanisms such as humanized rodents (Kaushansky 
et al., 2014) or the recreation of the human host tissue in vitro may provide alternative 
avenues of research into the pathology of severe malaria (Shelby et al., 2003, Pehrson et 
al., 2016).Although useful, many of these systems P. falciparum models have 
drawbacks.  
The rodent malaria species P. berghei, P. chabaudi, and P. yoelii provide an 
opportunity to study malaria pathophysiology in vivo and are extremely useful for 
researching the sexual parasite stages of the life cycle (Figure 1.3c). The ability to 
conduct transmission studies is hugely important as this allows the entire life cycle to be 
studied, which cannot be performed in vitro. In addition, the pathology of disease can 
also be examined especially as P. berghei is amenable to genetic manipulation (Fonager 
et al., 2011, Janse et al., 2006, Orr et al., 2012). However, features of human severe 
malaria such as iRBC sequestration in brain microvasculature are absent suggesting 
mechanisms that are specific to hosts (Craig et al., 2012). This may be attributed to the 
differences in the subtelomeric regions between rodent malaria species and human 
parasite with a primate origin (Otto et al., 2014a).  
Prior to the establishment of the P. falciparum in vitro culture system simian 
Plasmodium species were used extensively both in vivo and ex vivo. Ground-breaking 
studies used ex vivo matured P. knowlesi schizonts to study both merozoite invasion and 
schizont rupture microscopically (Dvorak et al., 1975), while in vivo work identified 
both agglutination and antigenic variation mediated by the schizont-infected cell 
agglutination proteins (SICA) (Brown and Brown, 1965), sequestration of schizont 
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infected cells (Miller et al., 1971), and identification of the first erythrocyte receptor 
essential for merozoite invasion (Miller et al., 1975) were studies that were all carried 
out in the simian malaria parasite P. knowlesi. Further simian malaria species can model 
features of P. falciparum and P. vivax malaria. Cerebral malaria and cytoadhesion can 
be modelled by P. fragile and P. cynomolgi (Craig et al., 2012), and the latter can also 
model the dormant hypnozoite stage which is a feature of P. vivax malaria (Dembele et 
al., 2014). The pathology of P. knowlesi severe malaria mirrors many features of severe 
P. falciparum malaria both in humans and several macaque species (Craig et al., 2012, 
Cox-Singh and Culleton, 2015). Although these simian malaria species can be useful for 
pathophysiology studies, P. knowlesi is of particular interest for the study of severe 
malaria, as it is naturally zoonotic, enabling studies both in vitro and in vivo using the 
same species. 
An important step in P. knowlesi research was the development of transfection 
methodology and the establishment of continuous in vitro cultures (Kocken et al., 2002, 
Moon et al., 2013). Kocken et al., (2002) developed an in vitro P. knowlesi culture (H- 
strain) in Rhesus macaque erythrocytes and transfection methods to genetically 
manipulate the P. knowlesi genome (Kocken et al., 2002). It was identified that the P. 
knowlesi H-strain in vitro culture reverted to an in vivo phenotype following passage in 
a Rhesus macaque enabling transmission studies to be performed (Kocken et al., 2002). 
Following A. stephensi feeding on P. knowlesi infected Rhesus macaques oocysts were 
detected in the midgut demonstrating that the culture was capable of producing 
gametocytes (Kocken et al., 2002) although completion of the life cycle was not 
achieved as P. knowlesi sporozoites are unable to invade the salivary glands of A. 
stephensi (Coatney et al., 1971, Kocken et al., 2002, Gruring et al., 2014). A 
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requirement for culturing the H-strain in vitro is access to a source of macaque 
erythrocytes which restricts research to facilities with access to non-human primate 
animal units or with resources to purchase macaque erythrocytes. The adaptation of P. 
knowlesi to continuous in vitro culture in human erythrocytes has greatly increased the 
feasibility of conducting P. knowlesi research (Moon et al., 2013). The generation of the 
PkA1-H.1 clone was achieved via long term in vitro culture in 80% human erythrocytes 
and 20% cynomoglus erythrocytes (Moon et al., 2013). The PkA1-H.1 clone has not 
been tested in vivo although it remains invasive to cynomolgus erythrocytes in vitro 
(Moon et al., 2013). Advantages of in vitro culture in human erythrocytes are that 
human erythrocytes are more readily available, the efficiencies of transfections have 
been reported as higher than in P. falciparum and mechanisms specific to human 
disease can now be studied (Moon et al., 2013). P. knowlesi is unique as it is the only 
human Plasmodium species with both a natural host for in vivo studies and an accessible 
in vitro culture system which can be used to study the P. knowlesi erythrocytic cycle. 
 
 
1.5    Invasion: How do Merozoites Invade Host  
   Erythrocytes? 
The invasion of merozoites into a susceptible erythrocyte is a highly structured process 
which is complete within approximately 30 seconds (Weiss et al., 2015, Gilson and 
Crabb, 2009). The molecular interactions which take place during the invasion process 
are highly organised and sequential. The invasion process is conserved between 
Plasmodium species, suggesting common mechanisms which can be broken down into 
key steps (Gilson and Crabb, 2009). These consist of merozoite attachment; merozoite 
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apical reorientation; junction formation; actin-myosin mediated invasion and 
erythrocyte resealing (Figure 1.4).   
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Figure 1.5 The structure of the invasive merozoite.  
The invasive merozoite is spatially organised for invasion. Merozoites contain 2 membranes with the 
outermost membrane being covered in a dense protein coat, facilitating attachment to RBCs. The inner 
membrane complex (IMC) is located below the outer plasma membrane. Proteins involved in the actin 
myosin motor complex are located between these two membranes. The Rhoptries and the micronemes 
are secretory organelles which secrete proteins during the invasion process. The Rhoptries consist of two 
distinct regions, the rhoptry bulb and the rhoptry neck, which contain distinct protein subsets (Counihan et 
al., 2013). Both organelles secrete the proteins at distinct time points during the invasion process. The 
dense granules are a secretory organelle dispersed throughout the cytoplasm and release their contents 
following the establishment of the PV (Culvenor et al., 1991). The exonemes (not shown) are the smallest 
known secretory vesicles which secrete proteins required for efficient egress (Yeoh et al., 2007, Janse and 
Waters, 2007, Collins et al., 2017). The cytoskeleton consists of the microtubules extending from the polar 
rings located at the apical end of the merozoite towards the posterior of the merozoite, spanning two thirds 
the length of the merozoite. The microtubules and polar rings give structure and apical orientation to the 
merozoite (Morrissette and Sibley, 2002). The apicoplast is an essential organelle homologous to 
chloroplast, although no longer photosynthetic and is involved in the production of essential metabolites 
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1.5.1   The merozoite 
A merozoite is the Plasmodium parasite life stage which mediates invasion into host 
erythrocytes, initiating the symptomatic stages of infection. The merozoite is not only 
the smallest Plasmodium life stage, but it is also one of the smallest eukaryotic cells. 
Merozoites are approximately 1 µm in length in P. falciparum, and 2 µm in P. knowlesi. 
All Plasmodium species share a common structure, with the nucleus surrounded by 
endoplasmic reticulum (ER) towards the posterior of the merozoite. Unique 
apicomplexan secretory organelles are located at the merozoite’s apical end (Figure 
1.5). A characteristic feature of Plasmodium merozoites is the presence of an organelle 
thought to be a chloroplast relic termed the apicoplast (Figure 1.5). This organelle 
possesses its own circular genome encoding 30 putative genes (Goodman and 
McFadden et al., 2014). The apicoplast is essential for parasite survival, and functions 
to synthesise metabolites unable to be synthesised or scavenged by the parasite 
(McFadden and Yeh, 2017, Gisselberg et al., 2013, Ke et al., 2014). The apicoplast has 
been identified to be involved in the synthesis of isopentenyl diphosphate, haem and 
fatty acids which are essential at different stages of the parasite life cycle (McFadden 
and Yeh, 2017).  
Merozoites possess four types of apical organelle involved in the release of parasite 
proteins during the invasion process and egress; the rhoptries, micronemes, dense 
granules and exonemes (Mercier et al., 2005). The rhoptries are the largest of the 
secretory organelles and consist of a neck and bulb region. The release of the rhoptry 
neck proteins occurs before release of the rhoptry bulb, suggesting organised structure 
within this organelle (Counihan et al., 2013). Members of the P. falciparum 
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Reticulocyte-Binding-homologue (PfRh) proteins locate to the rhoptry neck prior to 
invasion. The micronemes (Figure 1.5) are another organelle containing proteins 
involved in red blood cell invasion, such as the Erythrocyte Binding Proteins (PfEBAs). 
The dense granules (Figure 1.5) differ from the rhoptries and micronemes as they are 
not localised to the apical pole of the merozoite and are found throughout the merozoite 
cytoplasm (Mercier et al., 2005). Secretion of dense granule appears to follow invasion 
with the secreted proteins implicated in establishment of the parasitophorous vacuole 
(PV) and host cell modification (Culvenor et al., 1991). Previously, the subtilisin-like 
protein 1 (SUB1) was predicted to be released by dense granules; however SUB1 has 
been shown to be secreted by the exonemes into the PV during egress (Collins et al., 
2017, Yeoh et al., 2007, Collins et al., 2013b).  
 
1.5.2   Merozoite attachment and reorientation 
When a liver schizont ruptures it releases thousands of merozoites into the blood 
stream. In order for merozoites to survive and replicate they must invade an erythrocyte. 
The initial stage of the invasion process is the attachment of a merozoite to an 
erythrocyte which can occur on any region of the merozoite surface (Bannister and 
Dluzewski, 1990) (Figure 1.4A). This initial interaction is thought to be a weak 
interaction causing deformation of the host erythrocyte (Dvorak et al., 1975, Weiss et 
al., 2015). The merozoite (Figure 1.5) has a dense protein surface coat consisting of 
many different proteins such as glycosylphosphatidylinositol (GPI) anchored membrane 
proteins, transmembrane anchored proteins or peripherally-associated surface proteins 
(Figure 1.4 A) (Beeson et al., 2016). One of the most abundant proteins on the 
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merozoite surface is the GPI anchored merozoite surface protein (MSP) 1 (Gilson et al., 
2006). Proteolytic cleavage of MSP1 during schizont rupture results in the presence of 4 
different fragments during the invasion process MSP142, MSP183, MSP130 and MSP138 
(Stafford et al., 1994), with the MSP142 fragment being proteolytically cleaved during 
the invasion process into MSP119 and MSP133 (Blackman and Holder, 1992). The MSP1 
fragments have been implicated in binding to the erythrocyte receptors Band 3 (Goel et 
al., 2003, Kariuki et al., 2005), and Glycophorin A (Baldwin et al., 2015). Lin et al., 
(2016) propose that fragments of MSP1 bind with MSP3, MSP6, MSP7, MSPDBL1 and 
MSPDBL2 individually, forming multiple different complexes (Lin et al., 2016). 
Conversely, Baldwin and colleagues propose that MSPs form larger complexes 
comprising multiple different MSP proteins (Baldwin et al., 2015). Blockage of MSP1 
binding to the host erythrocyte surface using heparin, did not abolish binding to the 
erythrocyte but did prevent the weak deformation (Weiss et al., 2015).  This suggests 
MSP1 plays an early role in the attachment to erythrocytes, but is not responsible for the 
initial attachment with the initial interactions still unknown (Weiss et al., 2015). 
Although MSP1 has been shown to bind the erythrocyte receptors as discussed here, 
further data suggests that MSP1 plays an important role in binding the host erythrocyte 
cytoskeleton during egress, further discussed in Section 1.6 (Das et al., 2015). 
Following initial attachment and MSP1 binding, a strong deformation is observed which 
coincides with apical reorientation (Figure 1.4 B) (Weiss et al., 2015). The secondary 
interactions at the apical pole to the erythrocyte membrane involve two key protein 
families, the Reticulocyte binding-like protein family (RBP/Rh/NBP) (detailed in 
section 1.8.2) and the Duffy binding proteins (DBPs)/Erythrocyte binding antigens 
(EBAs) (detailed in section 1.8.1) (Cowman and Crabb, 2006). Both protein families are 
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conserved in all Plasmodium species, with multiple RBP and DBP/EBA members 
present in each species genome (Gunalan et al., 2013). P. knowlesi contains 2 functional 
RBPs and 3 functional DBPs (Miller et al., 1975), while P. falciparum contains 5 
functional RBPs and 3 functional EBAs and P. vivax contains 2 RBP forms with 
multiple sub-types of each protein, and  2 DBPs (Meyer et al., 2009, Li and Han, 2012, 
Carlton et al., 2008, Adams et al., 1990, Singh et al., 2005, Gunalan et al., 2016). The 
majority of RBP protein erythrocyte receptors remain unknown, with the interactions 
between PfRh5 with basigin and PfRh4 with Complement receptor 1 (CR1) being the 
only two reported for the Rh proteins in P. falciparum (Crosnier et al., 2011, Tham et 
al., 2010). The erythrocyte receptor DARC was identified as a binding partner for 
members of the P. knowlesi and P. vivax DBP family (Miller et al., 1975, Miller et al., 
1976), while the glycophorins have been identified as erythrocyte receptors for the EBA 
proteins in P. falciparum (Maier et al., 2003, Orlandi et al., 1992, Lobo et al., 2003). 
Members of the RBP and DBP/EBA protein families have been shown to be essential 
for merozoite invasion (Moon et al., 2016, Baum et al., 2009, Miller et al., 1975, Miller 
et al., 1976) although redundancy between RBPs and DBPs in P. falciparum appears to 
compensate for blocked invasion pathways (Stubbs et al., 2005). PfRh5 is the only 
essential Rh protein in P. falciparum and in addition to binding basigin PfRh5 can also 
the micronemal protein PfCyRPA in complex with PfRIPR and the merozoite surface 
protein PfP113 (Galaway et al., 2017). Although this is the model proposed for P. 
falciparum, the invasion process in P. knowlesi remains unclear, as no orthologue of 
PfRh5 is present in the P. knowlesi genome. However, PfP113, PfCyRPA and PfRIPR 
are all present in P. knowlesi (Pain et al., 2008). 
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1.5.3   Junction formation 
During the invasion process there is a release of intracellular protein stores from the 
rhoptry and microneme apical organelles functioning to secrete proteins involved in 
erythrocyte adhesion and formation of the PV (Figure 1.4) (Counihan et al., 2013). The 
trigger for release is predicted to be caused by PfRh5-Basigin binding in P. falciparum 
and was visualised using erythrocytes loaded with a calcium sensitive fluorophore, 
although it is unknown if this mechanism is present in other species (Weiss et al., 
2015). Following rhoptry release (Figure 1.7 A) the apical membrane antigen 1 
(AMA1) attaches to the merozoite surface enabling the binding to proteins secreted 
from the rhoptry neck (RON). This interaction has been shown to be essential for 
invasion of both Plasmodium and Toxoplasma gondii (Srinivasan et al., 2013, 
Alexander et al., 2005, Weiss et al., 2015, Yap et al., 2014). AMA1 binds to RON2 in a 
complex with both RON4 and RON5 that localised to the moving junction (Figure 1.7 
B) (Counihan et al., 2013, Srinivasan et al., 2013). RON2 contains multiple 
transmembrane domains, allowing it to cross the erythrocyte membrane (Besteiro et al., 
2009, Shen and Sibley, 2012) while RON4 localises to the cytosolic side of the 
erythrocyte membrane (Srinivasan et al., 2011). In Toxoplasma gondii members of the 
RON complex, including RON5 and RON8, traverses the host cell membrane linked to 
AMA1 on the merozoite surface via RON2 (Beck et al., 2014) committing the 
merozoite to invasion (Chen et al., 2011, Riglar et al., 2011, Srinivasan et al., 2013, 
Srinivasan et al., 2011). To date, knockout studies in P. berghei have shown that RON2, 
RON4 and RON5 are refractory to genetic deletion suggesting an essential role in the 
erythrocyte stages, however conditional knockouts have not been performed to verify 
that they are essential for junction formation (Giovannini et al., 2011, Bushell et al., 
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2017). Data from a conditional AMA1 knockout in both T. gondii tachyzoites and P. 
berghei merozoites has challenged the role of AMA1 in tight junction formation as 
invasion was not abolished in the AMA1 knockout (Bargieri et al., 2013). However, 
invasion was very low in an imperfect conditional knockout of AMA1 in P. falciparum 
(Yap et al., 2014). This data may suggest that an additional protein present in P. berghei 
and T. gondii but absent in P. falciparum may compensate for the role of AMA1 during 
the invasion process (Bargieri et al., 2013, Harvey et al., 2014). 
 
1.5.4   Actin-myosin mediated invasions 
In order for invasion to take place, the merozoite uses the tight junction described above 
to anchor itself to the erythrocyte membrane and force its way into the erythrocyte 
creating the PV. Although the exact mechanism is still not understood for merozoite 
invasion, a schematic of the current proposed method can be seen in Figure 1.6 
(Tardieux and Baum, 2016). The Glideosome Associated Protein (GAP) 50, GAP45, 
GAP40 and Myosin A tail domain interacting protein (MTIP) form a protein complex 
on the parasite IMC (Figure 1.6) (Cowman and Crabb, 2006). In turn MTIP binds to 
Myosin XIV (MyoXIV) which interacts with polymerising actin filaments between the 
IMC and the parasite membrane (Figure 1.6) (Douse et al., 2012, Baum et al., 2008). 
Recently, the roles of both aldolase and MTRAP (Figure 1.6) in the invasion process 
have been disproved (Shen and Sibley, 2014, Riglar et al., 2016). Currently, the proteins 
involved in linking the actin filaments to the erythrocyte membrane are unknown 
(Tardieux and Baum, 2016). Additionally, the orientation of the glideosome machinery 
remains unknown. Tardieux and Baum propose 3 possible mechanisms (Figure 1.6), 
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whereby extension of the actin filament to the posterior of the merozoite produces 
movement of the merozoite in the opposite direction into erythrocyte creating the PV 
(Figure 1.6). The actin filament is proposed to sit between the parasite adhesion 
attached extracellularly to the erythrocyte surface and the MyoXIV protein linked to the 
IMC (Figure 1.6 panel A). Alternatively, the second model proposes that the actin 
filament extends in the same direction that force is exerted. This model proposes 
inversion of MyoXIV, MTIP and actin, with the actin filament closely associating 
closely with the GAP proteins on the IMC and MTIP binding to the unknown parasite 
adhesin possibly via a linker protein (Figure 1.6 panel B). The second model proposed 
that the direction of actin filament extension is the same as the direction of movement. 
The final proposed method mirrors the mechanism shown in Figure 1.6 panel A, 
however the actin filament interacts directly with multiple parasite adhesins rather than 






Figure 1.6 Proposed mechanisms involving the Actin-Myosin motor complex.  
1. The Inner membrane complex binds GAP50, GAP45 and MTIP, which in turn binds MyoXIV (2). 
Polymerisation of the actin filament (3) causes MyoXIV to move backwards producing (4) backward force 
(5) Producing forward merozoite movement into the erythrocyte forming the PV (6) Rhomboid proteases 
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1.5.5   Shedding of the merozoite surface proteins 
An important feature of the active invasion process is the cleavage of the merozoite 
surface proteins as the tight junction moves to the posterior of the merozoite. This 
process is predicted to disrupt the interactions between the merozoite and the 
erythrocyte allowing invasion to occur (Olivieri et al., 2011). In P. falciparum, this 
process appears to be mediated by 2 Rhomboid proteases, ROM1 and ROM4, as well as 
the subtilisin-like protease SUB2 (Cowman et al., 2012). The SUB2 protease is 
implicated in cleaving the AMA1 protein, involved in tight junction formation, at the 
transmembrane domain in a non-sequence specific manner (Olivieri et al., 2011). 
Cleavage of AMA1 was also shown to be mediated by ROM1 (Baker et al., 2006), 
while ROM4 cleaved the EBA-175 surface adhesin in a sequence specific manner 
(O'Donnell et al., 2006). Interestingly, the ROM proteases were also shown to cleave 
the EBA proteins, the Rh proteins and other merozoite surface proteins showing their 
importance during the invasion process. The cleavage of specific merozoite surface 
proteins was able to be altered by producing a chimeric AMA1 and EBA-140 proteins 
by combining the extracellular domain of EBA-140 with the TM domain of AMA1 
(Baker et al., 2006). ROM4 was able to cleaved native EBA-140 and ROM1 only 
demonstrated weak cleavage of EBA-140. However incorporation of the AMA1 TM 
domain resulted in a switch in ability to cleave EBA-140 containing the TM domain of 
AMA1, and was now able to be cleaved by ROM1 and was unable to be cleaved by 
ROM4 showing not only that cleavage occurs in a sequence specific manner but also 
reveals the level of complexity (Baker et al., 2006). 
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1.6    Egress 
In order to continue the life cycle, merozoites must escape the host erythrocyte. The exit 
of merozoites from a schizont occurs in a conserved manner across Plasmodium 
species. Initial observations in P. knowlesi identified that movement of merozoites can 
be visualised inside mature schizonts prior to swelling and rupture (Dvorak et al., 
1975). Detailed studies have subsequently been performed in P. falciparum showing 
that initially the release of 1-2 merozoites occurs before the erythrocyte membrane curls 
outwards from the location of initial merozoite release followed by buckling of the 
erythrocyte membrane expelling the remaining merozoites, all taking place in less than 
400 ms (Abkarian et al., 2011). Although this process appears violent morphologically, 
it is actually a highly structured process molecularly as inefficient egress impacts 
subsequent merozoite invasion. 
As previously mentioned, serine proteases have been shown to process proteins 
involved in erythrocyte invasion but perhaps play a more important role in egress 
(Dowse et al., 2008). Three subtilisin-like (SUB) serine proteases are present in the P. 
falciparum, P. knowlesi and P. vivax genomes (Carlton et al., 2008, Pain et al., 2008, 
Gardner et al., 2002). A recently proposed mechanism for the initiation of egress 
demonstrates that the PV membrane is permeabilised 10-30 minutes prior to complete 
PV membrane rupture (Hale et al., 2017). Following this the cGMP dependent kinase 
PKG triggers SUB1 release from exonemes into the PV (Hale et al., 2017, Collins et al., 
2017, Collins et al., 2013a, Hopp et al., 2012). PfSUB1 was shown to have multiple 
substrates, including serine rich antigen (SERA) 4, 5 and 6 (Yeoh et al., 2007, Silmon 
de Monerri et al., 2011). Further SERA family members may also be processed by 
PfSUB1, as 9 are present in the P. falciparum genome. PfSERA5 and 6 were previously 
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shown to be essential, however a conditional knockout of SERA5 was viable 
(McCoubrie et al., 2007). Conditional disruption of SERA5 shortened the time to egress 
however the membrane was ruptured early and incompletely, reducing the dispersal of 
merozoites upon egress (Collins et al., 2017). Collins et al., suggest that SERA5 has a 
regulatory role during egress ensuring efficient egress and reinvasion, as the parasites 
lacking functional SERA5 had a reduced replication rate (Collins et al., 2017). 
In addition to the role PfSUB1 plays in processing SERA5, it has also been shown to 
process MSP1 (Yeoh et al., 2007, Koussis et al., 2009, Stallmach et al., 2015, Das et 
al., 2015). Processing of MSP1 at specific sites as discussed previously results in 4 
MSP1 fragments which form a complex following cleavage (Section 1.5.2) (Das et al., 
2015). The processing of MSP1 by SUB1 during egress activates the processed MSP1 
to bind heparin and spectrin (Das et al., 2015). Genetic disruption of MSP1 at sites 
cleaved by SUB1 and truncation of MSP1 identified a region of MSP1 able to bind 
spectrin that was required for parasite viability and absence of MSP1 processing 
resulted in egress defect (Das et al., 2015).  
 
1.7  Invasion Blocking Vaccine Candidates 
As discussed above, the RBPs and DBPs play important roles during erythrocyte 
invasion. This has led to RBPs being the focus for vaccine studies. Specifically, PfRh5 
is a current leading vaccine candidate against P. falciparum infection (Douglas et al., 
2011, Douglas et al., 2014, Ord et al., 2014, Osier et al., 2014). PfRh5 appears to be 
more conserved than other RBPs and it is hoped that this will improve vaccine efficacy. 
Nine different P. falciparum in vitro lines, three of which contained non-synonymous 
 
  59 
mutations in the PfRh5 gene, were challenged with antibodies raised against 
recombinant PfRh5 (3D7 line). Invasion was blocked in all 9 strains showing that the 
antibodies had activity against multiple PfRh5 variants (Bustamante et al., 2013). Aotus 
monkeys are experimentally susceptible to P. falciparum, which presents with anaemia 
and death if untreated. Douglas et al., showed that when Aotus monkeys were 
vaccinated with PfRh5 prior to challenge with P. falciparum, there were no fatalities 
and no primate required antimalarial treatment (Douglas et al., 2015). This is a 
promising step forward in the steps to prevent P. falciparum malaria. However, as P. 
falciparum is the only human malaria species that expresses PfRh5, this vaccine would 
not be able to protect from any of the other human malaria species. A current target for 
a P. vivax vaccine is the PvDBP (Chen et al., 2016). Blocking the PvDBP interaction 
with DARC would give a similar invasion phenotype to P. vivax infection of a Duffy 
negative individual. As the merozoite invasion ligands are essential to successful 
erythrocyte invasion and are expressed on the surface of merozoites they provide a good 
target for an invasion blocking vaccine. However, the RBPs and DBPs are not just 
important for vaccine studies; they function at a crucial point in the parasite life cycle 
which can determine the fate of the merozoite. The greater the number of successful 
invasions the higher the parasitaemia which is critical for survival of the parasite, but 
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1.8    Merozoite Invasion Proteins 
1.8.1    Duffy binding proteins 
The Duffy Binding Proteins (DBPs) are a multigene family responsible for binding to 
erythrocytes. The DBPs are predicted to function immediately prior to tight junction 
formation, and play a similar role to the RBPs (Lopaticki et al., 2011). The P. knowlesi 
genome contains 3 dbp genes, the P. falciparum genome encodes 4 eba genes and P. 
vivax encodes 2 dbp genes (Pain et al., 2008, Carlton et al., 2008, Gardner et al., 2002). 
The Duffy binding proteins, so called because of their erythrocyte receptor Duffy 
antigen receptor for chemokines (DARC), were first identified as being essential for the 
invasion of P. knowlesi and P. vivax (Miller et al., 1976, Miller et al., 1975). The DBPs 
function to attach merozoites to the erythrocyte surface, causing strong deformation 
prior to invasion (Weiss et al., 2015). 
1.8.1.1   P. falciparum erythrocyte binding antigens 
Of the 4 P. falciparum Erythrocyte binding antigens (EBA), EBA-181, EBA-175, EBL-
1 and EBA-140, erythrocyte receptors are known for the latter 3 parasite proteins, which 
bind to Glycophorin A, Glycophorin B and Glycophorin C respectively, Table 1.2 
(Duraisingh et al., 2003a, Maier et al., 2003, Mayer et al., 2009). The EBA proteins 
share a common structure consisting of an N-terminal signal sequence (RI) followed by 
the erythrocyte binding domain (RII). Within this binding domain there are two 
cysteine-rich DBL domains and a linking domain to a small cysteine-rich domain 
immediately prior to the transmembrane domain (Sim et al., 1994). In P. falciparum the 
EBAs localise to the micronemes of merozoites prior to invasion (Treeck et al., 2006). 
During the invasion process the EBA and PfRh proteins appear to function 
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cooperatively, as invasion is only inhibited by anti-Rh2a antibodies when EBA-181 is 
present, however if EBA-181 is present, invasion can be blocked suggesting a 
cooperative function (Lopaticki et al., 2011). This is mirrored in other members of the 
protein families as knock-out of EBA-175 results in increased PfRh4 expression which 
has been reported in both clinical isolates and laboratory strains suggesting a 
compensatory role between EBA-175 and Rh4. The compensatory role is further 
enhanced as invasion via EBA-175 and its receptor Glycophorin A is a sialic acid 
dependent invasion pathway whilst invasion via Rh4 and its receptor CR1 is a sialic 
acid independent pathway (Gaur et al., 2006, Nery et al., 2006, Stubbs et al., 2005). The 
benefit of being able to switch invasion pathways allows merozoites to invade a diverse 
range of RBCs.  
The presence of multiple adhesive proteins enables merozoites to invade erythrocytes 
via different invasion pathways potentially overcoming blockage of single merozoite - 
erythrocyte interaction (Lopaticki et al., 2011). Polymorphisms present in the EBA-181 
and EBA-140 proteins have been shown to be responsible for altering the affinity of the 
EBA protein for the erythrocyte receptor (Maier et al., 2009). This could suggest that 
the altered affinity for erythrocyte receptors could result in either an increased or 
decreased number of successful invasions however as P. falciparum uses multiple 
invasion pathways this would likely be masked by invasion via another pathway.  
1.8.1.2  P. vivax duffy binding proteins 
Previously it had been noted that black Africans appeared not to be susceptible to P. 
vivax infection (Miller et al., 1976). Following ground breaking work in P. knowlesi it 
was identified that the erythrocyte Duffy antigen was essential for P. vivax erythrocyte 
invasion (Miller et al., 1976, Miller et al., 1975). It was later identified that PvDBP was 
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responsible for binding to the Duffy antigen, Table 1.2 (Adams et al., 1992, Wertheimer 
and Barnwell, 1989). Recently the binding of PvDBP to the Duffy antigen was shown to 
occur as a dimer, with the initial PvDBP-Duffy interaction recruiting a second PvDBP 
receptor which associates and binds to the second Duffy antigen (Batchelor et al., 
2014). It remains unclear whether this binding pattern is unique to P. vivax or is present 
in other species. In addition to dimerization Batchelor et al, showed that single amino 
acid changes in regions of PvDBP proteins resulted in decreased binding to RBCs 
suggesting that mutations in key protein-protein interactions could result in fewer 
interactions between merozoites and RBCs suggesting fewer RBC invasions (Batchelor 
et al., 2014). Interestingly, P. vivax was found recently to have invaded Duffy-negative 
human erythrocytes at 3 geographically distinct regions in Africa (Angola and 
Equatorial Guinea, Mauritania and Kenya) (Mendes et al., 2011, Ryan et al., 2006, 
Wurtz et al., 2011). This suggests there may be invasion pathways for P. vivax 
independent of the Duffy invasion pathway. 
1.8.1.3   P. knowlesi duffy binding proteins 
As with P. vivax, Duffy-negative individuals are resistant to P. knowlesi erythrocytic 
stages (Miller et al., 1975). The P. knowlesi PvDBP orthologue was shown to be 
responsible for binding to the Duffy RBC surface antigen (Miller et al., 1975). The P. 
knowlesi genome encodes three DBP genes DBPα, DBPβ and DBPγ. Research showed 
that PkDBPα was able to bind both human and macaque erythrocytes while DBPβ and 
DBPγ were able to bind macaque erythrocytes but not human erythrocytes (Chitnis et 
al., 1996). Knockout studies have shown that PkDBPα was the parasite ligand that 
bound to the erythrocyte receptor DARC (Singh et al., 2005).  
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1.8.2  Reticulocyte binding protein family 
The Reticulocyte Binding proteins (RBPs) are a family of merozoite proteins that are 
thought to play important roles during invasion prior to junction formation. If some of 
the key RBP-RBC interactions are disrupted invasion can be blocked demonstrating 
their important role in the invasion process (Baum et al., 2009, Moon et al., 2016). The 
first member of this protein family was identified as a 235 kDa protein in the rodent 
malaria Plasmodium yoelli in the early 1980’s (Freeman et al., 1980, Holder and 
Freeman, 1981). Homologues of the 235 kDa protein were subsequently identified in 
other Plasmodium species, and termed the reticulocyte binding protein family, so named 
because in P. vivax the RBPs are implicated in selection of reticulocytes for invasion 
(Galinski et al., 1992). In P. falciparum the proteins are termed the reticulocyte binding-
like protein homology (PfRh), and in P. knowlesi they are termed the normocyte 
binding proteins (PkNBP). The number of genes present in each Plasmodium species 
varies, with pseudogenes also being present. Currently, 2 functional NBP proteins have 
been identified in P. knowlesi, 5 in P. falciparum, and approximately 11 were recently 
identified in P. vivax by de novo assembly of a field isolate genome sequence (Hester et 
al., 2013). The RBP gene family share a common genomic organisation with two exons 
separated by a small intron (Gunalan et al., 2013) and predominantly encode large 
proteins over  230 kDa (Gunalan et al., 2013). The proteins all contain an N-terminal 
signal peptide along with a single C-terminal transmembrane domain, and a short 
cytoplasmic tail. The exception to this is PfRh5 in P. falciparum, which contains a 
signal peptide, but has neither a cytoplasmic domain nor a transmembrane domain, and 
is smaller (63 kDa) than other proteins in the family (Rodriguez et al., 2008, Baum et 
al., 2009).  
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1.8.2.1   P. falciparum reticulocyte-binding-homologue proteins 
The P. falciparum Rh proteins are the most well characterised RBPs in all species. 
There are six genes in the P. falciparum genome, one of which is a pseudogene (PfRh3). 
The following rhoptry secretion the PfRhs (Rh1, Rh2a, Rh2b, Rh4 and Rh5) localise to 
the apical end of the merozoite consistent with a direct role for the Rh proteins in 
erythrocyte binding and invasion (Triglia et al., 2009, Baum et al., 2009). During this 
time, between schizont rupture and merozoite invasion, the PfRh1–4 proteins undergo 
proteolytic cleavage (Triglia et al., 2009). The PfRh1 processed fragments were capable 
of binding to host erythrocytes, and both were detected inside newly invaded iRBCs and 
in the culture supernatant, suggesting that there may be more than one binding domain 
(Triglia et al., 2009). A similar pattern of proteolytic cleavage has been reported for 
PfRh4 and PfRh2a/2b (Gunalan et al., 2011).  
The PfRh proteins share N-terminal homology (Sahar et al., 2011, Rayner, 2008). 
However, the PfRh2a/Rh2b proteins are strikingly similar, with the first 8 kb at the 5’ 
region of the genes identical and only differ in a short 3’ region of the gene (Rayner et 
al., 2000). This divergent 500 amino acids sequence at the C-terminus encompasses 
some of the ectodomain, the transmembrane domain and the cytoplasmic tail (Sahar et 
al., 2011). Interestingly, the differences observed in cytoplasmic domain between 
PfRh2a and PfRh2b alter its invasion pathway, as shown by a chimeric PfRh2a parasite 
containing the PfRh2b cytoplasmic domain (Duraisingh et al., 2003b, Dvorin et al., 
2010) (Table 1.2). This shows that the cytoplasmic domains of invasion proteins can be 
responsible for invasion phenotype (Dvorin et al., 2010). In addition, phosphorylation 
of PfRh4 cytoplasmic tail residues by casein kinase 2 has been shown to be essential to 
erythrocyte invasion (Tham et al., 2015). It is anticipated that further studies examining 
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intracellular signalling will reveal how merozoite – erythrocyte interactions trigger the 
subsequent stages of erythrocyte invasion (Tham et al., 2015).  
The erythrocyte receptors for two of the five PfRhs have been identified, Table 1.2. 
PfRh4 was identified to bind to CR1 (Tham et al., 2010) and PfRh5 was identified to 
bind basigin (Bartholdson et al., 2013). Homologues of PfRh5 are absent from other 
human malaria species, and are only found in species of the laverania subgenus, such as 
the gorilla malaria species P. reichenowi which is phylogenetically the most closely 
related to P. falciparum (Sundararaman et al., 2016, Wanaguru et al., 2013, Wright et 
al., 2014). Additionally, PfRh5 has a unique structure compared to other RBPs as it is 
the only family member which does not contain a C-terminal transmembrane domain 
(TM) (Baum et al., 2009). In addition to PfRh5 binding via its C-terminal end it has 
recently been shown to bind PfP113 N-terminally (Bartholdson et al., 2013, Galaway et 
al., 2017). As discussed previously this interaction is proposed to be important for 
rhoptry release enabling the formation of the tight junction consisting of AMA-1, 
RON2, RON4 and RON5 complex (Galaway et al., 2017) followed by microneme 
secretion to release a cysteine rich protein (PfCyRPA), and the PfRh5 interacting 
protein PfRIPR, Figure 1.7 (Reddy et al., 2015, Galaway et al., 2017). In this model 
PfCyRPA binds C-terminally to PfRh5 while PfRIPR does not bind directly to PfRh5 
but is linked via PfCyRPA resulting in the N-terminal disruption of PfRh5 and PfP113 
releasing the PfRIPR-PfCyRPA-PfRh5-Basigin complex from the merozoite surface 
(Crosnier et al., 2011, Galaway et al., 2017, Reddy et al., 2015).  
Although PfRIPR and PfCyRPA are both implicated in disrupting the PfP113-PfRh5-
Basigin complex their function in other Plasmodium spp. lacking PfRh5 remains 
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unknown. However, both P. knowlesi and P. vivax contain homologues of PfRIPR and 
PfCyRPA (Carlton et al., 2008, Pain et al., 2008). Identifying the role of these proteins 
in other species lacking homologues of Rh5 could help to identify their role during the 
invasion process.  
 
Figure 1.7 Proposed model of PfRh5 binding to the merozoite and erythrocyte surface.  
The proposed PfRh5 interactions with the erythrocyte receptor Basigin, the merozoite surface protein P113 
and the PfRh5 interacting proteins PfRIPR and PfCyRPA as detailed by Galaway et al (2017) A. Following 
initial attachment and rhoptry release (Panel A). PfRh5 is bound to the merozoite surface protein P113 via 
its N-terminal domain, allowing the C terminus of PfRh5 to bind Basigin on the erythrocyte surface (Panel 
A/1). B. This interaction is proposed to cause further rhoptry release (Panel B), allowing the tight junction 
to form through the interaction of the AMA1-RON complex (Panel B/2). C. Following tight junction 
formation and microneme secretion (Panel C) of the PfRh5 interacting proteins PfCyRPA and PfRIPR the 
PfRh5 protein is bound by PfCyRPA at the C terminus of PfRh5. PfCyRPA is predicted to bridge the 
interaction of PfRIPR and PfRh5, and upon PfRIPR binding causes disruption of the PfP113-PfRh5 
interaction, resulting in the PfRIPR-PfCyRPA-PfRh5-Basigin complex no longer tethered to the merozoite 
surface (Panel C/3).Figure adapted from (Galaway et al., 2017). 
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1.8.2.2   P. vivax reticulocyte binding proteins  
Initial work suggested that P. vivax contained 2 PvRBP genes, Pvrbp1 and Pvrbp2, 
responsible for selective invasion of reticulocytes (Wertheimer and Barnwell, 1989, 
Galinski et al., 1992). However, completion of the P. vivax genome revealed that there 
are subtypes of both Pvrbp1 and Pvrbp2, with the full repertoire consisting of 11 genes, 
3 of which are pseudogenes and three are partial coding genes, Table 1.2 (Carlton et al., 
2008, Hester et al., 2013, Hietanen et al., 2015). In comparison to P. falciparum, 
relatively little is known about the PvRBP proteins, as the lack of an in vitro culture 
system has hampered further research. Hietanen and colleagues showed that the full 
length PvRBP proteins are of a similar size to RBPs from other species (>280 kDa), 
although the binding partners are yet to be determined (Hietanen et al., 2015). Recently, 
the crystal structure of the PvRBP2a erythrocyte binding domain was solved, revealing 
that the N-terminal structure shared homology with PfRh5, suggesting a common 
structure between RBP proteins (Gruszczyk et al., 2016).  
1.8.2.3   P. knowlesi normocyte binding proteins 
Publication of the P. knowlesi genome led to the identification of 2 novel NBPs and a 
single pseudo-gene (Meyer et al., 2009, Pain et al., 2008). Meyer et al., showed that of 
the three genes present in the P. knowlesi genome (nbpxa, nbpxb and nbp1), only the 
Pknbpxa and Pknbpxb produced proteins with masses (324 kDa and 334 kDa 
respectively) similar to the orthologues in other Plasmodium species (Meyer et al., 
2009). Immunofluorescence and electron microscopy confirmed that like the PfRh 
proteins the NBPs localise to the apical end of merozoites consistent with a role during 
invasion, although they are thought to locate to the microneme (Figure 1.5) and not the 
rhoptry (Meyer et al., 2009). The PkNBPXb protein was found to bind erythrocytes 
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from Old World monkeys including Rhesus macaques and long-tailed macaques, but 
not New World monkeys such as the owl monkey (Meyer et al., 2009, Semenya et al., 
2012). This suggests a common receptor specific to the invasion of Old World monkeys 
(Semenya et al., 2012). Semenya et al., (2012) showed that the PkNBPXa protein but 
not the PkNBPXb protein bound to human erythrocytes, suggesting PkNBPXa is 
currently the only known PkNBP protein involved in human erythrocyte invasion 
(Semenya et al., 2012).  
Recent work has shown that the Pknbpxa gene is essential for P. knowlesi invasion of 
human erythrocytes (Moon et al., 2016, Meyer et al., 2009, Semenya et al., 2012). The 
Pknbpxa gene was disrupted while cultured in macaque erythrocytes in vitro, allowing 
invasion of macaque erythrocytes using Pknbpxb (Moon et al., 2016). When transferred 
to human erythrocytes merozoites lacking Pknbpxa were able to bind to the human 
erythrocyte surface but were unable to invade (Moon et al., 2016). No erythrocyte 
receptor has been identified for PkNBPXa binding is not restricted to Duffy positive 
erythrocytes (Semenya et al., 2012). Recent evidence has shown that the Pknbpxa gene 
is dimorphic, and individual residues only present in the more diverse cluster 2 type 
Pknbpxa are associated with high parasitaemia (Ahmed et al., 2014, Pinheiro et al., 
2015). Evidence of polymorphisms in invasion genes associating with high parasitaemia 
has not been reported for other RBPs. However this may be due to both the number of 
RBP members, and the redundancy shown between PfRhs and EBAs during invasion in 
P. falciparum. However, as Pknbpxa is essential for P. knowlesi invasion these 
individual residues may alter the affinity for the PkNBPXa protein to, the as yet 
unknown, erythrocyte receptor resulting in a stronger binding or more interactions with 
erythrocytes which in turn could lead to a higher parasitaemia. 
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Table 1.2 Currently known RBP and DBP proteins in P.falciparum, P. vivax and P. knowlesi. 
Species Protein RBC Receptor Reference 
P. falciparum    
 Rh1 Unknown– Receptor Y Triglia et al., 2005 
 Rh2a Unknown– Receptor Z Gunalan et al., 2011 
 Rh2b Unknown– Receptor Z Gunalan et al., 2011 
Pseudogene Rh3 -  
 Rh4 Complement receptor 1 Tham et al., 2010 
 Rh5 Basigin Crosnier et al., 2011 
 EBA-175 Glycophorin A Orlandi et al., 1992 
 EBA-181 Unknown– Receptor W Mayer et al., 2008 
 EBA-140 Glycophorin C Maier et al., 2003 
 EBL1 Glycophorin B Mayer et al., 2009 
Pseudogene EBA-165 - Triglia et al., 2001 
P. vivax    
 RBP1a Unknown Hester et al., 2013 
 RBP1b Unknown Hester et al., 2013 
 RBP2a Unknown Hester et al., 2013 
 RBP2b Unknown Hester et al., 2013 
 RBP2c 
(PvRBP2) 
Unknown Hester et al., 2013 
Pseudogene RBP2d - Kosaisavee et al., 
2012 
Pseudogene RBP3 - Kosaisavee et al., 
2012 
 DBP1 DARC Miller et al., 1976, 
Wertheimer et al., 
1989 
 DBP2 unknown Gunalan et al., 2016 
P. knowlesi    
 NBPXa Unknown Meyer et al., 2009 
 NBPXb Unknown Meyer et al., 2009 
Pseudogene NBP3 - Meyer et al., 2009 
 DBPα DARC Singh et al., 2005 
 DBPβ Unknown Singh et al., 2005 
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    Project aims and objectives 
The hypothesis of this work is that point mutations present in clinical Pknbpxa 
sequences are responsible for an increased parasite fold increase resulting in high 
parasitaemia, a marker of severe malaria.  The aim was to develop a translational 
approach, testing clinical associations with severe malaria in vitro. This would be 
achieved by replacing Pknbpxa in the PkA1-H.1 clone with a dimorphic copy containing 
mutations with putative associations with high parasitaemia.  
In order to achieve this, further genome sequencing of clinical sequences will be 
required. As our Biobank of patient samples are frozen without leukocyte depletion the 
parasite DNA will only compose a small proportion of the total DNA. In order to 
produce P. knowlesi DNA samples suitable for whole genome sequencing, we require 
an improved and more standardised leukocyte depletion method for frozen clinical 
samples. By introducing the Plasmodipur filter to the workflow of Ahmed et al., (2014) 
we aim to test the leukocyte depletion of mock clinical samples, analysing the quantities 
of human and P. knowlesi DNA pre and post leukocyte depletion using TaqMan qPCR. 
Following optimisation of the leukocyte depletion method we aim to progress to the 
leukocyte depletion of clinical samples, which if suitable would be genome sequenced.  
Following on from this, the clinical genome sequence data from the above aims will be 
added to the current 6 genome sequences already available. The genome data will be 
mapped to the reference genome sequence, and variant positions identified. Using this 
data, the full length cluster 2 Pknbpxa gene sequences will established and analysed for 
mutations associated with high parasitaemia. The cluster 2 Pknbpxa sequence will be 
recreated as a codon optimised synthetic Pknbpxa gene, with putative residues 
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associated with high parasitaemia introduced singly to the cluster 2 Pknbpxa sequence. 
Using published transfection methods different lines will be created replacing the 
parental Pknbpxa gene with the cluster 2 type sequences with and without residues with 
a putative association with high parasitaemia. Phenotyping clones of each line will be 
carried out analysing growth rate using flow cytometry, and competition assays to 
establish if clones containing single residue changes dominate the parasite population 
showing a growth advantage. 
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Chapter 2:   Materials and Methods 
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Section 1:     List of Reagents 
  
Reagent Manufacturer Product Code 
Agarose Bioline BIO-41026 
AlbuMAX
™
 II Gibco®, Invitrogen™ 11021029 
Ampicillin  Sigma-Aldrich 10835242001 
Antarctic Phosphatase New England Biolabs M0289S 
Anti-HA (Mouse) Sigma-Aldrich H9658 
Anti-Mouse (Goat) Alexa®-568 Invitrogen™ A1104 
Anti-HA (Mouse) Abcam 18181 
Basic Parasite Nucleofector® Kit 2 Lonza VAMI-1021 
Β-Mercaptoethanol Sigma-Aldrich M3148 
Buffered Tablets pH 7.2 VWR  36310W 
Bovine Serum Albumin Sigma-Aldrich A9647-100 
Calcium Chloride (CaCl2) Sigma-Aldrich C3881 
CO2
 
:O2: N2, L cylinder BOC 509965719 
D-(+)-Glucose Gibco®, Invitrogen™ 15023021 
Dimethyl sulfoxide Sigma-Aldrich D5879 





DpnI Thermo-Scientific FD1703 
Distilled water, DNase/RNase free Gibco® Invitrogen™ 10977-035 
D-Sorbitol Sigma-Aldrich 85529 
EDTA BD Vacutainer® Becton, Dickinson 
and Company 
366643 
Efficiency™ Dh5α™ E. coli Invitrogen™ 18265017 
EGTA Sigma-Aldrich E3889 
ElectroTen-Blue Electroporation 
Competent E. coli 
Agilent 200159 
Ethanol absolute VWR Chemicals 20821.330 
 




Gentamicin Reagent (50 mg/mL) Gibco®, Invitrogen™ 15750-060 
Glacial Acetic acid  Fisher Scientific A/0360/PB17 
Glycerol Sigma-Aldrich G2025 
GoTaq® G2 Flexi DNA polymerase Promega M7801 
Gurr® Giemsa’s improved R66 
solution 
VWR Chemicals 350864X 
HA-tagged Positive Control Thermo Scientific 26180X 
HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid) 
Gibco®, Invitrogen™ 15630-080 
Hoechst 33342  Thermo Scientific 62249 
Horse serum Gibco®, Invitrogen™ 11510516 
Histodenz™ Sigma-Aldrich D2158 
Human AB serum Interstate Blood 
Banks 
N/A 
Hydrochloric acid (HCl) Sigma-Aldrich 71826 
Hyperladder™ 1kb Bioline BIO-33053 
Hyperladder™ 50bp Bioline BIO-33054 
Hypoxanthine Sigma-Aldrich H9377 
Immersion Oil Sigma-Aldrich 5178650 
Instagene™ Matrix Bio-Rad 7326030 
KpnI restriction enzyme Promega R6341 
LB broth Sigma-Aldrich L3022 
LB broth with lennox agar Sigma-Aldrich L2897 
L-glutamine Sigma-Aldrich G8540 
MACs LD column MACs, Miltenyi 
Biotec 
130-042-901 
Magnesium Chloride (MgCl2) VWR 25108260 
MidiMACs MACs, Miltenyi 
Biotec 
130-042-302 
Methanol Fisher Scientific M/4000/17 
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NotI restriction enzyme New England Biolabs R0189S 
NucleoBond® Xtra Maxi Macherey-Nagel 740414.10 
NucleoSpin® Gel and PCR Clean-up Macherey-Nagel 740609.50 
NuPAGE LDS Sample buffer (4x) NuPAGE® Novex® NP0008 
P3 Primary Cell solution Lonza PBP3-02250 
Paraformaldehyde Fisher P/0840/53 
Phosphate buffered saline, 10x  Gibco®, Invitrogen™ 70011-036 
Phusion® New England Biolabs M0530L 
Plasmodipur  Europroxima 8011Filter10u 





Pyrimethamine Sigma-Aldrich P4200000 
QIAamp® DNA Blood Mini Kit Qiagen 51104 
QIAamp® DNA Mini Kit Qiagen 51304 
QIAprep® Spin Miniprep Kit Qiagen 27104 
RPMI 1640 with GlutaMAX™ Gibco®, Invitrogen™ 61870-010 
SacII restriction enzyme Promega R6221 
Saponin Sigma-Aldrich 47036-50G-F 
Sodium Acetate Sigma-Aldrich S8750 
Sodium Chloride Fisher Scientific S/3160/60 
Sodium Hydroxide Fisher Scientific S/4920/53 
SpeI restriction enzyme Promega R6591 
SYBR® Green I Invitrogen™ S7563 
SYBR® Safe Invitrogen™ S33102 
T4 ligase Thermo-Scientific M1801 





TaqMan® Universal PCR Master Mix Applied Biosystems® 
Invitrogen™ 
4304437 
Thermo Scientific™ Pierce™ Hoechst 
33342 Stain 
Thermo Scientific 62249 
Tris EDTA Buffer Sigma-Aldrich 93283 
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Triton X-100 Sigma-Aldrich T8787 
Trizma® Base Sigma-Aldrich T1503 
Tween® 20 Sigma-Aldrich P2287 
UltraPure™ 10x Tris-Borate-EDTA 
(TBE) Buffer 
Gibco®, Invitrogen™ 15581044 
Whatman paper, 11 µm Sigma-Aldrich Z274852 
Whatman paper, 6 µm Sigma-Aldrich Z240478 
XmaI restriction enzyme New England Biolabs R0180S 
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Section 2:   Cell Culture 
2.1    Cell Culture Solutions 
2.1.1    D-glucose  
Four grams of D-glucose (Invitrogen™) was dissolved in 40 mL of RPMI 1640 
GlutaMAX (Invitrogen™) to obtain a 0.1 g/mL solution. Aliquots of 10 mL were frozen 
at -20ºC. 
2.1.2   Heat inactivation of serum 
Horse serum (Invitrogen™) was heat inactivated in a water bath at 56ºC for 30 minutes. 
The serum was divided into aliquots and stored at -40ºC. 
2.1.3   Sodium hydroxide 
A 1M sodium hydroxide (Fisher Scientific) solution was made by dissolving 4 g of 
sodium hydroxide in 100 mL of distilled H2O. 
2.1.4   Hypoxanthine  
A 25 mg/mL solution of hypoxanthine (Sigma-Aldrich) was made by dissolving 0.1 g 
of hypoxanthine (Sigma-Aldrich) in 4 mL sodium hydroxide 1M. Aliquots of 1 mL 
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2.1.5   L-glutamine 
A 15 mg/mL solution of L-glutamine (Sigma-Aldrich) was made by dissolving 0.6 g of 
L-glutamine (Sigma-Aldrich) in 40 mL of RPMI 1640 GlutaMAX® (Invitrogen™). 
Aliquots of 1 mL were frozen at -20ºC. 
2.1.6   Incomplete medium 
RPMI 1640 containing GlutaMax® (Invitrogen™) was by supplemented with 10 mL 
0.1 g/mL D-glucose stock (Sigma-Aldrich) (2 g/L), 12.5 mL HEPES buffer 
(Invitrogen™) (5.957 g/L), 1 mL 25 mg/mL hypoxanthine stock (Sigma-Aldrich) (50 
mg/L) and 250 μL 50 mg/mL gentamicin sulphate (Invitrogen™) (25 mg/L) to give 500 
mL final volume. Incomplete medium was filter sterilised and stored at 4ºC for 4 weeks. 
2.1.7   Complete medium 
Complete medium was made by adding 10 mL 15 mg/mL L-glutamine stock solution 
(Sigma-Aldrich) (0.3 g/L) and 2.5 g AlbuMAX® (Invitrogen™) (5 g/L) to incomplete 
medium to give a final volume of 450 mL. Medium was warmed to dissolve the 
AlbuMAX® (Invitrogen™) before filtration through a 0.22 μm PES/PVDF 500 mL 
filter unit (Millipore/Nalgene). 50 mL of heat inactivated horse serum (Invitrogen™) 
was added to the sterile medium for a 10% (v/v) concentration of horse serum in 
complete medium. Complete medium was stored at 4ºC for 2 weeks. 
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2.1.8   Optiprep synchronisation solution 
Briefly, 1.25 mL of Optiprep was added to 4.75 mL sterile PBS pH 7.4. for a 25% v/v 
solution. The 25% solution was filter sterilised using a 0.22 µm PES filter. 
2.1.9   Histodenz stock solution 
A 27.6% w/v Histodenz solution was made by dissolving 27.6 g of Histodenz powder 
(Sigma-Aldrich) in 80 mL distilled H2O and heating to 60ºC until in solution. 1 mL of     
1 M HEPES (Invitrogen™) was added for a 10 mM concentration and adjusted to pH 7. 
The solution was adjusted to 100 mL using distilled H2O and filter sterilised through a 
0.22 μm PES filter. The Histodenz stock solution was stored as a 27.6% stock solution 
at 4ºC 
2.1.10  Histodenz synchronisation solution 
A 55% (v/v) Histodenz synchronization solution was made by adding 55 mL of the 
27.6% (w/v) Histodenz solution to 45 mL sterile incomplete medium. The 55% (v/v) 
Histodenz synchronization solution was stored at 4ºC.  
2.1.11 Freezing solution 
The freezing solution was made by combining 14 mL of 100% glycerol (Sigma-
Aldrich), 0.324 g sodium chloride (110.9 mM) (Fisher Scientific), 1.512 g of D-sorbitol 
(166 mM) (Sigma-Aldrich) and 36 mL distilled H2O. The freezing solution was filter 
sterilised through a 0.22 μm PES filter and stored at 4ºC. 
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2.1.12 Cryoretrieval solution 
A 3.5% (w/v) sodium chloride solution was made by adding 3.5 g of sodium chloride 
(Fisher Scientific) to 100 mL of distilled H2O. The cryoretrieval solution was filter 
sterilised through a 0.22 μm PES filter and stored at 4ºC. 
2.1.13 Phosphate buffered solution pH 7.2 
One phosphate buffer tablet (VWR), pH 7.2, was dissolved in 1 L of distilled H2O. 
2.1.14 Cytomix transfection solution (pH 7.6) 
Cytomix transfection solution was made using the stock buffers detailed in Appendix A. 
A 100 mL working solution was made in distilled H2O consisting of; 120 mM KCl,  
0.15 mM CaCl2, 2 mM EGTA, 5 mM MgCl2, 25 mM HEPES, 10 mM KH2PO4/K2HPO4. 
The pH was adjusted to pH 7.6 then filter sterilized through a 0.22 μm PES filter and 
stored at 4ºC. 
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2.2    Cell Culture Techniques 
2.2.1   Blood collection 
Ethical approval was obtained from the University of St Andrews Teaching and 
Research Ethics Committee (UTREC) to collect whole blood from volunteers with 
signed consent. Ethics forms, information form and consent form can be found in 
Appendix B.  
2.2.2   Preparation of blood for parasite culture 
Ten mL of whole blood collected into EDTA vacutainer tubes (Becton, Dickinson and 
Company) was transferred to a sterile centrifuge tube (Greiner) and centrifuged at 611 
rcf for 8 minutes with brake removed. The top plasma layer and the concentrated 
leukocyte layer, the buffy coat, on top of the red blood cell layer were removed by 
gentle aspiration. The remaining RBC lower fraction was washed twice by adding an 
equal volume of incomplete medium (section 2.1.6), mixing by gentle inversion and 
centrifuged as above. Following the final wash step, the RBCs were resuspended in an 
equal volume of incomplete medium (section 2.1.6) giving a 50% haematocrit. The 
RBCs were stored at 4ºC for up to 3 weeks. 
2.2.3    Routine in vitro culture of the P. knowlesi  
  PkA1-H.1 clone in human erythrocytes 
The P. knowlesi PkA1-H.1 clone (kindly donated by Dr Moon, LSHTM) was 
maintained in human RBCs following buffy coat removal (section 2.2.2) at a 2% 
haematocrit in complete medium (section 2.1.7). Medium was replaced every second 
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day and fresh RBCs were added to dilute the culture and keep the parasitaemia below 
5% for routine culture. 
2.2.4    Parasite synchronisation using MACS LD column 
An LD MACs column (Miltenyi Biotec) attached to a MidiMACs (Miltenyi Biotec) 
magnet was equilibrated with 3 mL of incomplete medium (section 2.1.6) and allowed 
to drip through. A PkA1-H.1 culture (> 100 µL of packed RBCs) containing mostly 
pigmented parasites was pelleted at 181 rcf, and resuspended in 4.5 mL incomplete 
medium (section 2.1.6). The infected RBC (iRBC) suspension was applied to the LD 
column and allowed to drip through. The pigmented iRBCs bind to the magnetised 
column if they contain hemozoin, allowing the uninfected RBCs and early stage 
parasites to pass through the column and be collected in a 50 mL tube. The column was 
washed three times with 5 mL incomplete medium (section 2.1.6) until the flow through 
was no longer red. The LD column was detached from the MACs magnet and 5 mL 
incomplete medium (section 2.1.6) was added and pushed through the column to flush 
out the pigmented iRBCs that were collected in a fresh tube. The recovered iRBCs were 
then pelleted at 181 rcf for 5 minutes. 
2.2.5   Optiprep synchronisation 
Briefly, cultures of PkA1-H.1 were centrifuged at 181 rcf and supernatant removed. The 
pelleted PkA1-H.1 culture was resuspended to a 50 % haematocrit and 2 mL was gently 
layered onto 5 mL of 25% sterile Optiprep in a 15 mL centrifuge tube. The tubes were 
centrifuged at 920 rcf for 12 minutes with brake removed. The upper brown layer 
containing schizonts was removed and added to 5 mL of incomplete medium (section 
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2.1.6) to neutralize the gradient. The resuspended schizonts were centrifuged at 181 rcf 
for 5 minutes. The supernatant was removed and the schizont pellet was resuspended in 
complete medium (section 2.1.7) and transferred to a 1.5 mL centrifuge tube. The 
schizont suspension was centrifuged briefly and the packed cell volume was estimated. 
The schizonts were resuspended in 1 mL complete medium (section 2.1.7) and divided 
for transfections or added to fresh RBCs and complete medium (section 2.1.7) for 
culturing. 
2.2.6   Histodenz gradient synchronisation  
For each gradient synchronisation, 5 mL of a Histodenz synchronisation solution 
(section 2.1.9) was added to 15 mL centrifuge tubes. Cultures of PkA1-H.1 were 
centrifuged at 181 rcf and supernatant removed. Pelleted cells were resuspended at a 
50% haematocrit and 2 mL of this was gently transferred to the top of the 5 mL 55% 
Histodenz density gradient. Tubes were centrifuged at 920 rcf for 12 minutes with no 
brake. The upper brown layer enriched with schizonts was removed and added to 
incomplete medium (section 2.1.6). The schizont suspension was then centrifuged at 
181 rcf for 5 minutes. The supernatant was removed and the schizont pellet was 
resuspended in complete medium (section 2.1.7) and transferred to a 1.5 mL centrifuge 
tube which was pulse centrifuged for 30 seconds. The schizont packed cell volume was 
estimated, resuspended in 1 mL complete medium and divided into aliquots for 
transfection or added to fresh RBCs and complete medium (section 2.1.7) for culturing. 
2.2.7   Cryopreservation 
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For cryopreservation of the P. knowlesi line PkA1-H.1, 15 mL cultures at a 2% 
haematocrit (300 µL) containing predominantly ring stage parasites (>5% parasitaemia) 
were centrifuged at 611 rcf and the supernatant was removed. The 300 µL of pelleted 
PkA1-H.1 culture were combined with 700 µL of warm freezing solution (section 
2.1.10). The 1 mL suspension was transferred to cryovials and immediately stored in 
LN2. 
2.2.8   Cryoretrieval 
Cryovials containing the cryo-preserved PkA1-H.1 culture were removed from LN2, 
thawed rapidly at 37ºC and resuspended in 1 mL of pre-warmed cryoretrieval solution 
(section 2.1.12). Cells were pelleted via centrifugation at 181 rcf for 5 minutes. The 
supernatant was removed and the cells resuspended in 1 mL cryoretrieval solution. Two 
further wash steps in cryoretrieval solution were performed. The pelleted PkA1-H.1 
infected RBCs were resuspended in complete medium (section 2.1.7) and fresh RBCs at 
a 2% haematocrit. The PkA1.H-1 culture was then gassed and returned to 37ºC. 
2.2.9   Monitoring in vitro PkA1-H.1 cultures 
Blood films were made daily for monitoring the growth of P. knowlesi A1-H.1 cultures 
in human RBCs. Approximately 30 µL of the culture was removed from the flask (T-25 
or T-75) and centrifuged in a 1.5 mL centrifuge tube at 900 rcf for 1 minute. The 
supernatant was removed and the RBC pellet was gently mixed using a pipette tip. 
Approximately 1 µL of resuspended cells were placed onto a glass microscope slide 
and, using the edge of another microscope slide a monolayer created. The monolayer – 
thin blood film, was air dried and fixed with 100% methanol (Fisher Scientific), and 
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stained with a 5% Gurr Giemsa’s improved R66 solution (VWR Chemicals) in buffered 
H2O (pH 7.2) for 30 minutes.  
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Section 3:   Microscopy 
2.3.1   Permeabilisation solution 
The permeabilisation solution for immunofluorescence studies was prepared by adding 
50 µL of Triton X-100 to 50 mL 1x PBS to give a 0.1% (v/v) Triton X-100 solution in 
PBS. 
2.3.2   Blocking solution 
A 3% (w/v) bovine serum albumin (BSA) blocking solution as per (Ruecker et al., 
2012) was made by dissolving 1.5 g of BSA in 50 mL 1x PBS. 
 
  87 
2.4    Microscopy Techniques 
2.4.1   Light microscopy 
Thin blood films were examined by light microscopy for parasitaemia and determining 
the parasite lifecycle stages. Parasitaemia was determined by examining a monolayer of 
the thin film using a Miller reticle, counting all RBCs inside the inner square and 
touching the lower and right edges and iRBCs in the larger square and those touching 
the lower and right edges. The parasitaemia was determined by using the following 
equation 
𝑖𝑅𝐵𝐶𝑠 𝑖𝑛 𝐿𝑎𝑟𝑔𝑒 𝑆𝑞𝑢𝑎𝑟𝑒
𝑅𝐵𝐶𝑠 𝑖𝑛 𝑆𝑚𝑎𝑙𝑙 𝑆𝑞𝑢𝑎𝑟𝑒 𝑥 9 
 𝑥 100 = % 𝑝𝑎𝑟𝑎𝑠𝑖𝑡𝑎𝑒𝑚𝑖𝑎 
2.4.2   Immunocytochemistry  
Immunofluorescence was performed as per Ruecker et al, 2012 (Ruecker et al., 2012). 
Briefly, thin blood films were dried and placed at -80ºC in zip-lock bags. Slides were 
removed from -80ºC and allowed to come to room temperature. Thin films were fixed 
with 4% paraformaldehyde in PBS for 30 minutes. Cells were permeabilised with 0.1% 
Triton X-100 in PBS for 10 minutes at room temperature followed by three 10 minute 
PBS washes. Slides were blocked at room temperature in 3% BSA in PBS for 1 hour. 
Immediately following this the slides were incubated at room temperature with 1:200 
mouse anti-HA (Sigma-Aldrich), Table 2.4, containing 1% BSA for 1 hour. Three 10 
minute washes in 1x PBS containing 0.1% Tween-20. Slides were stained with 1:1,000 
goat anti-mouse Alexafluor
®
568 (Thermo Fisher) diluted in 1% BSA for 1 hour at room 
temperature. Slides were washed three with PBS and immediately stained with 1 ug/mL 
Hoechst 33342 for 15 minutes. Coverslips were mounted with FluorSave
®
 reagent and 
imaged using the Leica DM5500 B. 
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2.4.3   Fluorescence microscopy  
Transfected parasites with the Pkconp230pGFP plasmid were resuspended in 15 µL 
incomplete medium (Section 2.1.6) and stained with 1 ug/mL Hoechst 33342 for 10 
minutes. The cell suspension was mounted on Vaseline edged slides sealed with a 
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Section 4:   Molecular Biology  
2.5    Molecular Biology Reagents 
2.5.1    Tris-Borate-EDTA (TBE) (1x) 
UltraPure TBE 10x (Gibco) was diluted with distilled H2O for a 1x working 
concentration. 
2.5.2   Sodium acetate pH 5, 3 M 
A 3M sodium acetate solution was prepared by dissolving 20.4 g of sodium acetate 
(Sigma-Aldrich) in 50 mL of distilled H2O. The pH was adjusted to 5.3 using glacial 
acetic acid (Fischer Scientific). 
2.5.3   Phosphate buffered saline (PBS) (1x concentration) 
PBS 10x (Invitrogen™) was diluted with distilled H2O for a 1x working concentration. 
2.5.4   Tris- buffered saline (TBS) 10x concentration 
A 10x Tris-Buffered saline solution was made by dissolving 12 g of Trizma® Base (20 
mM) (Sigma-Aldrich) and 44 g NaCl (150 mM) (Fisher Scientific) in 480 mL of 
distilled H2O. The pH was adjusted to pH 7.6 using concentrated HCl before adjusting 
the volume to 500 mL. 
2.5.5    Tris-buffered saline (TBS) 1x concentration 
A 1x TBS solution was made by diluting 100 mL 10x TBS with 900 mL distilled water. 
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2.5.6    Tris-buffered saline 0.1% Tween® 20 (TBS-T)  
One millilitre of Tween®-20, 1.095 g/mL (Sigma-Aldrich) was added to 1 L of 1x TBS 
for a 0.1% Tween®-20 concentration. 
  
 
  91 
2.6    Molecular Biology Methods 
2.6.1    Qubit DNA quantification 
DNA was quantified using the Qubit 2.0 system. A master-mix solution was created by 
adding High Specificity (HS) buffer and HS dye at a ratio of 189:1 respectively. 10 µL 
of either 10 ng/uL or 0 ng/uL standards were added to 190 µL of master-mix, vortexed 
for 2 seconds and incubated at room temperature for 2 minutes. Standards were then 
read on the Qubit 2.0 to create a standard curve. For experimental samples, 2 µL of 
DNA was added to 198 µL of the HS mastermix, and processed as previously for the 
standards.  
2.6.2    NanoDrop 2000 
The NanoDrop 2000 spectrophotometer was used to measure the DNA concentrations 
of samples. Briefly, 1 µL of DNase free water was used as a blank before 1 µL of DNA 
was measured. DNA quantity was measured in ng/uL and DNA purity represented as 
260/280. 
2.6.3    Gel electrophoresis  
Agarose (Bioline) was added to 1x Tris-borate-EDTA buffer (Gibco 10x stock) to make 
0.8-2% agarose gels. The agarose solution was heated until the solution was clear. The 
gel was allowed to cool and 3.5 µL of SYBR Safe (Invitrogen) was added per 50 mL 
gel. The gel was allowed to set in an electrophoresis cassette and submerge with 1x 
TBE buffer. Samples were prepared in 5 x loading dye (Bioline, BIO-37045) and then 
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electrophoresed at 110 V for 1 hour. Molecular ladders used were Hyperladder 1 kb 
(Bioline) and Hyperladder 50 bp (Bioline). 
2.6.4    Restriction digestion of plasmid DNA  
Plasmid DNA was digested as per the manufacturer’s instruction. Briefly, plasmid DNA 
was purified using Miniprep or Maxiprep (section 2.8.6 and 2.8.7) and added to 1x 
restriction digest buffer, 0.1 mg/mL BSA (for Promega enzymes) and 5-50 units of 
restriction enzyme, Table 2.1. The reaction was incubated at 37ºC for 1 hour per 
microgram of plasmid DNA. Incubation time varied depending on quantity of DNA and 
units of enzyme. The digestion was then heat inactivated at 65ºC for 20 minutes. 
Table 2.1  Restriction enzymes and compatible buffers. 
Restriction Enzyme Source Buffer 
NotI (NEB) E. coli Cutsmart 
XmaI (NEB) E. coli Cutsmart 
SpeI (Promega) S. natans B / C 
SacII (Promega) S. achromogenes C 
KpnI (Promega) E. coli J 
 
2.6.5    Gel extraction  
Size separated DNA was extracted from Gels using the NucleoSpin® Gel and PCR 
Clean-up, as per the Macherey-Nagel instructions. Briefly, 200 µL of NTI buffer was 
added per 100 mg of excised agarose gel and incubated for 5-10 minutes at 50ºC. 
Samples were centrifuged in the silica columns provided at 11,000 rcf for 30 seconds 
followed by two 700 µL washes with NT3 buffer using the same centrifugation 
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conditions. The column was then centrifuged at 11,000 rcf for 1 minute to remove 
residual NT3 buffer. Target DNA was eluted using 20 µL of nuclease free water 
(Gibco) pre-warmed to 50ºC and incubated for 5 minutes at room temperature. DNA 
concentration and quality was analysed using the NanoDrop 2000 spectrophotometer. 
2.6.6    Ligations 
Insert DNA and vector plasmid DNA were digested as described previously (Section 
2.6.4). The digested vector was incubated with 1 µL of Antarctic Phosphatase (NEB) 
and 1x Antarctic phosphatase buffer for 1 hour at 37ºC and heat inactivated at 70ºC for 
5 minutes. Digested DNA was separated by gel electrophoresis as described previously 
(section 2.6.3). DNA was visualised using a dark reader transilluminator (Clare 
Chemical Research) and the linear fragment extracted (section 2.6.3 - 2.6.6). The DNA 
concentration was measured using a NanoDrop 2000 sepctrophotometer (section 2.6.2) 
and the fragment ligated into the vector plasmid at insert:vector (I:V) molar ratios of 
either 3:1 or 5:1. The reactions were carried out in a 10 µL volume in 1.5 mL 
microcentrifuge tubes. Ligation buffer was used at a 1x concentration and 5 units of T4 
Ligase were used per reaction (ThermoFisher). The ligation mixture was then incubated 
at room temperature for 16 – 48 hours. 
2.6.7    DNA extraction from blood samples 
DNA was extracted from whole blood and PkA1-H.1 culture using the QIAgen DNA 
Blood Mini as per the Qiagen whole blood protocol. Briefly, 20 µL proteinase K and         
4 µL of RNase A (100 mg/ml stock) was added to 200 µL of whole blood or PkA1-H.1 
culture. Cells were lysed with the addition of 200 µL of AL buffer and vortexed for 15 
 
  94 
seconds. Samples were incubated at 56ºC for 10 minutes. Microcentrifuge tubes 
containing the lysed samples were centrifuged briefly to collect the solution and 200 µL 
of ethanol (96-100%) added prior to agitation via vortexing for 15 seconds. Samples 
were added to a DNA purification column and centrifuged at 6,000 rcf for 1 minute. 
The column was then washed with 500 µL of AW1 buffer, and subsequently washed 
with 500 µL AW2 centrifuging at 20,000 rcf 3 minutes. The column was centrifuged for 
1 minute to remove residual solution and then 50 – 200 µL of DNase- and RNase-free 
water, pre-warmed to 50ºC, was added to the column and incubated for 5 minutes at 
room temperature. Eluate was collected into a 1.5 mL Eppendorf via centrifugation at 
6,000 g. DNA was quantified using the NanoDrop 2000 spectrophotometer. 
2.6.8    InstaGene DNA extraction  
DNA was extracted from 3-10 µL of P. knowlesi A1-H.1 in vitro culture packed cell 
volume. Pelleted cells were incubated for 30 minutes in 1 mL DNase- and RNase-free 
water (Gibco). Microcentrifuge tubes were centrifuged at 13,500 rcf for 3 minutes. All 
but approximately 20 µL of supernatant was removed. Pelleted lysed RBC material and    
20 µL supernatant were combined with 100 µL InstaGene matrix and incubated at 56ºC 
for 30 minutes. Following the incubation the suspension was vortexed vigorously for 10 
seconds and boiled at 100ºC for 8 minutes. Boiled samples were vortexed as before and 
centrifuged as previously. The DNA containing supernatant was removed and 10 µL 
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2.6.9    Ethanol precipitation 
Sodium acetate (3 M) at pH 5.2 was added to a DNA solution for 10% final 
concentration. Three volumes of >96% ethanol was added to the DNA sodium acetate 
solution. The solution was vortexed and incubated at -20ºC for 1 hour. The DNA 
ethanol solution was centrifuged at 16,000 rcf for 10 minutes at 4ºC. The supernatant 
was decanted and 1 mL of 70% ethanol added and the centrifugation repeated. The 
supernatant was decanted and the DNA pellet was air dried. The DNA was resuspended 
in DNase- and RNase-free water or TE buffer (10 mM TrisHCl, 1mM EDTA, pH 8).  
2.6.10 DNA sequencing to verify cloning steps 
To validate ligations and mutagenesis based experiments, miniprep extracted DNA was 
sequenced using the facilities offered by the Dundee Sequencing Unit. Greater than 600 
ng of DNA at 20 ng/uL was submitted along with 15 µL of primer at 3.2 µM was 
submitted for sequencing. The DNA was sequenced on the applied Biosystems 3730 
DNA analyser (or the Applied Biosystems 3730XL DNA analyser). 
2.6.11 Restriction digestion of plasmid DNA for           
   transfection  
Briefly, 100 µg of Pkconpknbpxa_f1-3 or Pkconp230pGFP plasmid was suspended in   
500 µL of DNase- and RNase-free water (Gibco) containing 10x CutSmart ™ Buffer 
(NEB), and 50 units (5 µL) of the restriction enzyme KpnI. The restriction digest 
mixture was incubated at 37ºC for 5 hours followed by immediate ethanol precipitation 
of the linearised DNA (section 2.6.9). The linearised DNA pellet was resuspended in 
20-40 µL of DNase- and RNase-free water (Gibco) or TE buffer (10 mM TrisHCl, 1 
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mM EDTA, pH 8). A 1 µL sample was removed and diluted 1:10 to quantify the DNA 
concentration using the NanoDrop 2000 spectrophotometer (section 2.6.2).  
 
2.6.12 PCR 
Transfections were validated using PCR with primers specific for the Pkconpknbpxa_f1-
3 plasmid, the native pknbpxa gene and the flanking regions of the Pknbpxa gene (Table 
2.2). Briefly, PCR reagents were used according to the manufacturer’s instructions and 
optimised cycling conditions (Table 2.3.1 and 2.3.2). Annealing temperature and 
elongation time were dictated by primer sequence and amplicon length. DNA extracted 
from cultured PkA1-H.1 in vitro transfected lines were used as template.   
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Table 2.2  Table of primers 










F ag382-3cc CCGGGATAATccCGGTGATGATGATC 
R ag382-3cc CATCATCACCGggATTATCCCGGG 
F- gt1043/4ag CCCTGGTTGagAAAAGCCTGGATC 
R- gt1043/4ag CCAGGCTTTTctCAACCAGGGTTT 
F- g1982a GCATTGATAaCAGCAGCAGCGCAG 






Klaassen F GGGCAACGTGCTGGTCTG 




hDNA probe YAKYE -CTGGCCCATCACTTTGGCAAAGAA-BHQ1 
Pk probe FAM-CTCTCCGGAGATTAGAACTCTTAGATTGCT-BHQ1 
All primers were obtained from Eurofins Genomics MWG Operon  
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Table 2.3.1  GoTaq® G2 Flexi PCR mastermix 
Reagent Stock concentration Volume (µL) Final concentration 
F-Primer 10 µM 0.5 0.25 µM 
R-Primer 10 µM 0.5 0.25 µM 
Buffer 5x 4 1x 
MgCl2  25 mM 1.6 2 mM 
Nucleotide mix 
(dNTPs) 
1 M 0.4 0.2 mM 
GoTaq Flexi G2 
Polymerase 
10 U/µL 0.1 0.05 U/µL 
DNA - 2  >1ng 
H2O - To 20 µL - 
 
Table 2.3.2  GoTaq® G2 Flex PCR cycling conditions  
Temperature (oC) Time (minutes) Cycles 
94 4 1 
94 0.5  
55-65 1.5 x35  
72 0.5-3  
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Section 5:   Microbiology 
2.7    Reagents for Microbiology 
2.7.1   Ampicillin stock 
A 100 mg/mL ampicillin (Sigma-Aldrich) was created by dissolving 1 g of ampicillin in 
10 mL of distilled H2O. The 100 mg/mL ampicillin stock solution was filter sterilised 
using a 0.22 µm PES filter and stored at -20ºC. 
2.7.2   LB broth 
LB broth was made by dissolving 2 g of LB broth powder (Sigma-Aldrich) per 100 mL 
of distilled H2O. The LB broth was autoclaved and stored at room temperature.  
2.7.3   LB agar plate preparation 
LB agar was made by dissolving 3.5 g of LB broth powder containing Lennox agar 
(Sigma-Aldrich) in 100 mL of double distilled H2O. The LB agar solution was 
autoclaved and cooled to solidify and stored at room temperature. When required, stock 
LB agar was heated until fully melted and cooled prior to antibiotic addition. 100 µL of 
100 mg/mL ampicillin (Sigma-Aldrich) was added to the molten LB agar to a final 
concentration of 100 µg/ml. Approximately 10 mL of LB agar was poured into 10 cm
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2.8    Bacterial Culture Techniques 
2.8.1    Heat shock bacterial transformation 
DH5α Escherichia coli (Invitrogen) cells were thawed on ice and 25 µL transferred to 
fresh microcentrifuge tubes as required. Plasmid DNA less than 10 kb and less than 200 
ng was added to the bacterial cells on ice. The bacteria/DNA mixture was then heated at 
42ºC for 45 seconds and then placed on ice for 2 minutes. 500 µL of LB broth (Section 
2.6.2) was added to the transformed cells and incubated shaking at 210rpm for 1 hour at 
37ºC. The transformed Dh5α E. coli cells were then spread onto LB agar plates (Section 
2.6.3) containing 100 ug/mL ampicillin and incubated at 37ºC overnight. 
2.8.2   Bacterial cell electroporation  
For plasmids >10 kb, bacterial electroporation was used. Briefly, ElectroTen-Blue 
(Agilent) electro-competent E. coli cells were thawed on ice and 35 µL transferred into 
microcentrifuge tubes as required. For any ligation, 5 µL of StrataClean resin was added 
per 10 µL of ligation mixture. The ligation-resin mixture was vortexed for 15 seconds 
and centrifuged at 2,000 rcf for one minute. The supernatant was transferred to a fresh 
microcentrifuge tube and the wash step with the resin was repeated. Following the 
second wash step 5 µL of the supernatant containing the washed DNA from the ligation 
mix was added to 35 µL of ElectroTen-Blue electrocompetent E. coli. The DNA - E. 
coli mixture was then added to a chilled cuvette with a 1 mm gap, tapped to collect the 
solution to the bottom of the cuvette and then pulsed at 2250 Volts (Eppendorf 
Electroporator 2510). Transformed cells were immediately resuspended in 0.5 mL of 
pre-warmed LB broth, transferred to a microcentrifuge tube and incubated shaking at 
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210 rpm for 1 hour at 37ºC. The entire cell suspension was then plated out on LB agar 
plates containing the 100 µg/mL ampicillin (Section 2.6.3) and incubated at 37ºC 
overnight. 
2.8.3   Starter culture 
Bacterial colonies were selected from an LB agar plate or from a glycerol stock using a 
sterile pipette tip which was ejected into 10 mL of LB broth (Sigma-Aldrich) containing 
100 μg/mL ampicillin (Sigma-Aldrich) (section 2.6.1). The bacterial starter culture was 
grown at 37ºC overnight (16-18 hrs) at 210 rpm. 
2.8.4   Overnight culture 
Approximately 1-5 mL of the starter culture was added to 200 - 400 mL of LB broth 
containing 100 μg/mL ampicillin (section 2.6.1). The bacterial cultures were grown at 
37ºC overnight (16 – 18 hrs) at 210 rpm. 
2.8.5   Glycerol stock 
Glycerol stocks of transformed bacteria were made by mixing 750 μL bacterial culture 
with 250 μL 80% sterile glycerol in a microcentrifuge tube giving a final glycerol 
concentration of 20% and stored at -80ºC. 
2.8.6   Plasmid DNA extraction from starter culture E. coli 
Plasmid minipreps (Section 1) were performed according to the manufacurer’s 
instructions. Briefly, 5 – 10 mL of transformed bacterial starter culture was centrifuged 
at 3,200 rcf and the pellet resuspended in 250 µL of buffer A1 before transferring to a 
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microcentifuge tube. Buffer A2 (250 µL) was added to each sample and incubated at 
room temperature for 5 minutes to lyse the bacteria. Following incubation, 300 µL of 
buffer A3 was added to neutralise the lysis solution and the microcentrifuge tube was 
inverted 5 times. The microcentrifuge tube was then centrifuged at 11,000 rcf for 10 
minutes at room temperature. The plasmid containing supernatant was removed and 
added to the miniprep spin column and centrifuged at 11,000 rcf for 1 minute. 500 µL 
of buffer AW was then added to the spin column and centrifuged at 11,000 rcf for 1 
minute, then 600 µL of buffer A4 was added to the spin column and centrifuged at 
11,000 rcf for 1 minute. The spin column was then centrifuged at 11,000 rcf for 2 
minutes without the addition of any buffer to remove residual solution. The spin column 
was placed inside a microcentrifuge tube and 30 µL of nuclease-free water (Gibco) pre-
warmed to 50ºC was added and incubated for 5 minutes at room temperature to elute the 
plasmid DNA. The eluate was collected by centrifugation at 11,000 rcf for 1 minute. 
Plasmid DNA was analysed for concentration and quality on the NanoDrop 2000 
spectrophotometer. Plasmid DNA was stored at 4ºC for short term storage or -40ºC for 
long term storage. 
2.8.7   Plasmid DNA extraction from overnight culture 
    E. coli 
Plasmid maxipreps (Section 1) were performed according to the manufacurer’s 
instructions. Maxipreps was performed as per Macherey-Nagel instruction. Briefly, a 
200 – 400 mL overnight bacterial culture with an OD600 over 2 was collected by 
centrifugation at 6,000 rcf for 15 minutes at 4ºC and the supernatant removed. The 
Bacterial pellet was resuspended in 12 mL of RES buffer containing RNase A, 67 
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µg/mL, and transferred to a 50 mL centrifuge tube. 12 mL of LYS buffer was added to 
the centrifuge tube, inverted 5 times and incubated for 5 minutes at room temperature. 
The lysis buffer was neutralised with the addition of 12 mL of NEU buffer and inverted 
5 times. The maxiprep filter and column was equilibrated with 35 mL of EQU buffer 
before the lysed bacterial solution was added and allowed to drip through the filter and 
column into a waste centrifuge tube. The filter and column was washed with 15 mL of 
buffer EQU and allowed to drip through into the waste tube. The filter above the 
column was discarded and 25 mL of Wash buffer was added to the column and allowed 
to drip through. Plasmid DNA was eluted from the column by adding 15 mL of Buffer 
ELU and allowed to drip into a Nalgene round bottomed centrifuge tube (Nalgene, 
3119-0050). 10.5 mL of isopropanol was added and the mixture vortexed thoroughly. 
The plasmid containing eluate and isopropanol mixture was centrifuged at 15,000 rcf 
for 30 minutes at 4ºC to pellet the DNA. The supernatant was removed and 5 mL of 
70% ethanol was added to the plasmid DNA pellet and centrifuged at 15,000 rcf for 5 
minutes at room temperature. The supernatant was carefully removed and the DNA 
pellet was allowed to air dry for approximately 15 minutes. The DNA pellet was 
reconstituted in 300 µL of nuclease-free water (Gibco), and the concentration and 
quality were analysed using the NanoDrop 2000 spectrophotometer. 
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Chapter 3:   Purification of P. knowlesi DNA from 
      Frozen Whole Blood Samples 
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3.1     Introduction 
Since the first Plasmodium genome was sequenced in 2002 there has been an explosion 
of data arising from genome sequencing (Gardner et al., 2002). This has facilitated 
avenues of research and discoveries that previously would not have been possible, such 
as the discovery of novel proteins, further investigation of variant protein families, 
important epidemiological studies and tracking resistance to antimalarial drugs. To date 
genome sequences are available for all five human malaria species, P. falciparum, P. 
vivax, P. knowlesi and more recently P. malariae and P. ovale (Gardner et al., 2002, 
Carlton et al., 2008, Pain et al., 2008, Rutledge et al., 2017). Furthermore, genome 
sequences are available for the parasite species; P. reichenowi, P. coatneyi, P. 
cynomolgi, P. yoelii, P. berghei, P. gaboni (Tachibana et al., 2012, Carlton et al., 2002, 
Otto et al., 2014a, Otto et al., 2014b, Sundararaman et al., 2016). 
The reference genomes of the majority of Plasmodium species originate from 
experimental lines maintained in vitro or in vivo where high quantities of pure parasite 
DNA can be obtained. However, the sequencing of Plasmodium clinical whole blood 
samples requires the removal of leukocytes and host genomic DNA. The human 
genome is over 100 times larger than the parasite genome (Boissiere et al., 2012) 
resulting in much higher quantities of human DNA (hDNA) in clinical samples 
compared to the parasite genome. If clinical samples are not leukocyte depleted prior to 
DNA extraction, the resulting DNA mixture will primarily consist of hDNA with a very 
small portion of parasite DNA. This in turn results in a low number of reads that map to 
the parasite reference genome, and low read coverage making sequence reliability 
problematic (Bright et al., 2012). There are several published methods for leukocyte 
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depletion on fresh whole blood samples. The methods use a variety of different 
techniques such as; leukocyte depletion using hand packed CF-11 columns (Auburn et 
al., 2011, Chan et al., 2012, Sriprawat et al., 2009, Venkatesan et al., 2012); 
Plasmodipur filters (Grech et al., 2002, Hunt et al., 2004, Hunt et al., 2010, Janssen et 
al., 2001, Otto et al., 2014b, Pain et al., 2008, Roobsoong et al., 2015, Sriprawat et al., 
2009); Lymphoprep density gradient (Venkatesan et al., 2012); anti-HLA antibodies 
(Auburn et al., 2011); and Flow cytometry (Boissiere et al., 2012). Alternative methods 
have been developed to isolate parasite DNA, or remove the human DNA from a non-
leukocyte depleted sample (Bright et al., 2012, Melnikov et al., 2011, Oyola et al., 
2016).  
However, few of the techniques have been trialled on frozen whole blood clinical 
samples. To date, only one filtration method has been used to leukocyte deplete and 
recover parasite material from frozen whole blood (Pinheiro et al., 2015). The frozen 
clinical whole blood samples contain intact leukocytes that have survived freezing along 
with lysed leukocyte, RBC and infected RBC (iRBC) material from the freezing 
process. The filtration method uses layered Whatman filter papers of different pore sizes 
to selectively remove intact leukocytes which have survived the freezing process. The 
eluate containing RBCs, iRBCs and free parasite material is then pelleted and washed 
free of contaminating hDNA (Pinheiro et al., 2015). The authors had access to a 
biobank of clinical frozen whole blood samples from patients infected with P. knowlesi 
which were not leukocyte depleted prior to freezing. Pinheiro et al., (2015) trialled 
various methods of leukocyte depletion on the frozen clinical samples including CF-11 
filtration, but no material was recovered (Personal correspondence Dr Atique Ahmed). 
The final method consisted of three Whatman filter circles each with an 11 µm pore size 
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layered above three Whatman paper circles with pore a size of 6 µm inside the same 10 
mL syringe to create a column. The pore sizes were selected to remove both small and 
large lymphocytes that had survived freezing, but to allow the iRBCs or free parasite 
material to pass through. Although parasite DNA was recovered and P. knowlesi 
genome sequences were obtained, there was consistently a substantial presence of 
hDNA in all samples, demonstrated by only two samples having a PkDNA purity >70% 
(Pinheiro et al., 2015). This work suggests that only high parasitaemia samples would 
be suitable for procesing, due to the consistent hDNA presence after depletion. 
Furthermore, replication of the method with clinical samples with lower parasitaemias 
showed that insufficient hDNA was removed. This would limit the number of suitable 
samples available for leukocyte depletion.  
The aim of this work was to enhance the hDNA depletion ability of the Whatman 
method for clinical frozen whole blood samples, while recovering maximum parasite 
material and to improve standardisation by incorporating a Plasmodipur filter. The 
Plasmodipur filter is a commercially available filter unit which contains two 
membranes. The Plasmodipur filter has been used extensively for leukocyte depletion, 
including leukocyte depletion of P. knowlesi to generate the P. knowlesi reference 
genome (Pain et al., 2008). However, there has been no reported use of the Plasmodipur 
filters on frozen whole blood samples. 
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3.2    Methods 
3.2.1    Whole blood seeded with PkA1-H.1 in vitro culture 
Mock patient samples were created by mixing equal packed cell volumes of the P. 
knowlesi PkA1-H.1 in vitro culture (parasitaemias 1% to 1.5%) and non-leukocyte 
depleted donor whole blood (section 2.2.2). Following mixing, thin blood films were 
prepared to determine the percent parasitaemia and parasite life stage differential 
counts. The mixed seeded whole blood samples were divided into 200 µL packed 
iRBCs aliquots and frozen at -80°C to represent archived clinical samples. Percent 
parasitaemia and life stage of seeded samples are given, see Table 3.1. 
Table 3.1 Parasitaemia and percent life stage of seeded samples used for leukocyte depletion. 
Seeded Sample (SS) Parasitaemia (%) % Parasite Life stage  
(Rings : Trophs : Schizonts)* 
SS1 0.75 32 : 59 : 10 
SS2 0.56 48 : 44 : 07 
SS3 0.54 72 : 22 : 06 
*Parasite life stage was determined using giemsa stained blood films and categorised as ring, trophozoite 
or schizont. The percentage of ring stages, trophozoites and schizonts was counted for each seeded 
sample. 
 
3.2.2    TaqMan quantitative PCR of P. knowlesi and human    
   DNA 
The TaqMan quantitative PCR system allows for accurate quantification of DNA. 
TaqMan probes specific for hDNA and for P. knowlesi DNA (PkDNA) were used as in 
Figure 3.1. Quantitative PCR (qPCR) was used to determine the concentration of 
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parasite and human DNA in seeded or clinical blood samples. Primers were specific for 
the P knowlesi 18S rRNA gene (Rougemont et al., 2004) and the β-globin gene in 
hDNA (Klaassen et al., 2003), primer sequences given in Table 3.2. The P. knowlesi 
TaqMan probe was from (Divis et al., 2010) and the human TaqMan probe from 
(Klaassen et al., 2003), and the sequences are given in Table 3.2. The reagents and 
volumes required for a single 20 µL qPCR reaction are given in Table 3.3. The qPCR 
cycling conditions were an initial denaturation step of 95°C for 10 minutes, followed by 
55 cycles of: 95°C for 15 seconds and 60°C for 1 minute using the Rotor-Gene Q 
(QIAGEN). Primer and probe concentrations were optimised across a range of 









Figure 3.1   Schematic of TaqMan probe qPCR.  
A. The TaqMan probe (P) containing a 5’ fluorophore (R grey box) and 3’ quencher (Q orange box) binds 
to single stranded DNA after the template DNA has been denatured. Primers (blue rectangles) bind to the 
template DNA and extension is facilitated by a DNA polymerase. The close proximity of the quencher (Q) 
to the fluorophore (R) quenches fluorophore fluorescence. B. The strand displacement properties of the 
polymerase causes the fluorophore (R grey box) on the 5’ end of the probe to be dissociated from the 
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probe, which results in the fluorophore no longer being quenched. One fluorescent fluorophore is released 




Table 3.2 TaqMan probes used for qPCR.  





hDNA probe* YAKYE -CTGGCCCATCACTTTGGCAAAGAA-BHQ1 
Pk probe* FAM-CTCTCCGGAGATTAGAACTCTTAGATTGCT-BHQ1 
*Probes were obtained from Eurofins Genomics MWG Operon. (Divis et al., 2010, Klaassen et al., 2003)  
Table 3.3  Mastermix for TaqMan multiplex qPCR 
Reagent Stock concentration 
(uM) 
Volume (µL) Final concentration 
(nM) 
Klaassen-F 10 0.5 250 
Klaassen-R 10 0.5 250 
Plasmo 1 10 0.5 250 
Plasmo 2 10 0.5 250 
hDNA probe 10 0.2 100 
PkDNA probe 10 0.16 80 
TaqMan 
Mastermix 
2x 10 1x 
DNA extracted 
from whole blood 
- 5 - 
H2O - 2.64 - 
(Divis et al., 2010, Klaassen et al., 2003) 
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Table 3.4  TaqMan qPCR cycling conditions. 
Temperature (oC) Time Cycles 
95 10 min 1 
95 15 sec 
55 cycles 
60 1 min 
 
3.2.3    P. knowlesi and human DNA standard curves 
Standard curves of both hDNA and PkDNA were generated using TaqMan
®
 control 
genomic hDNA and PkDNA extracted from the P. knowlesi PkA1-H.1 in vitro culture 
(Section 2.6.7). DNA concentrations of the standards were measured using Qubit 2.0 
(Section 2.6.1). Serial dilutions of hDNA resulted in 9 dilutions ranging from 10 ng/µL 
to 39.1 pg/µL and similarly 10 dilutions of PkDNA ranging from 3.5 ng/uL to 6.8 
pg/µL. Triplicate qPCR reactions were used to prepare each species DNA standard 
curve, see Table 3.3. The qPCR conditions were as given in Table 3.4. A fluorescent 
threshold value was calculated by the Qiagen Rotor-Gene Q (Qiagen) software to 
convert fluorescence to DNA concentration. QPCR for all whole blood DNA samples 
were analysed using the Rotor-Gene Q (Qiagen). 
3.2.4    Whatman leukocyte depletion method 
Leukocyte depletion was carried out as described in Pinheiro et al., (2015). Briefly, 
diluted clinical whole blood samples were passed through three 6 µm Whatman filters 
below three 11 µm Whatman filters inside a 10 mL syringe by gentle centrifugation 
(125 rcf). The filter membranes were washed with ice cold PBS until the Whatman 
filters were no longer red. All eluate was combined and centrifuged at 2,021 rcf at 4°C 
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for 20 minutes. The pelleted intact RBCs and free parasite material were washed three 
times at 14,000 rcf for 2 minutes at 4°C with 1 mL PBS to remove soluble hDNA. The 
washed pellet was resuspended in a total volume of 200 µL PBS and DNA extraction 
performed as per section 2.6.7 (Pinheiro et al., 2015). 
3.2.5   Plasmodipur leukocyte depletion method 
Plasmodipur leukocyte depletion to remove surviving leukocytes that remained after 
freezing was carried out by diluting 200 µL of seeded whole blood samples (SS1 – SS3, 
Table 3.1) in 10 mL of cold PBS pH 7.4. The diluted sample was loaded into a 10 mL 
syringe with a Plasmodipur filter attached, and gently passed through into a 50 mL 
centrifuge tube. The filter unit was detached from the syringe and the plunger was 
removed. The filter was subsequently washed three times with 10 mL cold PBS pH 7.4. 
The eluate and PBS washes containing iRBCs, RBCs and parasite material were 
centrifuged at 2,021 rcf at 4 °C. The pelleted intact RBCs and free parasite material was 
washed three times at 14,000 rcf for 2 minutes at 4°C with 1 mL PBS to remove soluble 
hDNA. The washed parasite pellet was resuspended in a total volume of 200 µL PBS 
and DNA extraction performed as per section 2.6.7. 
 
 
3.2.6    Whatman-Plasmodipur leukocyte depletion method 
Briefly, clinical samples stored at -80ºC were thawed on ice and resuspended in 10 mL 
cold PBS pH 7.4 per 200 µL of frozen patient whole blood. Two 11 µm Whatman filter 
paper circles the diameter of a 10 mL syringe were placed inside a 10 mL syringe, with 
one syringe being used per 10 mL of dilute clinical sample. Each syringe was then 
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placed into a 50 mL centrifuge tube and pre-wet with 2 mL cold PBS pH 7.4. The PBS 
was passed through the Whatman filters by centrifugation at 11 rcf for 2 minutes at 4°C. 
Ten mL of the dilute clinical sample was added to each 10 mL Whatman constructed 
syringe and centrifuged at 20 rcf for 20 minutes at 4°C. Flow through was collected, 
stored on ice and 10 mL fresh PBS pH 7.4 was added to each syringe and centrifuged as 
before to wash the Whatman filter to collect any remaining parasite material. The 
second flow through containing retrieved material from the Whatman filter was 
combined to the first flow through on ice. A Plasmodipur filter (EuroProxima) for 
leukocyte removal was attached to a 20 mL syringe and pre-wet with 10 mL PBS. The 
flow through from the Whatman filtration step was added to the syringe and gently 
pushed through the Plasmodipur filter into a centrifuge tube. Gentle pressure was 
maintained evenly. The Plasmodipur filter was detached from the syringe, the plunger 
was removed, and the syringe reattached to the Plasmodipur filter. The Plasmodipur 
filter was washed with 20 mL PBS and collected into the same centrifuge tube. 
Plasmodipur filter was then washed three times in the same manner or until any red 
colouring had disappeared. The Plasmodipur flow through containing RBCs, iRBCs and 
free parasite material was centrifuged at 2,000 rcf at 4°C for 20 minutes. The 
supernatant was removed and the pellet resuspeneded in 1 mL PBS pH 7.4. The cell 
suspension was then centrifuged at 14,000 rcf for 2 minutes at 4°C. The supernatant was 
removed and parasite/RBC pellet resuspended in PBS. The PBS wash step was repeated 
5 times or until the supernatant was clear. The pellet was resuspended in 200 µL PBS 
for DNA extraction, see section 2.6.7. 
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3.2.7   Fold reduction of DNA following leukocyte depletion 
The fold change of both hDNA and Pk DNA was calculated by dividing post-leukocyte 
depletion total hDNA by the pre-leukocyte depletion total hDNA. For example, if the 
total pre leukocyte depletion hDNA concentration was 2000 ng and the post leukocyte 
depletion hDNA total was 5 ng then 5/2000 = 0.0025 fold change. However, for ease 
each fold change value has been converted by using 1 as the dividend and the fold 
change value as the divisor. For example, 1/0.0025 (fold change) = 400 fold reduction. 
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3.3    Results  
Upon examination of the clinical data associated with the biobank of clinical samples it 
was evident that each sample differed greatly when comparing, white blood cell count, 
parasitaemia, whole blood haematocrit, and parasite life stage. In addition, it was 
unknown how promptly samples had been frozen. Because of this, it was decided that to 
produce a more standardised leukocyte depletion method, replicate samples would be 
required for testing prior to progression to clinical samples. In order to achieve this, 
fresh whole blood would be seeded with P. knowlesi in vitro culture of known 
parasitaemias to create a mock clinical sample which would then be frozen, mirroring 
the samples in our biobank prior to leukocyte depletion. It was decided that TaqMan 
qPCR would be used to quantify both P. knowlesi and human DNA, as it would be more 
accurate and more informative than iRBC and WBC counts pre and post-leukocyte 
depletion. In addition, it would provide accurate quantification of each DNA population 
at low nanogram levels, enabling samples suitable for genome sequencing to be 
identified. 
 
3.3.1 Generation of standard curves for P. knowlesi and 
human DNA 
In order to accurately quantify both P. knowlesi DNA (PkDNA) and human DNA 
(hDNA) known quantities of DNA were required to create standard curve for both 
PkDNA and hDNA. This would allow samples with unknown DNA concentrations to 
be identified by analysing how many cycles were required to reach a threshold 
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fluorescence value which can then be converted to a DNA concentration using the 
standard curve which would be maintained between experiments. DNA was extracted 
from the PkA1-H.1 in vitro culture (section 2.6.7) and TaqMan® Control Genomic 
hDNA was used to create standard curves (section 3.2.3). TaqMan qPCR was carried 
out as in section 3.2.2 and Figures 3.2 and 3.3 respectively. A cycle threshold was 
applied to give the most predictive concentration for each curve. R
2
 squared values for 
PkDNA and for hDNA were 0.9927 and 0.996 respectively. 
 
Figure 3.2  Standard curve of human DNA generated to accurately quantify hDNA in clinical 
samples. 
A standard curve was generated for hDNA in order to quantify the hDNA in clinical samples containing a 
mixture of hDNA and PkDNA. A known concentration (10 ng/µL) of TaqMan control hDNA was serially 
diluted from 10 ng/µL to 0.04 ng/µL. hDNA was amplified using human specific primers and a human 
specific TaqMan probe (Klaassen et al., 2003). Quantification of hDNA was carried out using the cycling 
conditions as detailed in Table 3.4 using the Rotor-Gene Q (Qiagen) qPCR machine. A cycle threshold 
(CT) was applied to the standard curve data in order to best represent fluorescence value for each data 
point with the given DNA concentration, allowing for unknown hDNA concentrations to be calculated using 
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Figure 3.3 Standard curve of P. knowlesi DNA generated to accurately quantify PkDNA in 
clinical samples. 
A standard curve was generated for PkDNA in order to quantify the PkDNA in clinical samples containing a 
mixture of hDNA and PkDNA. A known concentration (3.5 ng/µL)  of PkDNA, isolated from the Pk A1-H.1 
in vitro culture using the QIAgen DNA blood mini kit, were serially diluted from 3.5 ng/µL to 0.0068 ng/µL. 
PkDNA was quantified using PkDNA specific primers and a PkDNA specific TaqMan probe (Divis et al., 
2010). Quantification of PkDNA was carried out using the cycling conditions as detailed in Table 3.4 using 
the Rotor-Gene Q (Qiagen) qPCR machine. A cycle threshold (CT) was applied to the standard curve data 
in order to best represent fluorescence value for each data point with the given DNA concentration, 
allowing for unknown PkDNA concentrations to be calculated using the following equation, concentration 
(ng/µL) = 10^(-0.274*CT+5.228). 
 
3.3.2 Plasmodipur leukocyte depletion of seeded whole 
blood  
In order to optimise the leukocyte depletion method a set of replicate samples were 
required that mirrored the frozen samples in our biobank. Donor whole blood was 
mixed with the PkA1-H.1 culture at a 1:1 ratio and frozen, providing a stock of replicate 
samples to optimise leukocyte depletion with. The frozen seeded samples (SS1 to SS3) 
were depleted using solely Plasmodipur filtration.  
Three aliquots of seeded sample 1 (SS1) were selected, two of these (SS1-1 and SS1-3) 
were leukocyte depleted using three 10 mL PBS pH 7.4 washes as in section 1.2.5, and 
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SS1-2 was processed with 5 mL PBS pH 7.4 washes. The ratio of human to parasite 
DNA in SS1 represented clinical isolates with high proportions of hDNA (mean total 
hDNA 3 ug and mean percentage of hDNA 88.9%) and low levels of PkDNA (mean 
total PkDNA 405 ng and mean percentage of PkDNA 11%, Table 3.5). Depletion of 
hDNA was seen in all three of these initial experiments, but to varying degrees. The 
depleted SS1-1 and SS1-3 samples had greater than 99.8% of hDNA removed, showing 
a fold reduction greater than 860 for both. The SS1-2 depletion had greater than 98.4% 
of hDNA removed with a 64 fold reduction in hDNA. The levels of post depletion 
PkDNA were similar for SS1-1 and SS1-3, however SS1-2 had lower levels of PkDNA, 
resulting in a lower percentage of PkDNA in the post-depletion sample compared with 
samples pre-depletion SS1-1 and SS1-3, see Table 3.5. 
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Table 3. 5 Plasmodipur leukocyte depletion of frozen whole blood seeded with the  
    P. knowlesi PkA1-H.1 in vitro culture.  
 
Pre-Depletion Post-Depletion 
  PkDNA ng (%) hDNA ng (%) PkDNA ng (%) hDNA ng (%) 
SS1-1 161.1 (7.4) 2026.2 (92.6) 69.5 (96.9) 2.2 (3.1) 
SS1-2 398.3 (10.0) 3595.2 (90.0) 23.8 (29.8) 56.1 (70.2) 
SS1-3 657.1 (15.8) 3495.2 (84.2) 69.7 (94.5) 4.1 (5.5) 
Mean 405.5 (11.1) 3038.8 (88.9) 54.3 (73.7) 20.8 (26.3) 
SS2-1 93.8 (0.8) 11737.1 (84.2) 9.5 (95.7) 0.4 (4.3) 
SS2-2 54.9 (0.7) 8308.5 (99.3) 15.9 (97.0) 0.5 (3.0) 
SS2-3 56.4 (0.7) 7786.0 (99.3) 38.6 (95.2) 1.9 (4.8) 
SS2-4 58.8 (0.7) 8195.7 (99.3) 19.0 (99.0) 0.2 (1.0) 
SS2-5 27.6 (0.9) 2967.5 (99.1) 6.4 (94.1) 0.4 (5.9) 
SS2-6 56.9 (0.8) 6883.4 (99.2) 35.4 (99.0) 0.4 (1.0) 
SS2-7 82.3 (1.0) 7874.0 (99.0) 44.0 (91.0) 4.4 (9.0) 
Mean 61.5 (0.8) 7678.9 (99.2) 24.1 (95.9) 1.2 (4.1) 
SS3-1 152 (2.1) 7041.6 (97.9) 57.0 (98.4) 0.9 (1.6) 
SS3-2 101.8 (1.7) 5825.1 (98.3) 48.6 (95.8) 2.1 (4.2) 
Mean 126.9 (1.9) 6433.3 (98.1) 52.8 (97.1) 1.5 (2.9) 
 
A further two whole blood samples seeded (SS2 and SS3, Table 3.1) with PkA1-H.1 
culture were used to validate the reproducibility and success of the Plasmodipur 
leukocyte depletion method. The seeded samples were homogenised thoroughly by 
pipetting prior to aliquoting and freezing. Seven replicates were used for seeded sample 
2 and a duplicate used for seeded sample 3. The Plasmodipur method was carried out as 
previously described (section 3.2.5), with the alteration that all seeded samples were 
diluted in 20 mL PBS pH 7.4 for Plasmodipur depletion, and 20 mL PBS wash steps 
were used. As seen with SS1, the SS2 pre-leukocyte depletion samples had high totals 
of hDNA (mean 7.6 ug, 99.2%) and low PkDNA (61.5 ng, 0.8%, Table 3.5). Following 
leukocyte depletion, the mean total hDNA was lower in samples receiving a 20 mL 
wash step (SS2) compared to a 5 mL or 10 mL wash step (SS1). Additionally, there was 
a higher recovery of parasite DNA in samples receiving a 20 mL wash step (SS2) 
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compared to the 5 mL or 10 mL wash steps used for SS1, suggesting the 20 mL wash 
step produced both greater hDNA depletion and greater recovery of PkDNA from the 
original starting material. 
The SS3 samples were processed as per the SS2 samples, diluting the seeded sample in 
20 mL PBS and using 20 mL wash steps. The purpose of the SS3 samples was to test 
whether the purification using 20 mL dilutions and wash steps was replicable with a 
different seeded sample. As with the SS1 and SS2 pre leukocyte depletion samples, the 
SS3 samples had high levels of hDNA and low levels of PkDNA (Table 3.5). The 
percentages of hDNA and PkDNA post-leukocyte depletion were similar to the post-
leukocyte depletion percentages of SS2 depleted samples (Table 3.5), and the 
percentage of hDNA and PkDNA recovered were also comparable to SS2 (Table 3.6). 
The optimisation of the Plasmodipur method enabled the progression to clinical 
samples. 
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Table 3.6 Fold reduction and percent recovery of DNA following Plasmodipur leukocyte  
    depletion of frozen whole blood seeded with the P. knowlesi PkA1-H.1 in vitro  









  PkDNA hDNA PkDNA hDNA PkDNA hDNA PkDNA hDNA 
SS1-1 161.11 2026.2 69.53 2.22 2.3 912.7 43.2 0.11 
SS1-2 398.28 3595.2 23.81 56.11 16.7 64.1 6.0 1.56 
SS1-3 657.09 3495.2 69.69 4.05 9.4 863.0 10.6 0.12 
SS1 
Mean 405.49 3038.9 54.34 20.79 9.5 613.3 19.9 0.60 
SS2-1 93.75 11737 9.51 0.43 9.9 27295.5 10.1 0.003 
SS2-2 54.85 8308.5 15.93 0.5 3.4 16617.0 29.0 0.01 
SS2-3 56.39 7786 38.63 1.93 1.5 4034.2 68.5 0.02 
SS2-4 58.79 8195.7 19.01 0.19 3.1 43135.3 32.3 0.002 
SS2-5 27.63 2967.5 6.38 0.4 4.3 7418.8 23.1 0.01 
SS2-6 56.93 6883.4 35.37 0.35 1.6 19666.8 62.1 0.01 
SS2-7 82.3 7874 43.99 4.36 1.9 1806.0 53.5 0.06 
SS2 
Mean 61.52 7678.9 24.12 1.17 3.7 17139.1 39.8 0.02 
SS3-1 151.95 7041.6 57.02 0.91 2.7 7738.0 37.5 0.01 
SS3-2 101.75 5825.1 48.59 2.13 2.1 2734.8 47.8 0.04 
SS3 
Mean 
126.85 6433.4 52.81 1.52 2.4 5236.4 42.7 0.03 
 
3.3.3 Whatman-Plasmodipur leukocyte depletion of 
clinical samples 
Leukocyte depletion of clinical samples was performed as for seeded samples SS2 and 
SS3. However, the Plasmodipur leukocyte depletion of the initial clinical sample was 
not as successful as with the seeded samples. When processed, the Plasmodipur filter 
retained a brown discolouration that was unable to be washed through the filter and no 
material was recovered following centrifugation. This prompted a pre-filtration step 
incorporating 3 of the larger 11 µm Whatman circles, as used in the Whatman method. 
This was introduced to remove debris from the clinical sample in order to prevent 
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blockage of the Plasmodipur filter. The modified syringe filter was constructed, and 
leukocyte depletion carried out as in section 3.2.6.  
Clinical samples were selected for newly modified Whatman-Plasmodipur leukocyte 
depletion based on the PkDNA content (greater than 100 ng, by qPCR section 3.2.2) or 
where available a parasite count greater than 35,000/µL based on reported parasitaemias 
from patient data. In total, 22 clinical samples were selected based on these criteria. The 
initial four clinical sample depletions using the combined Whatman-Plasmodipur 
method used three 11 µm Whatman filters per syringe. Two of these four depletions 
were unsuccessful, due to damaged Whatman filter papers and subsequent blockage of 
the Plasmodipur filter. For the remaining 18 samples two 11 µm Whatman filter papers 
were used in subsequent depletions to prevent clogging in the Whatman filter column 
before Plasmodipur leukocyte depletion.  
Following Whatman-Plasmodipur depletion, a parasite pellet was present in 15 out of 
the 22 clinical samples processed. The DNA quantities and purities following DNA 
extraction (section 2.6.7) can be seen in Table 3.7. As with the seeded samples, the pre-
depletion clinical samples contained high quantities of hDNA (median 96.5%) and low 
quantities of PkDNA (median 3.5%). Following Whatman-Plasmodipur depletion, the 
hDNA was a low proportion in thirteen of the fifteen depletions (median 8.2%). The 
resulting PkDNA percentage was high in 13 of the 15 samples (median 91.8%) although 
some of the samples had low quantities of PkDNA (Table 3.7). The fold reduction of 
hDNA was high with a median percent retention of 0.02%. The retention of PkDNA 
was lower (median 17.2%) than was seen with seeded samples (Table 3.6 and 3.8). 
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Thirteen of the fifteen samples contained PkDNA purities greater than 70 %, 9 of which 
had purities greater than 90 % PkDNA (Table 3.7). Eight of the fifteen depleted clinical 
samples contained greater than 100 ng of PkDNA as shown by the threshold in Figure 
3.5, with 100 ng PkDNA being the requirement for genome sequencing on HiSeq and 
MiSeq Illumina machines. Two samples, SKS069 and SKS225, had no leukocyte 
depletion (Figure 3.4) and had post-depletion hDNA percentages of 97% and 87.8% 
respectively (Table 3.7). The remaining five samples (SKS308, SKS339, SKS313, 
SKS132 and SKS352) all had purities of PkDNA greater than 80%, with PkDNA 
quantities below 75 ng, and hDNA quantities below 5 ng (Figure 3.5 and Table 3.7).  
Table 3.7  Post-Plasmodipur leukocyte depletion of clinical samples calculated by qPCR. 
  Pre-Depletion Post-Depletion 
  PkDNA ng (%) hDNA ng (%) PkDNA ng (%) hDNA ng (%) 
SKS325* 357 (3.7) 9355 (96.3) 290 (99.7) 0.9 (0.3) 
SKS343* 324 (6.4) 4738 (93.6) 169.3 (82.2) 36.7 (17.8) 
SKS069 235 (3.9) 5740 (96.1) 42.2 (3) 1350.5 (97) 
SKS071 1357 (9.3) 13201 (90.7) 163.2 (71.8) 64 (28.2) 
SKS074a 546 (11.4) 4258 (88.6) 216.3 (99.7) 0.8 (0.3) 
SKS132 182 (1.1) 16548 (98.9) 24 (96.6) 0.8 (3.4) 
SKS139 850 (5.8) 13882 (94.2) 139.0 (91.8) 12.4 (8.2) 
SKS201a 5842 (24.6) 17947 (75.4) 2287.1 (99.9) 2.9 (0.1) 
SKS225 505 (2.2) 22750 (97.8) 447.3 (12.2) 3227 (87.8) 
SKS231 716 (3.1) 22353 (96.9) 641.9 (99.4) 3.8 (0.6) 
SKS308 N/A N/A 74.5 (99.2) 0.6 (0.8) 
SKS313 151 (1.2) 12544 (98.8) 7.2 (80.8) 1.7 (19.2) 
SKS339 518 (2.9) 17292 (97.1) 43 (91.3) 4.1 (8.7) 
SKS344 1516 (4.5) 31852 (95.5) 161  (94.2) 9.9 (5.8) 
SKS352 110 (1.2) 8788 (98.8) 3.7 (84.4) 0.7 (15.6) 
Mean 935.86 (5.7) 14375 (94.3) 314 (80.4) 314.4 (19.6) 
Median 511.5 (3.5) 13542 (96.5) 161 (91.8) 3.8 (8.2) 
1st IQR 370 (2.3) 12873 (93.8) 42.6 (81.5) 0.8 (0.7) 
3rd IQR 1103.5 (6.2) 20150 (97.7) 253.1 (99.3) 24.6 (18.5) 
*denotes samples were processed with three 11 µm filter paper 
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Figure 3.4  Total human DNA yield following Whatman-Plasmodipur depletion of frozen 
clinical samples.  
Clinical samples were processed using the Whatman-Plasmodipur leukocyte depletion and the DNA was 
extracted using the Qiagen DNA blood mini kit. The hDNA was quantified using the Klaassen-F and 
Klaassen-R primers in combination with the hDNA TaqMan probe (Klaassen et al., 2003) and cycled as in 
Table 3.4.  Data shown is the mean qPCR reading of technical triplicates. 
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Figure 3.5  Total P. knowlesi DNA yield following Whatman-Plasmodipur depletion of frozen 
clinical samples. 
Clinical samples were processed using the Whatman-Plasmodipur leukocyte depletion and the DNA was 
extracted using the Qiagen DNA blood mini kit. The PkDNA was quantified using the Plasmo1 and 
Plasmo2 primers in combination with the PkDNA probe (Divis et al 2010) and cycled as in Table 3.4. Data 
shown is the mean qPCR reading of technical triplicates. The dotted line denotes 100 ng of DNA, the 
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Table 3.8 Fold reduction and percent recovery of Whatman-Plasmodipur depleted P. 
knowlesi frozen clinical samples. 
  Fold DNA Reduction Percentage of DNA Retained 
  PkDNA hDNA PkDNA hDNA 
SKS325* 1.2 11005.9 81.2 0.01 
SKS343* 1.9 129.1 52.3 0.77 
SKS069 5.6 4.3 18.0 23.53 
SKS071 8.3 206.2 12.0 0.49 
SKS074a 2.5 5677.3 39.6 0.02 
SKS132 7.6 19700.0 13.2 0.01 
SKS139 6.1 1118.6 16.4 0.09 
SKS201a 2.6 6188.6 39.1 0.02 
SKS225 1.1 7.0 88.6 14.18 
SKS231 1.1 5944.9 89.6 0.02 
SKS313 21.0 7335.7 4.8 0.01 
SKS339 12.0 4238.2 8.3 0.02 
SKS344 9.4 3230.4 10.6 0.03 
SKS352 29.8 12923.5 3.4 0.01 
Mean 7.9 5550.7 34.1 2.8 
Median 5.8 4957.8 17.2 0.02 
*denotes samples were processed with three 11 µm filter paper 
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3.4    Discussion 
The Whatman-Plasmodipur method successfully leukocyte depleted frozen P. knowlesi 
clinical samples to hDNA levels suitable for Illumina sequencing. Clinical samples 
were diluted in 20 mL PBS and filtered through two 11 µm Whatman filter papers per 
10 mL syringe. The eluate was then filtered through a Plasmodipur filter and washed 
repeatedly with 20 mL PBS. The eluate was centrifuged and the parasite pellet was 
washed of soluble hDNA. Filtration through the two 11 µm Whatman filter papers was 
designed to remove debris from the frozen sample and prevent blocking the 
Plasmodipur filter. The Plasmodipur filter was more efficient compared to the 6 µm 
Whatman leukocyte depletion as in Pinheiro et al., (2015). The adapted method was 
devised to enhance hDNA removal, while endeavouring to maximise recovery of 
PkDNA. The Plasmodipur filter was selected due to the standardisation of the filters, in 
comparison to the homemade CF-11 columns, which have been reported to be variable 
(Auburn et al., 2011) and debate over retention of specific life stages (Janse et al., 1994, 
Sriprawat et al., 2009). Plasmodipur filters had previously been used to successfully 
leukocyte deplete fresh whole blood from a Rhesus macaque infected with P. knowlesi, 
with the purified parasites being used for DNA extraction and sequencing (Pain et al., 
2008), but until now have not been used on frozen whole blood samples. 
Here the results show that Plasmodipur filtration alone performed well for seeded 
samples, depleting 98% of hDNA. However, processing of a clinical sample using the 
Plasmodipur filter alone resulted in a brown colouration of the filter and no recovery of 
RBCs, iRBCs or parasite material. The adapted method depleted greater than 99% of 
hDNA from 13 clinical samples, which was greater than the depletion reported by 
(Pinheiro et al., 2015). However, two samples did not show sufficient removal of 
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hDNA. In addition, a parasite pellet was unable to be retrieved from 7 samples during 
leukocyte depletion. The reasons for this ranged from extensive lysis of the clinical 
sample, blockage in the Plasmodipur filter and blockage or damage to the 11 µm 
Whatman filter papers. The 13 successful purifications resulted in 8 samples with 
PkDNA quantities and purities suitable for genome sequencing on Illumina platforms. 
Additionally, as per Boissiere et al., (2012) whole genome amplification could be 
incorporated to amplify the DNA content of the 5 samples below 100 ng of total 
PkDNA, all of which had greater than 80% PkDNA (Boissiere et al., 2012).  
The clinical data for the samples which failed to produce a parasite pellet following 
leukocyte depletion were analysed for any feature which associated with the recovery of 
P. knowlesi DNA. The parasite life stage was analysed by plotting the percentage of 
parasites in each life stage (ring, trophozoite, schizont or gametocyte) for each clinical 
sample against the percent recovery of PkDNA. A negative correlation (-0.56) was 
identified when the percentage of trophozoites in clinical samples was plotted against 
the percentage of PkDNA retained following leukocyte depletion (Appendix C). This 
may be a result of either; late stage parasites being prone to agglutination causing 
clumping and blockage of filters, or, increased lysis of late stage parasites during 
storage at -80°C producing more cell debris, increasing the risk of blockages (Jeffery, 
1962, Wilson et al., 1977). It would be useful to test this with further samples to give 
some indication of the potential for using the Whatman-Plasmodipur method on 
particular frozen clinical isolates, as success may be dictated by parasite asexual life 
stage. Testing would require synchronous cultures to be sampled throughout the life 
cycle and stored at -80°C. This would provide samples which have identical 
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parasitaemias, but with each replicate containing progressively more mature parasites 
enabling a direct comparison between retrieval of PkDNA and parasite life stage. 
To date, there are a variety of filtration methods used for leukocyte depletion of malaria 
samples, such as cellulose packed syringes, commercially available Plasmodipur filters, 
non-woven filters and the Whatman filtration method (Janse et al., 1994, Tao et al., 
2011, Fulton and Grant, 1956, Pinheiro et al., 2015, Venkatesan et al., 2012, Auburn et 
al., 2011). However, only the Whatman filtration method has reported purification of 
parasite material from frozen clinical whole blood samples and subsequent genome 
sequencing using filtration. One method previously described the isolation of P. 
falciparum from frozen clinical samples (Boissiere et al., 2012), where flow cytometry 
was used to isolate 200 P. falciparum nuclei, followed by whole genome amplification. 
This process yielded genome sequence data for P. falciparum where 62% of reads 
mapped to the P. falciparum reference genome. Although not sequenced, the mean 
PkDNA percentage for clinical samples presented here was greater than 80%. The 
difference between the two methods may be because the target region for flow 
cytometry is based on fluorescence intensity of propidium iodide stained nuclei and cell 
size (Boissiere et al., 2012). This could result in debris containing human nuclear 
material being incorrectly sorted as parasite nuclei. Additionally, this technique requires 
access to a flow cytometer with cell sorting abilities which is not common lab 
equipment. Conversely, the Whatman-Plasmodipur methods described here requires 
only a centrifuge making it not only more efficient but more readily accessible for the 
research community.  
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The whole genome amplification described by Boissiere et al., could be a pivotal 
inclusion to the Whatman-Plasmodipur method obtaining samples suitable for genome 
sequencing. The median hDNA removal for the method presented here is greater than 
99%, however there are samples which contain less than 100 ng of PkDNA and less 
than 20% hDNA, therefore the incorporation of whole genome amplification for low 
PkDNA recovery samples could enable them to be sequenced. If the amplification is not 
biased towards species, these high percentage PkDNA fractions should remain but with 
a greater quantity. Further research has shown that if leukocyte depletion was not 
performed on clinical samples prior to long term storage, the parasite DNA is able to be 
isolated from the mixed DNA population using biotin tagged RNA probes. Briefly, 
control genomic DNA is sheared to approximately 250 bp and is used as the template 
DNA for creating the baits. The sheared ends were repaired and dA tailed prior to the 
ligation of an adapter oligonucleotide sequence. PCR was then carried out using primers 
specific for the adapter sequence followed by amplification of the PCR product using a 
primer containing a T7 promoter. The PCR product is then amplified using T7 RNA 
polymerase in the presence of biotinylated uracil, producing biotinylated RNAs 
complimentary to regions throughout the genome (Melnikov et al., 2011). Following 
this the biotinylated RNA baits can be incubated with a mixed DNA population, and 
pulled down using streptavidin coated beads (Melnikov et al., 2011). The streptavidin 
beads are washed to remove any unbound DNA, and the genomic parasite DNA can be 
eluted. Whole genome amplification can then be performed to increase the total yield of 
parasite DNA to levels suitable for genome sequencing (Melnikov et al., 2011). 
However, this process seems to enrich for regions of the genome where the RNA-baits 
are targeted which could result in bias read coverage to RNA bait regions of the 
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genome, although it appears this did not affect the genome sequencing outputs 
(Melnikov et al., 2011). However, Bright et al., show that selection of P. vivax DNA 
using RNA baits, resulted in genome sequence outputs that biased against GC % rich 
areas of the genome, compared against a leukocyte depleted sample (Bright et al., 
2012). Oyola et al., 2016 describe a method to selectively amplify P. falciparum 
genomic DNA using primers specific to the P. falciparum genome. However, the 
subtelomeric regions, which contain variable gene families such as var, rif stevor and 
phist gene families, were not covered (Oyola et al., 2016, Gardner et al., 2002, Witmer 
et al., 2012). Also, the element of bias toward specific regions of the genome where 
primers are located, is not fully addressed. This suggests that leukocyte depletion would 
be preferable for: (a) high GC content genomes like P. knowlesi; and (b) subsequent 
genome analysis of repeat gene families. 
In order to further develop the Whatman-Plasmodipur method, testing of sample 
selection parameters could have been performed. The mock clinical samples were 
frozen immediately following homogenisation, and when processed they did not cause 
blockages of the Whatman or Plasmodipur filters. However, the clinical samples used in 
this study may not have been stored as rapidly as in this study. In order to recreate the 
variability of frozen clinical P. knowlesi whole blood samples, the seeded samples could 
have been incubated at room temperature prior to freezing. Additionally, clinical 
samples may have undergone freeze-thaw events, and this too could have been tested 
with seeded samples. The parasite life stage could also have been analysed by obtaining 
synchronous cultures of rings, trophozoites and schizonts to analyse the retrieval of 
parasite material following the freezing process.  
 
  132 
The Whatman-Plasmodipur method presented here improved upon the hDNA depletion 
published by Ahmed et al., (2014) using archived frozen clinical samples. The method 
results in low quantities of hDNA, and high purity PkDNA, important for genome 
sequencing, enabling genomic research to be conducted on archived clinical samples. 
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Chapter 4:   Plasmodium knowlesi A1-H.1 
transfection to knock-in a clinically 
relevant variant of the gene Pknbpxa  
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4.1  Introduction 
Severe malaria is a highly complex disease involving variable parasite and host factors 
(Miller et al., 2002). A common theme in severe P. knowlesi and P. falciparum malaria 
is high parasitaemia (Daneshvar et al., 2009). The accessibility of new rapid genome 
sequence platforms has opened novel opportunities to explore the role for parasite 
genetic variability in severe malaria (Pinheiro et al., 2015, Chokejindachai and Conway, 
2009). Genetic variation at invasion gene loci may affect the specificity or affinity of 
merozoite invasion proteins for RBC receptors. An experimental cross of two P. 
falciparum lines exhibiting differing abilities to invade and replicate in Aotus 
nancymaae erythrocytes was performed (Hayton et al., 2008). Only progeny with 
specific inherited markers from the parent able to invade A. nancymaae erythrocytes 
were able to invade A. nancymaae erythrocytes. Further analysis revealed that a single 
amino acid substitution in the P. falciparum reticulocyte binding-like homologue 5 
(PfRh5) protein was responsible for this change in phenotype in parasite tropism and 
also parasite invasion rate (Hayton et al., 2008, Mayer et al., 2002, Mayer et al., 2004). 
This suggests that small differences in invasion proteins can have profound effects on 
invasion characteristics, thereby altering parasite invasion phenotypes. An association 
between markers of severe malaria and the PfRh proteins has not yet been reported, but 
variants of the P. knowlesi normocyte binding protein Xa (pknbpxa), a protein essential 
for the invasion of human RBCs by P. knowlesi (Meyer et al., 2009, Semenya et al., 
2012, Moon et al., 2016), were recently implicated in progression to severe disease in P. 
knowlesi malaria in Malaysian Borneo (Ahmed et al., 2014). Ahmed and colleagues 
identified that a dimorphism was present in an 885 bp 5’ region of the P. knowlesi 
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Pknbpxa gene, with one of the dimorphic clusters being more diverse (cluster 2) (Figure 
4.1). In addition, 34% of P. knowlesi clinical isolates with cluster 2 type Pknbpxa 
sequences contained a proline at amino acid 200 which was found to be associated with 
clinical markers of severe disease, including high parasitaemia (p = 0.02) (Figure 4.1, 
Ahmed et al., 2014), suggesting that mutations in the Pknbpxa gene may be involved in 
virulence. Development of the P. knowlesi in vitro culture in human RBCs has provided 
a model where the association with high parasitaemia can be carried out. However, 
phylogenetically the PkNBPXa protein sequence in the PkA1-H.1 clone does not cluster 
with either dimorphic cluster 1 or 2 and instead appears ancestral to both clusters 
meaning that the Pknbpxa sequence does not represent either cluster 1 or cluster 2. 
The work presented here employs whole genome sequence data, generated from P. 
knowlesi clinical isolates (Pinheiro et al., 2015), to assemble the full-length sequence of 
Pknbpxa cluster 2 variants. This sequence data was subsequently used to guide the 
construction of a transfection plasmid to knock-in and replace the wild-type Pknbpxa 
gene with a clinically relevant Pknbpxa isoform. The experimental line, P. knowlesi 
PkA1-H.1, which has been adapted to in vitro culture in human erythrocytes was 
employed for this purpose (Moon et al., 2013). 
 









Figure 4.1 Haplotype network of the dimorphic 885 bp fragment of Pknbpxa.  
Construction of a minimum spanning haplotype network, using the Arlequin v3.5.1.2 software, showed that 
in 138 P. knowlesi clinical isolates the N-terminal 885 bp region of Pknbpxa were organised into 75 
haplotypes. Numbers within each node represent the number of clinical isolates with the same haplotype 
and grey nodes represent a sequence that has 1 SNP difference to the neighbouring node, but the 
sequence did not appear in the sample set. Sixty one (44%) clinical isolates were sorted by the software 
into 12 haplotypes forming cluster 1 (green nodes) and 77 (56%) clinical isolates were sorted into 63 
haplotypes forming cluster 2 (Blue and Yellow nodes). Cluster 1 and cluster 2 are separated by 29 SNPs 
which defined the haplotypes, and therefore the dimorphism separating cluster 1 and cluster 2. Additional 
data suggests that each cluster may be specific for Macaque species, which could explain the differing 
levels of variation in each cluster at this locus, although more macaque isolates are required (Divis et al., 
2015). Yellow nodes represent clinical isolates that contained a non-synonymous mutation producing a 
proline at amino acid 200 instead of a serine (S200P), previously termed the 913C mutation, identified by 
Ahmed et al to associate with high parasitaemia. The increased diversity in cluster 2 compared with cluster 
1, and the presence of the S200P mutation solely in cluster 2 could suggest an evolutionary advantage in 
the invasion of human RBCs. Boxed haplotypes represent the clinical isolates that have been genome 
sequenced.  In cluster 1 two of the three genome sequences are from the same haplotype when analysing 
the 885bp N-terminal region of Pknbpxa. As shown in cluster 2, two of the three genome sequences 
(ERR274221 and ERR274222) contain a proline at residue 200, denoted by the yellow node.  Figure 
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4.2    Methods 
4.2.1   Next generation sequence alignment 
Fastq files containing HiSeq and MiSeq reads previously generated from P. knowlesi 
clinical isolates (Pinheiro et al., 2015) with study accession code PRJEB1405 and 
accession codes ERR274221, ERR274222, ERR274223, ERR274224, ERR274225, 
ERR366425 and ERR366426, were downloaded from the EMBL-EBI European 
Nucleotide Archive (http://www.ebi.ac.uk/ena/data/view/PRJEB1405). The P. knowlesi 
reference genome (version 11.1) was downloaded from PlasmoDB 
(www.plasmodb.org/plasmo/). The Pknbpxa locus of interest was incorrectly annotated 
with 3 exons on chromosome 14 in the original reference genome (Pain et al., 2008). 
The genomic Pknbpxa coding sequence was replaced with the Meyer et al., (2009) 
published Pknbpxa sequence (PKNH_1472300) enabling the P. knowlesi clinical 
genome sequences to be aligned correctly at this locus (Meyer et al., 2008, Pinheiro et 
al., 2015). The Bowtie 2 program was used to align paired end reads (100bp) to the 
edited reference genome. Files were output as .sam files and converted to .bam files 
before sorting and indexing. BEDtools was then used to measure the coverage for each 
alignment to the reference.  
4.2.2   Variant call analysis 
The samtools mpileup function (Li et al., 2009) was used in combination with BCFtools 
to identify variant positions. Only bases with a base alignment quality (BAQ) score 
above 13 were called as variant bases to remove possible sequencing errors from further 
analysis.  The BCFtools (Li, 2011) VarFilter command was used to remove single 
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nucleotide polymorphisms (SNPs) with an allele frequency less than 0.9. In 
combination with the removal of sequencing errors, inserts and deletions were also 
removed from further analysis. 
4.2.3   Pknbpxa DNA sequence extraction 
The Pknbpxa gene is located at 3,176,653 bp on chromosome 14 of the corrected 
Pinheiro et al., (2015) P. knowlesi reference genome sequence. Chromosome 14 from 
the previously mentioned clinical genome sequences were aligned to the reference 
genome sequence using the genome browser software Artemis (Carver et al., 2012). 
Alignment to the reference, and visualisation of the Pknbpxa locus enabled the Pknbpxa 
genes sequences from the clinical isolates to be extracted and saved as fasta files. The 
seventh genome sequence (ERR274223) was not analysed as this was a post-treatment 
sample isolated from a patient where a pre-infected sample was obtained (ERR274222) 
(Pinheiro et al., 2015). The full-length Pknbpxa gene sequences from all 6 isolates were 
extracted as FASTA files with insertions and deletions removed. Three of the sequences 
were in Pknbpxa cluster 1 (ERR274224, ERR274225 and ERR366425) and three in 
cluster 2 (ERR274221, ERR274222 and ERR366426). 
4.2.4  Nucleotide diversity calculation  
Nucleotide diversity in the Pknbpxa gene was calculated using DnaSP with a step size 
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4.2.5   Selection of Pknbpxa cluster 2 variation  
The Pknbpxa gene sequence in the PkA1-H.1 line contained SNPs present in both 
cluster 1 and 2, suggesting it is ancestral to both clusters. In order to examine the impact 
of the S200P mutation, only present in cluster 2, the residues defining cluster 2 were 
identified. This would allow a Pknbpxa sequence containing only the cluster 2 sequence 
to be transfected into the PkA1-H.1 line, followed by the Pknbpxa cluster 2 sequence 
containing the S200P mutation. The cluster 2 sequence was defined as SNPs present in 
all three Pknbpxa cluster 2 sequences that resulted in a non-synonymous amino acid 
changes as seen in Figure 4.2 (all mutations detailed in Appendix D). Where there was 
not 100% consensus on amino acid positions between the three sequences in cluster 2, 
the most frequently occurring amino acid between both clusters was selected. 
Alignments of both DNA and amino acid sequences were performed using Clustal 
Omega (Sievers et al., 2011) and Jalview software (Waterhouse et al., 2009). 
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4.2.6    Synthesis of the cluster 2 Pknbpxa gene 
The following assignment of the Pknbpxa gene sequence to represent cluster type 2 was 
performed in silico. Positions identified as defining cluster type 2 were used to inform 
the construction of the synthetic Pknbpxa cluster type 2 gene for transfection 
experiments using single-crossover homologous recombination with the PkconGFP 
plasmid (Figure 4.5) developed for P. knowlesi transfection by Moon et al., (2013) 
(Figure 4.13). The Pknbpxa gene sequence from the corrected P. knowlesi reference 
genome was extracted along with the 186 bp intron separating exon 1 and exon 2, and 
243 bp of the 5’ non-coding region Figure 4.3. A 3x HA tag (5’ TAC CCA TAC GAT 
GTT CCA GAT TAC GCT 3’, 84 bp) was added to the 3’ end of the Pknbpxa coding 
region and immediately prior to the stop codon. The restriction site motifs NotI, XmaI 
and SacII in the PkconGFP plasmid were selected to remove the Pk HSP70 promoter and 
the GFP coding sequence (Figure 4.3 A), The NotI restriction site was added to the 5’ 
end of the synthetic Pknbpxa sequence and the SacII restriction site was added to the 3’ 
end of the sequence. A 1 kb region of homology was retained in the synthetic gene 
sequence to direct plasmid integration into the genomic Pknbpxa locus. Synonymous 
mutations were introduced at position 1010 bp in the synthetic Pknbpxa sequence to 
create the XmaI restriction site (5’ cccggg 3’), and at position 4931 bp creating the SpeI 
restriction site (5’ actagt 3’). The NotI and XmaI restriction sites flanked the region of 
homology in the Pknbpxa synthetic fragment 1(_f1) (Figure 4.3). This region was 
synthesized by GeneArt™ (Invitrogen™) and was delivered in a pMA-RQ vector 
(Plasmid map Appendix E).  
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Non-synonymous mutations to represent Pknbpxa cluster 2 (Section 4.2.5) and 
additional restriction sites to facilitate cloning were introduced into the remaining 
Pknbpxa 7874 bp fragment that was flanked by XmaI (5’ end) and SacII (3’ end) 
(Figure 4.2, and Appendix D). The 7874 bp region was synthesised as two fragments 
(Figure 4.3). Synonymous mutations were introduced 4514 bp (4940 bp, including non-
coding region and intron) into the remaining Pknbpxa sequence to create the SpeI 
restriction site (5’ actagt 3’), and forming Pknbpxa_fragment 2 (_f2) flanked by XmaI 
and SpeI and the final fragment Pknbpxa_f3 was flanked by SpeI and SacII. A 16 bp 
link sequence containing the SacII restriction site was added immediately following the 
SpeI restriction site on the 3’ end of Pknbpxa_f2 to allow ligation of the Pknbpxa_f3 
fragment during transfection plasmid construction. The Pknbpxa_f2 and Pknbpxa_f3 
fragments were codon optimized ensuring that the NotI, KpnI, XmaI, SpeI and SacII 
restriction site motifs were not disrupted at any position. The Pknbpxa_f2 and 
Pknbpxa_f3 sequences were synthesized by GeneArt™ (Invitrogen™).  
Briefly, the GeneArt™ synthesis process involved de novo synthesis of overlapping 
short oligonucleotides covering the 3 Pknbpxa sequences individually (Pknbpxa_f1, 
Pknbpxa_f2 and Pknbpxa_f3). The overlapping oligonucleotides were ligated using 
rounds of PCR to construct each Pknbpxa fragment (GeneArt™). The Pknbpxa 
fragments were flanked by the SfiI restriction site and cloned into the pMA-RQ plasmid 
(Appendix E).  
  
 




Figure 4.3 Schematic of the Pknbpxa gene fragments and location of restriction sites used 
for cloning.  
The Pknbpxa gene from the corrected P. knowlesi genome consists of a short non-coding region (291 bp), 
a small exon1 (54 bp) and a much larger exon2 (8398 bp) separated by a short intron (186 bp). Pknbpxa 
was divided into three fragments as follows; fragment 1 (green box) representing the region of homology' 
Fragment 2 Pknbpxa_f2 (purple box) and Pknbpxa_f3 (red box) were codon optimized for E. coli codon 
usage to alter the DNA sequence but code for the same protein. Cluster 2 mutations were created in the 
Pknbpxa_f2 and Pknbpxa_f3 coding sequences thereby introducing the amino acid substitution associated 
with cluster 2. A 3xHA tag (black box) was introduced at the 3’ end of Pknbpxa_f3 fragment. Synonymous 
mutations were used to create XmaI and SpeI restriction enzyme sites at 1010 bp and 4938 bp 
respectively for subsequent cloning steps. A naturally occurring KpnI restriction enzyme motif (blue line, 
578 bp) was located centrally in Pknbpxa_f2, towards the 5’ end of exon2.  
 
4.2.7    Restriction digestion of the PkconGFP plasmid  
The PkconGFP and the Pkconp230pGFP plasmids were kind gifts from Dr Moon 
(NIMR/LSHTM) (Figure 4.3). The PkconGFP plasmid contained the human 
dihydrofolate reductase selection marker (hDHFR), used for stable integration, (Figure 
4.5a) under the control of a P. knowlesi specific promoter (PkEF1a 5’ UTR, Figure 
4.5a). Additionally, the PkconGFP plasmid contained the restriction sites NotI, XmaI and 
SacII, all required for cloning the Pknbpxa_f1, Pknbpxa_f2 and Pknbpxa_f3 fragments 
sequentially. The PkconGFP Plasmid was digested using the restriction enzymes NotI 
and XmaI as per the manufacturer’s instructions (section 2.6.4). This removed the 
HSP70 5’UTR and GFP coding regions not required for PkconPknbpxa_f1-3 plasmid 
construction. 
 






Figure 4.4 Schematic of PkconPknbpxa_f1-3 construct linearized at the KpnI restriction site. 
Restriction digest at the KpnI (578 bp) motif linearizes the construct in the middle of the 1010 bp region of 
homology, resulting in ends flanked with ~500 bp Pknbpxa homologous sequence. Human Dihydrofolate 
reductase (hDHFR) gene was included to select for transfected cells. 
KpnI 
 






















Figure 4.5 Map of the PkconGFP and Pkconp230pGFP transfection plasmids.  
(A)The PkconGFP and (B) the Pkcon p230pGFP plasmids were a kind gift from Dr Moon (LSHTM). Both 
plasmids contained the PkHSP70 5’ UTR (purple box) followed by the GFP coding region (thick green 
arrow), and the PbDT3’UTR (thin green arrow). The PkEF1a 5’UTR promoter (purple) at the 5’ end of the 
Human Dihydrofolate reductase (hDHFR) gene (thick green arrow highlighted in the red box) followed by 
the Pfhrp2 3’UTR (thin green arrow). (A) Digestion of the PkconGFP construct at the NotI and XmaI sites 
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(*) (1.3 kb) allowed for the removal of the 5’ HSP70 promotor and the subsequent ligation steps of the 
Pknbpxa_f1 fragment, followed by digestion at (**) SacII and XmaI (*) for Pknbpxa_f2 and Pknbpxa_f3 
ligation steps (B) In the Pkconp230pGFP plasmid the Pkp230p locus was situated immediately adjacent to 
the 3’ end of the Pfhrp2 3’UTR. Restriction digest site KpnI (Δ) allows the plasmid to be linearised centrally 
in the p230p locus prior to transfection for stable integration into the p230p genomic locus. Plasmid maps 
adapted from Moon et al., 2013. 
 
 
4.2.8    Sequential ligation of synthetic Pknbpxa Cluster 2 
    fragments 1-3 into the PkconGFP plasmid 
The synthetic Pknbpxa fragments 1-3 (Insert) and PkconGFP plasmid (Vector) were 
digested using restriction enzymes (see section 2.6.4 and 4.2.7). Restriction enzymes 
were selected based on the unique sites within the region to be removed from the 
PkconGFP plasmid (Figure 4.5A), or to excise the Pknbpxa fragment from the pMA-RQ 
plasmid. This allowed sequential ligation of all three Pknbpxa synthetic fragments 
(Figure 4.3) using T4 ligase (section 2.6.6).  
4.2.9    Identification of further mutations in Pknbpxa cluster 
2 linked with S200P 
The previously described 913C mutation described by Ahmed et al (2014) and here 
termed S200P is found 598 bp into the Pknbpxa gene sequence. This was a non-
synonymous SNP that encoded a proline (P) at amino acid position 200. The other 
clinical sequences encoded a serine (S) at this position. The amino acid change S200P is 
associated with high parasitaemia. In silico protein alignments using Clustal omega and 
Jalview were used to highlight further mutations that were linked with the S200P 
mutation in cluster 2. 
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4.2.10 Site-directed mutagenesis 
Site directed mutagenesis (SDM) was conducted following the Quikchange II kit 
manufacturer’s instructions (Agilent). Briefly, clinically relevant mutations were 
introduced into the pMA-RQ Pknbpxa_f2 plasmid (6 kb) using the primers detailed in 
Table 4.2. SDM primers were designed to have the desired mutations located centrally 
in both the forward and reverse primers, but otherwise to be complementary to the 
target sequence at all other positions. A Phusion
®
 high-fidelity enzyme was used so that 
no additional mutations were incorporated into the gene sequence. The primers were 
used at a concentration of 250 nM combined with 0.4 U of Phusion
®
 high-fidelity DNA 
polymerase (NEB), 1x GC buffer and 200 µM dNTPs in a 20 µL reaction volume. A 
total of 20 ng of template DNA (pMA-RQ PkNBPXa_frag2) was used for each SDM 
PCR. Cycling conditions are given in Table 4.1, with annealing temperature Tm 
approximately 5ºC lower than the calculated Tm to allow for the primer containing the 
mismatch mutation to anneal. The pMA-RQ_Pknbpxa_f2 (Appendix E plasmid map) 
template DNA was digested with 1 µL (10 U) of DpnI. The DpnI digestion was 
incubated at 37ºC for 30 minutes followed by heat inactivation at 80ºC for 20 minutes. 
The SDM PCR product (5 µL) was analysed by gel electrophoresis (section 2.6.3) on a 
1% agarose gel to identify if a DNA band was present at the expected size of 6 kb. The 
remaining PCR product was transformed into DH5α E. coli, as detailed in section 2.8.1, 
and spread onto LB agar plates containing ampicillin (100 µg/mL) and incubated at 
37ºC
 
overnight. Colonies were selected and inoculated in LB broth with ampicillin for 
starter cultures (section 2.8.3). Minipreps were performed as in section 2.8.6 and DNA 
sequencing (as described in section 2.6.10) was used to confirm the presence of the 
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introduced mutation in the pMA-RQ_Pknbpxa_f2 plasmid (section 2.6.10, Appendix E 
Plasmid map; Appendix H SDM sequencing verification). 
Table 4.1 Site directed mutagenesis cycling conditions. 
Temperature (oC) Time Cycles 
98 5 min 1 
98 30 s 
 
-5 from Tm 30 s x25 
72 30 s/Kb  
72 5 min 1 









Table 4.2 Primers used to create mutant copies of PkconPknbpxa_f2. 
Amino Acid Change SDM Primer Primer sequence (5’ – 3’) 
S 200 P F-ag382cc CCGGGATAATccCGGTGATGATGATC 
R-ag382cc CATCATCACCGggATTATCCCGGG 
G 420 E F-gt1043ag CCCTGGTTGagAAAAGCCTGGATC 
R-gt1043ag CCAGGCTTTTctCAACCAGGGTTT 
S 733 N F-g1982a GCATTGATAaCAGCAGCAGCGCAG 
R-g1982a GCTGCTGCTGtTATCAATGCTATCGG 
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4.2.11 Transfection and drug selection 
4.2.11.1 WR99210 drug selection for transfected  
    parasites 
A 0.4 mg/mL (1 mM) WR99210 stock solution in DMSO was made and stored at -
80ºC. A 250 nM working solution was made by sequentially diluting the 1 mM stock 40 
times (25 µM) and then 1 in 100 volumes of RPMI 1640 for a 250 nM concentration. 
The working solution was filter sterilised using a 0.22 µm PES syringe filter and stored 
at 4ºC. The 250nM WR99210 working solution was used at a 1:100 ratio, to obtain a 
final concentration of 2.5 nM of WR99210 in complete medium.  
 
4.2.11.2 Pyrimethamine drug selection for transfected  
    parasites 
A 2 mg/mL pyrimethamine stock solution in DMSO was made and stored at -80ºC. A 
20 µg/mL working solution was made in RPMI 1640 medium by diluting 50 µL of the 
stock solution in 4.95 mL of RPMI 1640. The working solution was filter sterilised 
using a 0.22 µm PES syringe filter and stored at 4ºC. The 20 µg/mL pyrimethamine 
working solution was used at a 1:800 ratio, to obtain a final concentration of 25 ng/mL 
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4.2.12 Transfection of the P. knowlesi PkA1-H.1  
    experimental line with PkconPknbpxa_f1-3 plasmids 
4.2.12.1 Amaxa I transfection system 
 
The PkA1-H.1 clone was grown for transfection studies as per (Moon et al., 2013). 
Once the culture contained a high proportion of schizonts the culture was synchronised 
using either LD MACs synchronisation (section 2.2.4), Optiprep synchronisation 
(section 2.2.5) or Histodenz™ synchronisation method (sections 2.2.6), allowing the 
separation of  multinucleated schizonts from ring stages and trophozoites. The isolated 
late stage parasites were re-cultured with fresh RBCs for a 1% parasitaemia and allowed 
to reinvade. Synchronization was repeated over several days to progressively produce a 
stage specific synchronous culture (as described in sections 2.2.4-2.2.6). Once the 
culture reached a parasitaemia greater than 4% and a volume greater than 2 mL packed 
RBCs, the culture was monitored to assess the synchronicity and life stage of the 
parasites. Thin blood films were taken and analysed to assess the maturity of the 
culture, staging the parasites using the following 5 categories: ring stage (R), early 
trophozoite (ET), late trophozoite (LT), early schizont (ES) and late schizont (LS). A 
parasite would be defined as an early schizont if there were 4 or less nuclei present and 
as a late schizont if there were greater than 4 nuclei. When the culture was enriched for 
late stage schizonts the culture was synchronised as previously described (section 
2.2.6). The size of the schizont cell pellet volume was estimated by visually comparing 
with RBC pcv pellets ranging from 40 µL to 150 µL. The pelleted schizonts were 
resuspended in 1 mL of complete medium (section 2.1.7) and divided to obtain 10 µL of 
schizonts per 1.5 mL centrifuge tube. Individual aliquots were centrifuged briefly, the 
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supernatant was removed and the schizont pellet resuspended in 100 µL of the 
following mixture; the linear PkconPknbpxa_f1-3 or Pkconp230pGFP transfection 
efficiency control (Figure 4.5 B) (20 - 40 µg) plasmids, previously linearised at the 
KpnI site (sections 2.6.9 and 2.6.11), were resuspended in 10 µL DNase free water, 
added to 100 µL of basic parasite nucleofector
® 
solution 2 supplemented with P2 
(Lonza). The schizont/linear plasmid mix (100 µL) was transferred to an electroporation 
cuvette, inserted into the Amaxa nucleofector 1 and pulsed using the U-033 setting. The 
electroporated cells  (100 µL) were then transferred to a 1.5 mL microcentrifuge tube 
containing 500 µL of pre-warmed complete medium (section 2.1.7) supplemented with 
150 µL of packed, fresh, uninfected RBCs, 750 µL final volume. All of the aliquots 
were electroporated individually in the same manner. Following electroporation, cells 
were transferred to a microcentrifuge tube and agitated at 37ºC at 650 rpm for 30 
minutes to promote parasite reinvasion following transfection. Following the incubation 
period, the cell suspensions (750 µL) were transferred to a T-25 tissue culture flask 
containing 4.5 mL of complete medium and cultured as in section 2.2.3. Pyrimethamine 
drug selection at a final concentration of 25 ng/mL was added 20 hours post-
electroporation. Thin blood films (section 2.2.9) were used to monitor the cultures from 
approximately 20 hours post-transfection until iRBC's were seen. 
4.2.12.2   Bio-Rad transfection system 
 
The schizont pellets were prepared for electroporation as per section 4.2.12.1. The 
Optiprep™ synchronisation method was used as per section 2.2.5 in replacement of the 
LD synchronisation method. Individually, aliquots of 10 µL schizonts in complete 
medium were gently centrifuged in a benchtop mini centrifuge and the supernatant 
removed. Pelleted schizonts were resuspended in 480 µL of cytomix pH 7.6 (see section 
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2.1.14), containing 20-40 µg of PkconPknbpxa_f1-3 or Pkconp230pGFP plasmids 
previously linearised at the KpnI site (sections 2.6.9 and 2.6.11). The schizont cytomix 
solution was transferred to an electroporation cuvette (4 mm gap) and electroporated at 
2500 V, 25 µF (7 - 12 ms), or transferred to an electroporation cuvette (2 mm gap) and 
electroporated at 310 V, 950 µF (0.7 - 0.9 ms). The electroporated cell suspension was 
then transferred to a 1.5 mL microcentrifuge tube containing 500 µL of pre-warmed 
complete medium (section 2.1.7). The steps taken following electroporation were as 
described in section 4.2.12.1.  
4.2.12.3  Lonza 4D transfection system  
 
The PkA1-H.1 clone was grown to a parasitaemia greater than 4% in greater than 4 mL 
RBCs as in section 2.2.3. The schizont preparation differed from section 4.2.12.1, with 
the multinucleated cells being isolated by Histodenz™/Nycodenz
®
 synchronisation 
(section 2.2.6). The schizonts were resuspended in complete medium (section 2.1.7) 
containing 10% human serum (Interstate Bloodbank). RBCs were added to produce a 
2% haematocrit and incubated at 37ºC for 1 - 3 hours with gentle rocking, in culture 
conditions as in section 2.2.3. Thin blood films (section 2.2.9) were made, stained and 
counted hourly starting at 1 hour to monitor reinvasion, counting only the ring stage 
parasites. Once ring stages were observed at a parasitaemia greater than 1%, the cultures 
(1 – 3 hours) were Histodenz™ synchronised (section 2.2.6) to remove the remaining 
schizonts. The lower fraction of the synchronisation containing the ring stage parasites 
were then re-cultured in complete medium containing 10% human serum until mature 
schizonts were visible in the thin films, approximately 24 - 27 hrs post-synchronisation. 
The schizonts were monitored until segmented schizonts were observed (Figure 4.12). 
The schizont rich cultures were then Histodenz™ synchronised (section 2.2.6) and the 
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pelleted schizont volume estimated as above. The schizonts were resuspended in 1 mL 
complete medium containing 10% human serum and divided to obtain approximately 10 
µL of pcv schizonts per aliquot and incubated at 37ºC. Individual aliquots were 
centrifuged briefly and the supernatant was removed. The pelleted schizont iRBCs were 
resuspended using 100 µL of P3 solution supplemented with solution A (Lonza), 
containing 20 µg of PkconPknbpxa_f1-3 or Pkconp230pGFP (10 µL in TE buffer), 
previously linearised at the KpnI site (sections 2.6.9 and 2.6.11). The schizont/P3 
solution/linear plasmid solution (100 µL) was transferred to an electroporation cuvette, 
inserted into the Lonza 4-D Nucleofector and pulsed using the FP-158 setting. The 
electroporated cell suspensions were cultured as described in section 4.2.12.1 with 
alterations of culturing in 6 well plates with 10% human serum used in place of 10% 
horse serum. 
4.2.13   Limiting dilution to clone transfected parasite lines 
Accurate parasite counts (section 2.4.1) were performed for the PkA1-H.1 in vitro 
culture transfected with the PkconPknbpxa_f1-3 plasmid. Transfected lines were 
sequentially diluted to achieve approximately 3 iRBCs per mL in 5 mL volume of 
complete medium. Fresh uninfected RBCs were added to the diluted iRBCs to give a 
2% haematocrit. The diluted culture was divided between wells of a 96 well flat bottom 
plate (100 µL per well). Plates for limiting dilution were incubated at 37ºC in an air 
tight chamber gassed with 5:5:90 (O2:CO2:N2). Spent complete medium was exchanged 
with fresh complete medium every 3-4 days and 1 µL (1%) of fresh RBCs was added 
once every 7 days. After 2 weeks, thin blood films were generated to identify wells 
containing iRBCs. The wells containing iRBCs were maintained in culture and split 
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regularly to bulk up parasitaemia and RBC volume. Once greater than 200 µL of RBCs 
and 2% parasitaemia has been reached, half of each culture was removed for Instagene 
DNA extraction and insert detection (section 2.6.8).  
4.2.14    Integration PCR to confirm PkconPknbpxa integration  
    at the Pknbpxa locus 
PCR was used to validate integration of the PkconPknbpxa_f1-3 plasmid in transfected 
lines at the native Pknbpxa locus. Briefly, primers were designed to specifically amplify 
only the transfected Pknbpxa locus at 3 locations (Primer pair B, C and D, Table 4.3 and 
Figure 4.13), and the untransfected Pknbpxa locus (Primer pair A, Table 4.3 and Figure 
4.13). DNA was extracted for PCR as described in section 2.6.7 and PCR conditions are 
given in Tables 2.3.1 and 2.3.2. PCR products were analysed by gel electrophoresis as 
in section 2.6.3. Validation of the Pkconp230pGFP plasmid integration was carried out 
as per Moon et al. (2013). Briefly, primer pair E ol145 and ol144 amplified a 1.4 kb 
region of the transfected p230pGFP locus and primer pair F ol145 and ol146 amplified 
a 1.3 kb region of the native p230p locus (Moon et al., 2013). Primer sequences can be 
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Integrated Pknbpxa cluster 
2 locus amplicon 
A F-A1-H.1 R-A1-H.1 1.6 kb 1.6 kb * 
B F-NotI R-A1-H.1 - 1.6 kb (Pkcon backbone to 
the native Pknbpxa) 
C F-SpeI R-SpeI - 500 bp (internal region of 
synthetic Pknbpxa) 
D F-A1-H.1  R-XaTf-
2706 
- 3 kb (genomic loci to 









E ol145 ol146 1.3 kb - 
F ol145 ol144 - 1.45 kb (p230p genomic 
loci to the p230pGFP 
backbone) 
*In these assays native Pknbpxa DNA will be present in any untransfected cells remaining in the 
transfected cell population as transfections efficiencies are not 100%. 
Locations for each primer Figure 4.13  
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4.3   Results 
The ability to transfer DNA sequences from clinical isolates into in vitro culture for the 
testing of associations with severe malaria is an important tool to help dissect the role of 
parasite factors involved in pathogenesis. The aim of this chapter was to identify the 
SNPs defining the cluster 2 sequence of the Pknbpxa gene using the sequence outputs 
from Chapter 3 and introduce these into the PkA1-H.1 clone using a synthetic copy of 
the Pknbpxa gene. Following this, the previously identified S200P mutation and further 
mutations conserved to sequences containing the S200P would be introduced into the 
synthetic Pknbpxa gene and transfected into the PkA1-H.1 clone. Achieving this would 
enable direct comparison of parasites expressing the Pknbpxa cluster 2 amino acid 
sequence with those containing the same sequence with the addition of residues changes 
associated with high parasitaemia, with the rationale being that mutations in the 
essential Pknbpxa gene are altering the invasion and/or growth rate of the parasite. 
4.3.1  Assembly of full length Pknbpxa gene sequences    
   from clinical isolates 
Six P. knowlesi genome sequences from clinical isolates were available from the 
European Nucleotide Archive (ERR274221, ERR274222, ERR274224, ERR274225, 
ERR366426 and ERR366425). All sequences had greater than 88% of the genome 
covered at a read depth greater than 10 reads and Pknbpxa was represented. The 
genome data were used to assemble full-length Pknbpxa (8367 bp) from the six clinical 
P. knowlesi isolates sequenced (see section 4.2.3). Of the six Pknbpxa sequences 
available 3 were cluster 1 type (ERR274224, ERR274225 and ERR366425) and 3 were 
cluster 2 type (ERR274221, ERR274222 and ERR366426). The 885bp haplotype has 
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been highlighted on Figure 4.1 to give greater information as to the position of these 
sequences in the population structure. The nucleotide diversity of the assembled full 
length Pknbpxa sequences are given in Table 4.4. The nucleotide diversity of cluster 1 is 
lower than the diversity seen in cluster 2. Cluster 1 is less variable in the 5’ region of the 
Pknbpxa gene (Figure 4.1) however the nucleotide diversity calculated here only 
represents 3 full length cluster 1 Pknbpxa sequences, 2 of which are found in the same 
885 bp Pknbpxa haplotype (Figure 4.1). Cluster 2 sequences have more synonymous 
and non-synonymous mutations compared with cluster 1, resulting in a cluster 2 dN/dS 
ratio greater than 2. The dN/dS ratio for the cluster 1 sequences is lower than cluster 2, 
but is still greater than 1. This suggests that cluster 2 is under a greater selection 
pressure at the Pknbpxa locus compared with cluster 1. When both clusters are 
compared together (Table 4.4), the nucleotide diversity, dN/dS, synonymous and non-
synonymous mutations all increase. This is due to the dimorphic positions which are 
conserved within each cluster now being included in the analysis. In order to analyse the 
population structure more accurately, further Pknbpxa gene sequences from cluster 1 
and 2 would be required. 
 
Table 4.4 Nucleotide diversity, synonymous and non-synonymous mutations for clinical 










Cluster 1 (3) 0.0051 26 38 1.46 
Cluster 2 (3) 0.00861 35 73 2.08 
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4.3.2    Defining Pknbpxa cluster 2 sequence  
Pknbpxa alignment identified 65 non-synonymous cluster 2 specific SNPs (section 
4.2.5). In total, 91 cluster 2 SNPs were identified, 3 in exon 1 and 88 in exon 2. 
Pknbpxa  cluster 2-specific SNPs informed the synthesis of the clinically relevant 
codon-optimised Pknbpxa gene to include 52 of 65 amino acid changes specific to 
Pknbpxa cluster 2 type parasites for subsequent plasmid construction and knock-in 
transfection (Figure 4.2 and Appendix D). Thirteen cluster 2 specific SNPs occurring in 
the first 160 amino acids of the Pknbpxa protein were removed, as these were located 
within the region of homology required to be identical to Pknbpxa in the PkA1-H.1 
clone to enable recombination into the Pknbpxa locus. This left 52 residues specific for 
cluster 2 in the Pknbpxa cluster 2 type gene (Figure 4.2 and Appendix D). 
4.3.3          Synthesis of a cluster 2 type Pknbpxa gene  
To knock-in a Pknbpxa gene containing the cluster 2 specific variation identified in 
section 4.3.2, a synthetic Pknbpxa gene containing codon optimized regions was 
synthesized (section 4.2.4). The Pknbpxa gene sequence from the corrected P. knowlesi 
reference genome sequence was used, and mutations encoding the 52 cluster 2 non-
synonymous mutations were incorporated in silico. A 1 kb region of homology (section 
4.2.4) was synthesized by GeneArt™ Invitrogen™, flanked by NotI and XmaI 
restriction sites (Figure 4.3). The XmaI restriction site (1010 bp, Figure 4.3) was 
introduced in silico to facilitate subsequent Pknbpxa_f1 cloning steps without disrupting 
the coding region (Figure 4.6 and Figure 4.7). The remaining Pknbpxa cluster 2 
sequence (7872 bp) containing the 52 non-synonymous mutations was divided into two 
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segments (Pknbpxa_f2 and Pknbpxa_f3; Figure 4.3) and cloning facilitated using 
synonymous mutations to create the SpeI (4938 bp, Figure 4.3) restriction site linking 
Pknbpxa_f2 and Pknbpxa_f3 gene fragments. The Pknbpxa_f2 and Pknbpxa_f3 
fragments were codon optimized (Figure 4.7). Restriction digestion and gel 
electrophoresis of each plasmid confirmed the desired Pknbpxa fragment sizes prior to 
cloning (Appendix E). 
 
Figure 4.6 Alignment of the region of homology in Pknbpxa_f1 and Pknbpxa_f2 codon 
optimized fragments representing cluster 2.  
The top sequence represents the PkconPknbpxa_f1-3 transfection plasmid, the bottom sequence 
represents the Pknbpxa sequence extracted from the corrected P. knowlesi genome sequence. The XmaI 
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restriction enzyme motif is highlighted and separates the Pknbpxa_f1 region of homology and the codon 
optimized Pknbpxa_f2 fragment. 
 
 
Figure 4.7 Amino acid sequence alignment of the 3 clinical PkNBPXa sequences with the 
corrected P. knowlesi PkNBPXa reference sequence.  
The top sequence (PKH_1472300) is the PkNBPXa amino acid sequence from the corrected P. knowlesi 
Pknbpxa genome sequence. The second top sequence is the amino acid sequence of the 
PkconPknbpxa_f1-3 plasmid. The bottom 3 sequences are the amino acid sequences from the 3 cluster 2 
type genome sequences. The XmaI restriction site codes for amino acids 196-198, showing the separation 
of the Pknbpxa_f1 region of homology and codon optimized Pknbpxa_f2 sequence. The PkconPknbpxa_f1-
3 amino acid sequence (second top) is identical to the corrected PkNBPXa sequence (Top) until the SRD 
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4.3.4    Constructing the PkconPknbpxa_f1-3 transfection  
   plasmid  
The Pknbpxa_f1 gene fragment representing the region of homology (Figure 4.5A) was 
ligated into the adapted PkconGFP plasmid (Figure 4.5a) containing the GFP coding 
sequence and the hDHFR resistance gene (Section 4.2.7), using the NotI and XmaI sites 
(green, Figures 4.3 and 4.9). The resulting PkconGFP_Pknbpxa_f1 construct was 
validated by Sanger sequencing, and restriction enzyme digestion (sections 2.6.3 and 
2.6.10, Figure 4.8; Appendix F alignment of sequencing and restriction digests). 
The validated PkconGFP_Pknbpxa_f1 construct was digested with the XmaI and SacII 
restriction enzymes to remove the GFP coding sequence (Figure 4.9 and 4.10), leaving 
the linearized PkconPknbpxa_f1 plasmid prepared for ligation with the codon optimised 
Pknbpxa_f2 fragment (purple, Figure 4.3), also digested at the XmaI and SacII sites 
(Figure 4.9 and 4.10). The Pknbpxa_f2 fragment was ligated immediately adjacent to 
Pknbpxa_f1 coding sequence and the resultant construct validated as above, Figure 4.9 


















Figure 4.8 Confirmation of Pknbpxa fragment ligation by sequencing.  
The ligation mixture was transformed into competent E. coli and grown in the presence of ampicillin (100 
µg/mL), and plasmid DNA extracted by Miniprep. Successful cloning of all restriction sites was validated by 
sequencing, using the following primers F-NotI, F-XmaI, R-XmaI, F-SpeI, R-SpeI and F-SacII. Each primer 
was designed to produce an amplicon which traversed the ligation site. Sequencing was carried out by 
Dundee sequencing & services using Sanger Sequencing. Each panel shows the alignment of the 
sequencing read against the in silico predicted ligation product. The bottom track in each panel, 
Pkconpknbpxa_f1-3, is the sequence of the plasmid constructed in silico while the top track is the 
sequencing read produced using primers for each restriction motif. The box in each alignment highlights 
the correctly aligned sequence demonstrating successful ligation.  
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The PkconPknbpxa_f1-2 plasmid, containing the Pknbpxa_f1 and f2 fragments (Figure 
4.3 green and purple respectively) was digested using the restriction enzymes SpeI and 
SacII, removing a 16 bp sequence separating the two restriction sites (Figure 4.10). The 
Pknbpxa_f3 (red in Figure 4.3) fragment, also cut at SpeI and SacII motifs, was ligated 
into the PkconPknbpxa_f1-2 plasmid generating the PkconPknbpxa_f1-3 14kb P. knowlesi 
transfection plasmid (Figure 4.11). The ligation product was validated by Sanger 
sequencing (Appendix F) to ensure each fragment was correctly orientated and no 
insertions or deletions were introduced during the cloning steps (Figures 4.8 and 4.11). 
 
Table 4.5  Cloning Strategy for the cluster 2 type synthetic gene. 
 
Pknbpxa fragments Fragment 
size (bp) 
5’ restriction site in 
PkconPknbpxa_f1-3 
(bp) 
3’ restriction site in 
PkconPknbpxa_f1-3 
(bp) 
Pknbpxa_f1 1015 NotI (1-8) XmaI (1010-1015) 
Pknbpxa_f2 3950 XmaI (1010-1015) 
SpeI (4937-4943), 
SacII (4953-4959)* 
Pknbpxa_f3 with 3x 
Haemagglutinin (HA) 
tag 
3940 SpeI (4937-4943) SacII (8871-8877) 
*a 16 bp spacer sequence was used to introduce the Pknbpxa_f2 fragment using SacII. The introduced 
SpeI and SacII sites were then used to ligate the Pknbpxa_f3. 
  
 











Figure 4.9 Map of the PkconGFPPknbpxa_f1 plasmid. 
The PkHSP70 promoter at the 5’ end of the GFP coding sequence in the PkconGFP plasmid was removed 
using the NotI and XmaI restriction sites. The Pknbpxa_f1 homology region was ligated into the plasmid 
using the NotI and XmaI restriction sites. Digestion at the XmaI and SacII sites removed the GFP coding 
sequence allowing for the ligation of the Pknbpxa_f2 codon optimised sequence.  
  
 











Figure 4.10 Map of the PkconPknbpxa_f1-2 plasmid.   
The successful ligation of the codon optimised fragment Pknbpxa_f2 using the XmaI and SacII restriction 
sites introduced the SpeI restriction site. An SpeI restriction site at the 3’ end of the Pknbpxa_f2 coding 
region was followed by a 16 bp linker sequence and the SacII restriction site. This enabled subsequent 
cloning of the Pknbpxa_f3 fragment using the SpeI and SacII restriction sites.  
  
 














Figure 4.11 Map of the PkconPknbpxa_f1-3 plasmid.  
Restriction digestion of the PkconPknbpxa_f1-2 with the restriction enzymes SpeI and SacII removes the 16 
bp linker sequence between the two restriction enzyme motifs, enabling the ligation of the 3939 bp 
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Tf 1        
1 PkconPknbpxa_f1-3 (20) LD MACs 30:12:25:20:13 
 
kit2 Amaxa I (U-033) W+ N 
2 Pkconp230pGFP (20)** LD MACs 30:12:25:20:13 
 
kit2 Amaxa I (U-033) W+ N 
Tf 2        
1 PkconPknbpxa_f1-3 (30) LD MACs 8:9:47:16:21 
 
Kit1 Amaxa I (U-033) W+ N 
2 Pkconp230pGFP (20)** LD MACs 8:9:47:16:21 
 
Kit1 Amaxa I (U-033) W+ N 
3 Pkconp230pGFP (20)** LD MACs 8:9:47:16:21 
 
Kit2 Amaxa I (U-033) W+ N 
4 No Plasmid DNA LD MACs 8:9:47:16:21 
 
Kit1 Amaxa I (U-033) W+ N 
Tf 3        
1 PkconPknbpxa_f1-3 (20) Optiprep 30:12:25:20:13 2:5:61:18:13 Kit2 Amaxa I (U-033) P+ N 
2 PkconPknbpxa_f1-3 (20) Optiprep 30:12:25:20:13 2:5:61:18:13 Kit2 Amaxa I (U-033) P+ N 
3 Pkconp230pGFP (20)** Optiprep 30:12:25:20:13 2:5:61:18:13 Kit1 Amaxa I (U-033) P+ N 
4 Pkconp230pGFP (20)** Optiprep 30:12:25:20:13 2:5:61:18:13 Kit1 Amaxa I (U-033) P+ N 
Tf 4        
1 PkconGFP (20)** Optiprep 0:1:55:47:32 
 
Kit2 Amaxa I (U-033) P+ N 
2 Pkconp230pGFP (20)** Optiprep 0:1:55:47:32 
 
Kit2 Amaxa I (U-033) P+ N 
3 PkconPknbpxa_f1-3 (40) Optiprep 0:1:55:47:32 
 
Kit2 Amaxa I (U-033) P+ N 
4 PkconPknbpxa_f1-3 (40) Optiprep 0:1:55:47:32 
 
Kit1 Amaxa I (U-033) P+ N 
5 No Plasmid DNA Optiprep 0:1:55:47:32 
 
Kit2 Amaxa I (U-033) P+ N 
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added at 20hrs 
Growth within 
4 weeks 
Tf 5        
1 PkconPknbpxa_f1-3 (20) Optiprep 3:0:11:20:66 
 
Kit1 Amaxa I (U-033) P+ N 
2 PkconPknbpxa_f1-3 (30) Optiprep 3:0:11:20:66 
 
Kit1 Amaxa I (U-033) P+ N 
3 PkconPknbpxa_f1-3 (40) Optiprep 3:0:11:20:66 
 
Kit1 Amaxa I (U-033) P+ N 
4 Pkconp230pGFP (20)** Optiprep 3:0:11:20:66 
 
Kit1 Amaxa I (U-033) P+ N 
5 No Plasmid DNA Optiprep 3:0:11:20:66 
 
Kit1 Amaxa I (U-033) P+ N 
Tf 6        
1 Pkconp230pGFP (50)** Optiprep 24:11:22:26:17 0:1:25:43:32 CytoMix BioRad (310 V) P+ N 
2 PkconPknbpxa_f1-3 (50) Optiprep 24:11:22:26:17 0:1:25:43:32 CytoMix BioRad (310 V) P+ N 
3 Pkconp230pGFP (50)** Optiprep 24:11:22:26:17 0:1:25:43:32 CytoMix BioRad (2500 V) P+ N 
4 PkconPknbpxa_f1-3 (50) Optiprep 24:11:22:26:17 0:1:25:43:32 CytoMix BioRad (310 V) P+ N 
Tf 7        
1 PkconGFP (20)** Histodenz 
 
6:1:17:55:23 CytoMix BioRad (310 V) P+ N 
2 Pkconp230pGFP (20)** Histodenz 
 
6:1:17:55:23 CytoMix BioRad (310 V) P+ N 
3 PkconPknbpxa_f1-3 (40) Histodenz 
 
6:1:17:55:23 CytoMix BioRad (310 V) P+ N 
4 No Plasmid DNA Histodenz 
 
6:1:17:55:23 CytoMix BioRad (310 V) P+ N 
5 No Plasmid DNA Histodenz 
 
6:1:17:55:23 CytoMix BioRad (310 V) - Y 
Tf 8        
1 PkconGFP (20)** Histodenz 
 
0:0:21:53:26 CytoMix BioRad (310 V) P+ N 
2 Pkconp230pGFP (20)** Histodenz 
 
0:0:21:53:26 CytoMix BioRad (310 V) P+ N 
3 PkconPknbpxa_f1-3 (40) Histodenz 
 
0:0:21:53:26 CytoMix BioRad (310 V) P+ N 
4 No Plasmid DNA Histodenz 
 
0:0:21:53:26 CytoMix BioRad (310 V) P+ N 
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Tf 9        
1 PkconGFP (50)** Histodenz 
 
0:0:11:45:44 CytoMix BioRad (2.5 kV) P+ N 
2 Pkconp230pGFP (50)** Histodenz 
 
0:0:11:45:44 CytoMix BioRad (2.5 kV) P+ N 
3 PkconPknbpxa_f1-3 (100) Histodenz 
 
0:0:11:45:44 CytoMix BioRad (2.5 kV) P+ N 
4 PkconGFP (50)** Histodenz 
 
0:0:11:45:44 CytoMix BioRad (310 V) P+ N 
5 Pkconp230pGFP (50)** Histodenz 
 
0:0:11:45:44 CytoMix BioRad (310 V) P+ N 
6 PkconPknbpxa_f1-3 (100) Histodenz 
 
0:0:11:45:44 CytoMix BioRad (310 V) P+ N 
7 No Plasmid DNA Histodenz 
 
0:0:11:45:44 CytoMix BioRad (2.5 kV) P+ N 
Tf 10        
1 Pkconp230pGFP (20)** Histodenz 
 
6:0:24:43:26 P3  4-D Nucleofector P+ N 
2 PkconPknbpxa_f1-3 (40) Histodenz 
 
6:0:24:43:26 P3  4-D Nucleofector P+ N 
3 PkconGFP (20)** Histodenz 
 
6:0:24:43:26 P3  4-D Nucleofector P+ N 
4 PkconPknbpxa_f1-3 (40) Histodenz 
 
6:0:24:43:26 P3  4-D Nucleofector P+ N 
5 PkconGFP (20)** Histodenz 
 
6:0:24:43:26 P3  4-D Nucleofector P+ N 
6 Pkconp230pGFP (20)** Histodenz 
 
6:0:24:43:26 P3  4-D Nucleofector P+ N 
7 Pkconp230pGFP (10)** Histodenz 
 
6:0:24:43:26 P3  4-D Nucleofector P+ N 
8 PkconPknbpxa_f1-3 (20) Histodenz 
 
6:0:24:43:26 P3  4-D Nucleofector P+ N 
9 No Plasmid DNA Histodenz 
 
6:0:24:43:26 P3  4-D Nucleofector P+ N 
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Tf 11        
1 No Plasmid DNA 1 Histodenz  0:0:19:42:39 - - - Y 
2 No Plasmid DNA 2 Histodenz  0:0:19:42:39 P3 4-D Nucleofector - Y 
3 No Plasmid DNA 3 Histodenz  0:0:19:42:39 P3 4-D Nucleofector P+ N 
4 PkconPknbpxa_f1-3 (40) Histodenz  0:0:19:42:39 P3 4-D Nucleofector P+ Y 
5 Pkconp230pGFP (20)** Histodenz  0:0:19:42:39 P3 4-D Nucleofector P+ Y 
6 PkconPknbpxa_f1-3 (40) Histodenz  0:0:19:42:39 P3 4-D Nucleofector P+ N 
7 Pkconp230pGFP (20)** Histodenz  0:0:19:42:39 P3 4-D Nucleofector P+ N 
Tf12 – LSHTM         
1 PkconPknbpxa_f1-3 (20) Nycodenz 
  
P3 4-D Nucleofector P+ Y 
2 PkconPknbpxa_f1-3 S200P (20) Nycodenz 
  
P3 4-D Nucleofector P+ Y 
3 Pkconp230pGFP (20)** Nycodenz 
  
P3 4-D Nucleofector P+ Y 
Tf13 – LSHTM         
1 PkconPknbpxa_f1-3 (20) Nycodenz 
  
P3 4-D Nucleofector P+ Y 
2 PkconPknbpxa_f1-3 S200P (20) Nycodenz 
  
P3 4-D Nucleofector P+ Y 
3 Pkconp230pGFP (20)** Nycodenz 
  
P3 4-D Nucleofector P+ Y 
Tf14 – LSHTM         
1 PkconPknbpxa_f1-3 (20) Nycodenz 
  
P3 4-D Nucleofector P+ Y 
2 PkconPknbpxa_f1-3 S200P (20) Nycodenz 
  
P3 4-D Nucleofector P+ Y 
3 Pkconp230pGFP (20)** Nycodenz 
  
P3 4-D Nucleofector P+ Y 
Tf15 – LSHTM        
1 PkconPknbpxa_f1-3 G420E (20) Nycodenz 
 
0:0:12:43:45 P3 4-D Nucleofector P+ Y 
2 PkconPknbpxa_f1-3 S733N (20) Nycodenz 
 
0:0:12:43:45 P3 4-D Nucleofector P+ N 
3 Pkconp230pGFP (20)** Nycodenz 
 
0:0:12:43:45 P3 4-D Nucleofector P+ Y 
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Tf16 – LSHTM        
1 PkconPknbpxa_f1-3 G420E (20) Nycodenz 
  
P3 4-D Nucleofector P+ N 
2 PkconPknbpxa_f1-3 S733N (20) Nycodenz 
  
P3 4-D Nucleofector P+ N 
3 Pkconp230pGFP (20)** Nycodenz 
  
P3 4-D Nucleofector P+ N 
* For transfections the parasite life stages were assessed more thoroughly by categorising as Ring (R), early trophozoite (ET), late trophozoite (LT), early schizont (ES, <4 nuclei) and 
late schizont (LS, >4 nuclei). Life stages were assessed either prior to synchronisation (Pre-Synch) or a sample was removed following synchronisation but immediately prior to 
transfection (Post-Synch). 






4.3.5   Transfecting the P. knowlesi PkA1-H.1 experimental  
   line 
In order to replace the Pknbpxa locus in the PkA1-H.1 in vitro clone with the 
PkconPknbpxa_f1-3 plasmids, an electroporation based transfection system was used. 
The PkconPknbpxa_f1-3 plasmids were linearized at the KpnI restriction site to promote 
single crossover homologous recombination (Figure 4.13). A range of transfection 
optimisation experiments were performed in an attempt to obtain successful 
transfections with the PkconPknbpxa_f1-3 plasmid as detailed in Table 4.6. Parameters 
tested included; varying DNA concentration, parasite synchronization methods and 
schizont enrichment, different electroporation conditions and equipment, and 
transfection buffer (Table 4.6).  In particular, the synchronisation method was changed 
from LD MACs magnetic (Section 2.2.4) and Optiprep (section 2.2.5) to use 
Histodenz/Nycodenz density gradient synchronisation (section 2.2.6), as this produced a 
tighter synchronisation and fewer uninfected RBCs in the schizont preparation prior to 
transfections (Table 4.6 and  Figure 4.12). Growth within 4 weeks represents presence 






Figure 4.12 Comparison of synchronisation methods to isolate segmented schizonts prior to 
transfection.  
Brightfield images of Giemsa stained thin blood films (section 2.2.9) showing multinucleated schizonts 
purified via A. an Optiprep density gradient (section 2.2.5, Tf6 - Table 4.6) where parasites were allowed to 
mature until the point of rupture before synchronisation, and B. a Nycodenz density gradient (Section 
2.2.6) where synchronisation was performed prior to the bulk of the culture reaching the point of having 
multiple fully formed daughter merozoites. The harvested schizonts were incubated gently shaking at 37ºC 
in complete medium until segmented schizonts were visible in thin blood films. The segmenter schizonts 
were then gently pelleted and resuspended in transfection buffer. As shown, the Nycodenz 
synchronisation produced a tighter schizont population and fewer uninfected RBCs compared to the 
Optiprep density gradient. Sides were imaged on an Olympus U-TV1X-2 and captured using a Leica 
DFC450C camera (Leica). Scale bar = 20 µm. 
 
Transfection experiments TF 1 - 10 were not successful (Table 4.6). Parasite growth 
was observed in transfections TF11–4 (PkconPknbpxa_f1-3) and TF11–5 
(Pkconp230pGFP). These transfections were conducted using the 4-D nucleofector 
(Lonza) in combination with Histodenz synchronised schizonts that contained 39% late 
stage schizonts, containing greater than 4 nuclei (Table 3.6), which were then grown in 
complete medium with horse serum (Table 4.6, Section 4.2.12.3). However, there was 
no increase in parasitaemia above 0.1% by day 7 post transfection suggesting that a 
small population of the parasites may have been transfected. In order to capture this 




were added to 300 µL of complete medium containing 6 µL of red blood cells. The 
parasitaemia was carefully monitored and the cultures were gradually bulked up. 
TF11.4 transfected with PkconPknbpxa_f1-3 was successfully recovered, bulked up to 
6% parasitaemia in 1.2 mL PCV and cryopreserved (see growth monitoring Appendix I) 
but TF11-5 was lost (see Immunofluorescence Appendix I, prior to loss).   
4.3.6    PCR to demonstrate construct integration in  
    the Tf11.4 line 
A PCR assay was developed to confirm that the PkconPknbpxa_f1-3 plasmid in TF11.4 
had integrated correctly into the Pknbpxa locus (Figure 4.13). Primer pair A (F-A1-H.1 
& R-A1-H.1, Table 4.3) was designed to amplify a 1.6 kb region of the parental 
Pknbpxa locus. The F-A1-H.1 bound to a non-coding region outside the Pknbpxa gene 
at the 5’ end, and the R-A1-H.1 primer bound to a region of the parental Pknbpxa gene 
which differed sufficiently from the cluster type 2 Pknbpxa sequence (Figure 4.13). 
Primer pair B (F-NotI&R-A1-H.1, Table 4.3) was designed to amplify a 1.6 kb 
sequence specific to the 3’ end of the transfected Pknbpxa locus (Figure 4.13). The F-
NotI primer was specific for a unique region in the backbone of the PkconPknbpxa_f1-3, 
300 bp away from the NotI restriction site at the beginning of Pknbpxa_f1. As 
previously mentioned the R-A1-H.1 primer was specific for the parental Pknbpxa 
sequence (Figure 4.13). Primer pair C (F-SpeI&R-SpeI) was designed to amplify a 500 
bp central region of the transfection plasmid (Table 4.3). DNA was extracted from the 
parental PkA1-H.1 clone and the Tf11.4 transfection experiment (Tf11.4, Table 4.6) for 
PCR analysis to validate integration of the construct into the Pknbpxa locus (Section 




from the PkA1-H.1 clone (Figure 4.14, panel A lane 2) and the Tf11.4 transfection 
(Tf11.4, Figure 4.14 panel A lane 3) when primers designed to detect the untransfected 
locus were used (Figure 4.13). Primers specific for the transfected Pknbpxa locus (F-
NotI & R-A1-H.1Xa) failed to produce any amplicon from template DNA extracted 
from the parental PkA1-H.1 clone (Figure 4.14, panel B lane 2) or from the Tf11.4 
transfection (Figure 4.14, panel B lane 3) suggesting there had been no integration of 
the construct into the Pknbpxa locus. However, a 500 bp PCR product was present 
when DNA from both the Tf11.4 transfection (Figure 4.14, panel C lane 3) and the neat 
PkconPknbpxa_f1-3 construct (Figure 4.14, panel C lane 4) were amplified using primers 
specific to a central region of the cluster 2 Pknbpxa sequence. This shows that the 
construct was present in the parasites from the Tf11.4 transfection experiment, however 
episomal maintenance of the plasmid opposed to integration into the Pknbpxa locus was 
predicted 
 
Figure 4.13 Schematic for stable genomic integration of the cluster 2 type Pknbpxa.  
Single crossover homologous recombination occurring in the region of homology between the linearised 
PkconPknbpxa_f1-3 construct (white), and the Pknbpxa genomic locus (grey). The mechanism of single 
crossover homologous recombination by a linear construct promotes recombination at the region of 
homology (marked by horizontal lines) which results in insertion of the construct (white) into the 
homologous region in the parental locus (grey and white boxes). This creates a second Pknbpxa copy 
downstream of the cluster 2 type Pknbpxa and importantly not under the control of a promoter. Integration 




type 2 sequence under the control of the natural promoter at the 5’ end of the gene. Four primer sets were 
designed to amplify regions of the transfected or parental line. Primers F-A1-H.1 & R-A1-H.1 specifically 
amplified a 1.6 kb region of the parental Pknbpxa. Primers F-NotI & R-A1-H.1 amplified a 1.6 kb region 
from the backbone of the construct into the parental Pknbpxa copy. Primers F-SpeI & R-SpeI amplified a 3 
kb region from a non-coding region outside the Pknbpxa locus to the synthetic cluster type 2 Pknbpxa 
sequence. Primers F-A1-H.1 & R-XaTf2706 amplified a central 0.5 kb region of the synthetic Pknbpxa. 
Primer sequences can be found in Table 2.2.  
 
 
Figure 4.14 Integration PCR showing failed Tf11.4 transfection. 
PCR analysis carried out on DNA extracted from the PkA1-H.1 clone, the Tf11.4 PkconPknbpxa_f1-3, and 
the circularised PkconPknbpxa_f1-3 construct failed to confirm integration of the construct at the Pknbpxa 
locus. Adjacent to each panel is the primer pair and expected amplicon, with * denoting that the primer set 
is specific for the transfected Pknbpxa locus. A. A PCR product was only produced from reactions 
containing DNA extracted from the PkA1-H.1 clone and the Tf11.4 line. B. No PCR product was produced 
in any reaction for the transfected locus. The absence of a 1.6 kb PCR product suggests that the construct 
has not integrated into the Pknbpxa locus following transfection of Tf11.4.C. A 0.5 kb PCR product was 
produced from the Tf11.4 and the transfection construct extracted DNA, confirming presence of the 
plasmid in the Tf11.4 line, but suggests the construct is episomally maintained. No amplicon was detected 
in the negative control (lane 5). Lane 1 is the DNA marker hyperladder 50 bp (Bioline). The gel image has 
been cropped for presentation and the corresponding ladder is inserted next to panels B and C. A gap has 
been left to signify the ladder was not run adjacent to lanes in panel B or C. The full gel image can be 








4.3.7 Identification and generation of mutations  
associated with high parasitaemia  
As only the initial 885bp of the Pknbpxa sequence had previously been analysed, the six 
full length Pknbpxa amino acid sequences were aligned and the S200P (913C) amino 
acid position was identified, with only 2 of the six clinical sequences (ERR274221 and 
ERR274222) encoding a proline (Black box, Appendix G). Using this information, the 
rest of the Pknbpxa protein was analysed for any amino acid positions that were 
conserved in the sequences that contained a proline at amino acid 200. Two additional 
amino acid changes were identified, consisting of a Glutamic acid at amino acid 420, 
(Blue box, Appendix G) and a Serine at amino acid 733 (Red box, Appendix G). Along 
with the S200P mutation the G420E and S733N mutations were also introduced into the 
pMA-RQ_Pknbpxa_f2 plasmid independently by site directed mutagenesis (section 
4.2.10). Mutations were introduced into the pMA-RQ_Pknbpxa_f2 plasmid and 
subsequently cloned into the PkconPknbpxa_f1-3 plasmid, as the transfection plasmid 
was too large to obtain efficient amplification with the SDM primers (Plasmid map 
Appendix H). The SDM primers for each mutation are given in Table 4.2. The 6 kb 
pMA-RQ_Pknbpxa_f2 plasmid was amplified using primer pair ag382cc (S200P, Table 
4.2) in both GC buffer and HF buffer. A 6 kb band was present for all annealing 
temperatures for GC buffer (lanes 6-9, Figure 4.15) but not the High Fidelity (HF) 
buffer (lanes 2-5, Figure 4.15). The PCR product from lanes 6-9 were bacterially 
transformed to increase copy number and presence of the ag382cc mutation, 
representing the S200P amino acid change, was validated by direct PCR sequencing 
(see PCR sequencing alignment Appendix H). The gt1043ag (G420E, Table 4.2) and 




buffer and validated by direct PCR sequencing (see G420E and S733N PCR and 
sequencing results Appendix H). The three mutated pMA-RQ_Pknbpxa_f2 plasmids 
(pMA-RQ_Pknbpxa_f2_S200P, pMA-RQ_Pknbpxa_f2_G420E and pMA-
RQ_Pknbpxa_f2_S733N) were digested with XmaI and SpeI to isolate the Pknbpxa_f2 
mutated fragments, and the PkconPknbpxa_f1-3 transfection plasmid was digested with 
XmaI and SpeI to remove the Pknbpxa_f2 fragment without the mutation. The three 
mutant Pknbpxa_f2 fragments were then individually ligated into the PkconPknbpxa_f1-3 
transfection plasmid, creating the following three transfection plasmids; 












Figure 4.15 Creation of the S200P mutation in the pMA-RQ_Pknbpxa_f2 construct. 
The pMA-RQ Pknbpxa_f2 plasmid was PCR amplified using primers (F-ag382cc; 
CCGGGATAATccCGGTGATGATGATC and R-ag382cc; CATCATCACCGggATTATCCCGGG) specifically 
designed to introduce two mismatch mutations into the Pknbpxa_f2 gene sequence. The high fidelity 
Phusion enzyme (NEB) was used in combination with either the high fidelity (HF) (lanes 2 – 5) or GC rich 
buffer (lanes 6 – 9). A thermal gradient was used (65 – 63ºC) for the annealing temperature to allow 
primers containing mismatch mutations to bind to the template DNA construct. Primers to amplify a 10 kb 
region of Lambda DNA were used as a positive control using both HF buffer (lane 10) and GC buffer (lane 
11). Uncut the pMA-RQ_Pknbpxa_f2 construct  Lane 12 was uncut pMA-RQ Pknbpxa_f2 plasmid that was 




4.3.8 Transfection of the P. knowlesi A1-H.1 clone with 
Pknbpxa cluster 2 S200P, G420E and S733N  
Transfection experiments Tf12, Tf13 and Tf14 (Table 4.6) were conducted in Dr Robert 
Moon’s Laboratory at the London School of Hygiene and Tropical Medicine. Pk-
conPknbpxa_f1-3, PkconPknbpxa_f1-3_S200P, PkconPknbpxa_f1-3_G420E and 
PkconPknbpxa_f1-3_S733N were used to transfect the PkA1-H.1 clone (See section 
4.2.12.3 and Table 4.6). 
Parasites transfected with the PkconPknbpxa_f1-3 (Tf12.1, Tf13.1 and Tf14.1) and 
PkconPknbpxa_f1-3_S200P (Tf12.2, Tf13.2 and Tf14.2) constructs all grew to produce 
drug resistant populations within 4 weeks (Table 4.6). The Pkconp230pGFP control 
plasmid was used to calculate transfection efficiency (Tf12.3, Tf13.3 and Tf14.3, Table 
4.6) 1 day after electroporation using live cell microscopy (section 2.4.3) by counting 
the ratio of GFP-positive parasites to the number of parasites stained with the Hoechst 
DNA stain. Transfection efficiencies ranged from 16% in Tf13.3 to 34% for Tf14.3. 
The drug resistant parasite lines produced in transfection experiments Tf13.1, Tf12.1 
(PkconPknbpxa_f1-3) and Tf13.2 (PkconPknbpxa_f1-3 S200P) (Table 4.6) were assayed 
using the integration PCR and primer pairs A and B as previously described (Table 4.3, 
Section 4.14). PCR was conducted as in section 2.6.12 and 4.2.14 on DNA extracted 
from the in vitro cultures (section 2.6.7) and from the PkA1-H.1 untransfected control. 
An additional primer pair F-A1-H.1 and R-XaTf-2706 was designed to amplify a 3 kb 
region at the 5’ end of the transfected Pknbpxa locus (Figure 4.13). The F-A1-H.1 
forward primer bound in the non-coding region at the 5’ end of the native Pknbpxa 




cluster 2 type Pknbpxa sequence, making the primer pair transfection specific (Figure 
4.13). Using this primer pair specific for the transfected locus, produced a 3 kb PCR 
product from the Tf13.1 template DNA (Figure 4.16, panel A lane 6). Additionally, a 
faint 3 kb band was detected for the Tf13.2 experiment transfected with the 
PkconPknbpxa_f1-3 S200P construct (Figure 4.16, panel A lane 5). Importantly, no 
amplicon was detected in PCRs using the parental PkA1-H.1 clone as template DNA 
(Figure 4.16, lane 2). The PCR primer pair F-A1-H1 & R-A1-H.1, specific for the 
untransfected Pknbpxa locus produced an amplicon of the expected size (1.6 kb) in the 
parental clone (Figure 4.16, panel B lane 2) and all transfected lines (Figure 4.16 panel 
B, Tf12.1 lane 3; Tf13.2; lane 4; Tf13.2 lane 5; Tf13.1 lane 6). The primers F-NotI & R-
A1-H.1 (specific for the transfected Pknbpxa locus) produced a 1.6 kb amplicon DNA 
extracted from the Tf13.1 transfection experiment (Figure 4.16, panel C lane 6) (Table 
4.6). Additionally, a faint band at 1.6 kb was seen in PCRs with template DNA from the 
Tf12.2, and Tf13.2 experiments, transfected with the PkconPknbpxa_f1-3 S200P 
construct (Figure 4.16, panel C lanes 3-5). These amplicons were not generated in PCR 
analysis of untransfected control DNA (Figure 4.16, panel C lane 2). Due to time 
constraints Tf14, 15, and 16 were not assayed. 
Transfections using the control Pkconp230pGFP plasmid (Tf13.3) were assayed using 
integration PCR. Primer pairs were designed to amplify a 1.4 kb region of the 
transfected p230p locus (ol145 & ol144), and a 1.3 kb region of the untransfected p230p 
locus (ol145 & ol146). The PCR product of expected size for the transfected p230p 
locus (1.45 kb) was detected only in the Pkconp230pGFP transfection experiment Tf13.3 
(Figure 4.17, panel A lane 4) (Table 4.8). A 1.3 kb amplicon was detected in both the 




primer pair which amplifies the untransfected p230p locus produced bands of 1.3 kb 
when PCRs were carried out on DNA extracted from both transfected lines and the 
untransfected parental clone (Figure 4.17, panel B lanes 2-5). 
These results collectively suggest that the parasites transfected with the 
PkconPknbpxa_f1-3 construct successfully integrated this DNA into the Pknbpxa locus 
in experiment Tf13.1. Additionally; parasites transfected with the PkconPknbpxa_f1-3 
S200P construct may also have integrated the plasmid into the Pknbpxa locus, albeit at a 
low level. All transfected lines were cryopreserved and the Tf13.1 line was used for 






Figure 4.16  Successful integration of the cluster 2 type construct at the Pknbpxa locus. 
Agarose gel electrophoresis of a PCR to confirm integration of transfection constructs into the Pknbpxa 
locus. PCR analysis was performed on DNA extracted from the PkA1-H.1 clone along with 3 independent 
transfections Tf12.2_S200P, Tf13.2_S200P and Tf13.1. Adjacent to each panel is the primer pair and 
expected amplicon, with * denoting that the primer set is specific for the transfected Pknbpxa locus. 
A. A 3 kb PCR product was produced from reaction containing DNA extracted from the Tf13.1 line, 
strongly suggesting integration of the construct into the Pknbpxa locus. B. PCR product was present in all 
lanes except the negative control, as this primer pair was specific for the parental Pknbpxa locus 
C. A 1.6 PCR product was produced from the PCR using DNA from transfection Tf13.1, again suggesting 
successful integration of the construct at the Pknbpxa locus. Additionally, faint bands are visible for the 
transfections Tf12.2 and Tf13.2, but no PCR product is visible from the PCR containing the PkA1-H.1 
DNA. This may suggest that these lines are transfected, albeit at an extremely low level. No amplicon was 
detected in the negative control (lane 7). Lane 1 is the DNA marker hyperladder 1 kb (Bioline). The gel 
image has been cropped for presentation and the corresponding ladder is inserted next to panels B and C. 
A gap has been left to signify the ladder was not run adjacent to lanes in panel B or C. The full gel image 















Figure 4.17 Successful integration of the GFP construct into the p230p locus. 
DNA extracted was extracted from the parental PkA1-H.1 clone (lane 5) and transfected lines; Tf13.1 (lane 
2), Tf13.2 (lanes 3), Tf13.3 (lane 4) for PCR analysis to validate integration of the p230pGFP plasmid into 
the p230p locus. Adjacent to each panel is the primer pair and expected amplicon, with * denoting that the 
primer set is specific for the transfected p230pGFP locus. A. Template DNA was amplified with the primers 
ol145&ol144 designed to amplify the p230pGFP transfected locus. A 1.4 kb amplicon was observed only in 
the PCR using template DNA from the Tf13.3 transfection experiment (panel A, lane 4).F: Template DNA 
was amplified with the primers ol145&ol146 designed to amplify a 1.32 kb amplicon from the parental 
p230p locus. A 1.32 kb amplicon was observed in all transfected lines (lanes 2-4) and the parental clone 
(lane 5). No amplicon was detected in the negative control (lane 6). Lane 1 is the DNA marker hyperladder 
1 kb (Bioline). The gel image has been cropped for presentation and the corresponding ladder is inserted 
next to panels B and C. A gap has been left to signify the ladder was not run adjacent to lanes in panel B. 
The full gel image can be found in appendix J. 
 
 
4.3.9    Immunofluorescence staining of the HA-tagged  
   PkNBPXa in transfected parasite lines 
Immunocytochemistry was carried out on the Tf13.1 uncloned line. Due to the lack of a 
commercial antibody against the PkNBPXa protein, a triple HA tag was incorporated at 
the 3’ end of the synthetic Pknbpxa gene sequence prior to the stop codon (section 
4.2.6). Transfected protein expression was detected within the Tf13.1 transfected line 




Pknbpxa_f1-3 plasmid is expressed, the positive HA staining would be detected, 
confirming the expression of the transfected plasmid. The HA specific staining was 
visualised with a goat anti-mouse Alexafluor
®
568 secondary antibody (Invitrogen).  
Punctate anti-HA fluorescence was detected in the P. knowlesi PkconPknbpxa_1-3 
Tf13.1 line, suggesting expression of the Pknbpxa_f1-3 protein (Figure 4.18, panel B). 
Positive HA staining was predominantly on the outer periphery of the stained parasite 
cell body (Figure 4.18, panel D). Furthermore, this punctate HA staining was in close 
proximity to the Hoechst stained nuclei suggesting that the HA staining was of parasite 
origin and not artefact (Figure 4.18, panel C red and blue arrows). In addition, 
hemozoin pigment appears as dense black material surrounded by individual merozoites 
suggestive of a mature segmented schizont (Panel A) although contrast for brightfield is 
poor (Figure 4.18, panel A). A very low proportion of schizonts in the transfected line 
contained punctate HA stained, suggesting that only a small proportion of the parasites 
were successfully transfected (Figure 4.18, panel C green arrow). Untransfected control 
schizont infected cultures, PkA1-H.1 clone, were negative for HA-staining and positive 
for Hoechst staining (Figure 4.18, panels B, C and F).  
4.3.10 Dilution cloning of the Tf13.1 line  
In order to obtain a clone of the Tf13.1 line transfected with PkconPknbpxa_f1-3, 
dilution cloning was used. The PkconPknbpxa_f1-3 (TF13.1) line was serially diluted 
until there were approximately 3 parasites/mL in 10 mL complete medium (section 
2.1.7). Packed RBCs (200 µL) were added and the culture was divided between 100 
wells in 96 well plates, and cultured for 2 weeks (Section 4.2.13). After 2 weeks of 




100 diluted cultures, of which 33 wells had visible cell growth. The culture of the 33 
wells continued for a further 3 weeks until Instagene DNA extractions were able to be 
performed (section 2.6.8). Integration PCR primers (section 4.2.14) specific for the 
transfected and untransfected lines were used to detect if the Pknbpxa locus was 
transfected. No clones were positive for the transfected locus, and the control DNA 
extracted from the T13.1 line was positive for the transfected Pknbpxa locus (Section 
2.6.7). The primers for the native locus were not positive in all lanes, suggesting the 
DNA extraction was inefficient or the culture parasitaemia was too low. Repeats of 
these PCRs could not be performed as cultures became contaminated preventing a 
repeat DNA extraction. 
Dilution cloning of the transfection experiment Tf13.1 failed to produce a transfected 
clone, suggesting a high percentage of parasites maintained the plasmid episomally. As 
per Triglia et al., (1998) drug selection was removed from the cultured Tf13.1 
transfection experiment for 3 weeks, followed by further pyrimethamine selection until 
drug resistant parasites were detected in the culture. Parasites recovered and were grown 
under pyrimethamine selection until able to be cryopreserved. Due to time constraints 
the dilution cloning of the transfection experiment Tf13.1 cycled in pyrimethamine was 

















Figure 4.18  Detection of the HA tagged Pknbpxa cluster 2 type protein in schizonts isolated 
from the Tf13.1 experiment. 
Panels A-D are purified schizonts from the PkconPknbpxa_f1-3 transfection Tf13.1. Panels E-H are purified 
schizonts from the parental PkA1-H.1 clone. Schizonts were stained as in section (2.4.2) with an Anti-HA 
antibody (Sigma), and detected using the Alexafluor®-568 secondary antibody. Schizonts were then 
stained with Hoechst 33342 (section 4.2.2). Brightfield images shows presence of late stage schizonts 
containing hemozoin and individual merozoites in panels A, D, E and H (black and white arrows, 
respectively). Red fluorescence (red arrows) can be seen in panels B, C, and D but is absent in panels F, 
G and H. Red fluorescence shows positive HA staining of HA-tagged Pknbpxa protein. Parasite DNA 




of panels A-C and panel H is an overlay of panels E-G. Scale bar = 10 µm. Parasites were imaged using a 





4.4    Discussion 
Single cross over homologous recombination was used to replace the homologous 
Pknbpxa gene in the PkA1-H.1 clone with clinically relevant variants defining Pknbpxa 
cluster 2. Full-length Pknbpxa sequences (approx 9kb) were assembled from six P. 
knowlesi genome sequences generated from clinical isolates (Pinheiro et al., 2015). 
Variation at this locus was further informed by 75 Pknbpxa haplotypes identified in 
clinical isolates reported by Ahmed et al., (2014). Using codon optimisation and 
Pknbpxa variation occurring in contemporary clinical isolates, a synthetic Pknbpxa gene 
sequence was derived to represent Pknbpxa cluster 2 (Pinheiro et al., 2015). The 
synthetic sequence included a region of homology and was otherwise codon optimised 
to ensure that recombination had a high chance of occurring at the correct position in 
the Pknbpxa locus and that the clinically relevant Pknbpxa cluster 2 sequence was 
superimposed on the P. knowlesi A1-H.1 clone.  
The PkA1-H.1 clone is reported to be derived from the original Human (H strain) 
infection with P. knowlesi (Chin et al., 1965, Moon et al., 2013, Moon et al., 2016). 
Prior to adaptation of this line to human erythrocytes, it was cultured in vivo using 
Rhesus macaques (Moon et al., 2013). However, the P. knowlesi genome sequence 
(Pain et al., 2008), believed to be the H strain is in fact likely to be a distinct Malaysian 
isolate (Butcher and Mitchell, 2016, Assefa et al., 2015). It is unknown how well the 
reference Pknbpxa sequence (Meyer et al., 2009, Pain et al., 2008), and the PkA1-H.1 
Pknbpxa gene sequence (Moon et al., 2013) represent current clinical isolates. 
Therefore, replacing the Pknbpxa sequence in the PkA1-H.1 clone with a clinically 
relevant cluster 2 Pknbpxa sequence would allow characterisation and invasion 




sequence common to Pknbxpa cluster type 2 allowed individual mutations associated 
with high parasitaemia to be introduced. 
Using the full length Pknbpxa sequence extracted from clinical genome sequences it 
was established that the published 913C mutation from the 885bp sequence of Pknbpxa 
(Ahmed et al., 2014) encoded a proline at residue 200 (S200P). This residue was 
conserved in the two sequences that associated with high parasitaemia (Appendix G). 
Using the information that two sequences (ERR274221 and ERR274222) had an 
association with high parasitaemia the entire Pknbpxa protein sequence was examined 
identifying only 2 further residues conserved in the clinical isolates ERR274221 and 
ERR274222, G420E and S733N. 
The substitution of a single lysine at residue 204 in PfRh5 has been shown to result in a 
switch in host tropism (Hayton et al., 2008). Although PfRh5 and PkNBPXa only share 
small amounts of homology at the N-terminus, both are essential to erythrocyte invasion 
(Baum et al., 2009, Semenya et al., 2012, Moon et al., 2016). This suggests that single 
non-synonymous mutations in essential adhesive genes could play an important role in 
erythrocyte invasion. In addition to the proline at residue 200 in the Pknbpxa protein we 
have identified two further residues (Glutamic acid at residue 420 and Asparagine at 
residue 733) in the Pknbpxa sequences which are confined to those that associate with 
high parasitaemia. Although the structure of PkNBPXa is unknown, a region of 
PkNBPXb (184 – 531 aa) has been shown to bind to Rhesus macaque erythrocytes 
(Meyer et al., 2009, Semenya et al., 2012). This PkNBPXb binding region encompasses 
two out of the 3 mutations identified in PkNBPXa protein (S200P and G420E). In 
addition, the residues in Rh5 that interact with basigin cluster between residues 197 – 




here are located. The hypothesis that single residue substitutions in the cluster 2 type 
Pknbpxa protein result in an increased parasitaemia could be interrogated using the lines 
created here. Phenotypic analysis of these lines would be performed by analysing 
growth rates of the cluster 2 sequence compared with the cluster 2 sequence containing 
single residue substitutions. Analysis would be performed by counting parasitaemias via 
flow cytometry to ensure the parasitaemias are counted accurately and reliably. 
Following this, and depending on flow cytometry results, competition assays would be 
used to determine whether the clone expressing the cluster 2 sequence with single 
residue substitutions exhibited an invasion advantage over the cluster 2 type sequence. 
Samples would be taken at weekly time points to quantify the proportion of each clone 
in the mixed culture. By using TaqMan qPCR we could show how quickly, one clone 
begins to dominate the parasite population in the culture. The clones would also be 
phenotyped for differences in selection for human RBC blood groups and RBC 
maturity, to identify if the association with high parasitaemia in clinical isolates can be 
attributed to a larger proportion of RBCs able to be invaded. In addition, a pulldown 
study using an HA tagged Pknbpxa clone would have been carried out. In order to 
maximise the possible interactions of PkNBPXa with an RBC erythrocyte receptor, 
purified merozoites would have been incubated with RBCs in the presence of the 
cytochalasin D, an inhibitor of actin polymerisation. This would have halted the 
merozoites mid invasion, enabling the cross linking of the merozoites adhered to the 
erythrocyte surface, and subsequent pulldown of the HA tagged PkNBPXa. 
 
By using single crossover homologous recombination, along with codon optimised 




transfected with the PkconPknbpxa_f1-3 plasmid was obtained. Although the 
optimisation steps for transfection were thorough, transfections were not 100% 
effective, even when transfections were performed using the exact Moon et al., (2013) 
protocol.  The size of the plasmid, 14 kb, in combination with the relatively short 500 
bp homology arms may have impacted upon the efficiency of homologous 
recombination (Kung et al., 2013, Pfander et al., 2011). However, the homologous arm 
lengths could not be increased, as this may have included the promoter region causing 
the transfected gene and the native gene to both be expressed. Additionally, consistent 
gene expression between transfected lines would be required for comparisons of growth 
rate. Single cross over homologous recombination had previously been used in the P. 
knowlesi PkA1-H.1 in vitro culture for both knock-in and knock-out studies (Moon et 
al., 2013, Tarr et al., 2014, Moon et al., 2016, Yusuf et al., 2015). However, only partial 
gene sequences were used to tag genes, rather than replace a full copy and all plasmids 
were below 10 kb. Here we demonstrate that the P. knowlesi A1-H.1 culture adapted to 
human erythrocytes and the P. knowlesi transfection system developed by Moon et al., 
(2013) supported whole gene knock-in for disease phenotyping experiment.  
Use of the 4-D nucleofector resulted in recovery of parasites containing the 
PkconPknbpxa_f1-3 plasmid in the presence of horse serum. However it took over 30 
days for the parasites to recover under drug selection and no integration of the construct 
was detected by PCR. Transfection specific amplicons were produced from the DNA of 
transfections carried out in the presence of human serum opposed to horse serum. The 
increased parasite growth in human serum (Moon et al., 2013) may have aided the 
growth of transfected cells, therefore shortening the duration of drug selection before 




stage parasites may have resulted in the successful growth of the Tf12-15 transfections, 
as segmented schizonts are the desired life stage for transfections (Janse et al., 2006). 
Importantly, the transfection efficiencies calculated in this study were performed using 
the Pkconp230pGFP plasmid and were similar to those reported by Moon et al., (2013). 
However, using a larger GFP construct targeted to the p230p locus would have provided 
a more appropriate control for the transfections carried out here with the 
PkconPknbpxa_f1-3 construct. 
Integration PCR experiments revealed that the PkconPknbpxa_f1-3 (Tf13.1) plasmid was 
correctly inserted in the Pknbpxa locus in the transfected line Tf13.1. The transfection 
of the PkconPknbpxa_f1-3_S200P (Tf13.2) was analysed by integration PCR and a faint 
band representing the transfected locus was detected suggesting a low integration 
efficiency. The reason for this remains unclear, as transfections were performed and 
maintained at the same time, with the plasmid differing at only 2 nucleotides.  
The Tf13.1 line showing positive integration of the PkconPknbpxa_f1-3 plasmid at the 
Pknbpxa locus was taken forward for validation of protein expression. Due to the 
addition of the HA tag in the Pknbpxa_f1-3 gene, the transfected PkNBPXa protein was 
able to be detected using an anti-HA antibody. Positive anti-HA staining of Tf13.1 
schizonts suggests that the Pknbpxa_f1-3 protein was expressed. This staining appeared 
as a punctate fluorescent pattern which overlaid onto single merozoites as visualised 
with Hoechst DNA staining in the same preparation. Nuclear staining had a similar 
pattern showing merozoites but was located slightly differently to the anti-HA signal 
(figure 4.18) which was more peripheral in the same merozoites. The HA staining 
pattern is consistent with the position of an apical organelle in outward facing 




merozoites. The apical orientation has been reported for other RBP proteins with the 
PfRh proteins localising to the rhoptries (Taylor et al., 2002). Additionally, Meyer et al, 
(2009) report the localisation of Pknbpxa to the microneme as shown by electron 
microscopy (Meyer et al., 2009). The results from this lay the groundwork for invasion 
phenotyping of these transfected lines. 
The association between invasion efficiency and growth rate in the transfected lines 
containing Pknbpxa variants associated with high parasitaemia has yet to be determined. 
In order to identify whether the PkconPknbpxa_f1-3 transfected lines expressing the 
S200P, G420E or S733N mutations exhibit any growth change, all transfected lines will 
require limiting dilution cloning. Once cloned, these lines can be characterised for 
growth efficiency and invasion phenotype.  In addition, in vitro competition assays 
between the transfected lines and the parent P. knowlesi A1-H.1 culture in human and 
macaque red blood cells, differing by type and age, would determine any changes in 
parasite growth and invasion efficiency in vitro. These results would add context to the 
studies by Ahmed et al., (2014) where an association between Pknbpxa and disease 
severity was suggested.  
Since starting this project a new transfection system using CRISPR Cas9 transfection 
plasmids has been developed (Ghorbal et al., 2014, Wagner et al., 2014, Zhang et al., 
2014) and may support gene-knock-in more efficiently. In the case of reproducing 
clinically relevant P. knowlesi loci, longer homology arms consisting of the upstream 
and downstream regions flanking the Pknbpxa gene would have been possible in the 
CRISPR system. This is because the Cas9 directed by the guide RNA creates two 
double strand breaks, removing the parental Pknbpxa gene. However, longer homology 




recombination, as this method disrupts the Pknbpxa gene creating a duplicated copy, but 
importantly without a promoter at the 5’ end. If longer homology arms had been used 
the parental Pknbpxa duplicate may have been expressed, as the promotor region at the 
5’ end of Pknbpxa would also have been duplicated. Therefore by using CRISPR it 
would have allowed the whole gene to be replaced as the homology arm could have 
entirely comprised non-coding regions outside the Pknbpxa locus (Ghorbal et al., 2014, 
Wagner et al., 2014, Zhang et al., 2014). In addition to potential increases in efficiency, 
replacement of the Pknbpxa gene using CRISPR technologies would prevent the 
requirement for a codon optimised Pknbpxa synthetic gene. This could result in 
clinically relevant genes being directly amplified by PCR for CRISPR –CAS 9 
transfection, substantially reducing time and costs currently required for codon-
optimization and gene synthesis using the single homologous crossover system. 
Incorporation of CRISPR into this work flow would increase the ability to assay 












The aim of this project was to optimise a translational approach to studying genomic 
associations with severe malaria. By analysing the genome sequence data along with the 
patient clinical data, candidate genes and mutations associated with high parasitaemia 
could be identified. Recreating these mutations in vitro would allow for in-depth 
analysis to assess their role in severe disease. With access to a Biobank of frozen 
clinical isolates improved methods were required to isolate parasite DNA from frozen 
whole blood using a cost effective and simple method. Once P. knowlesi DNA was 
obtained and whole genome sequencing performed full length Pknbpxa gene sequence 
data along with clinical data would be available. This would enable residues associated 
with severe malaria to be introduced into the in vitro culture enabling associations with 
severe malaria to be studied. This translational approach, recreating clinical loci within 
an in vitro P. knowlesi PkA1-H.1 experimental line, allowed for further investigations 
into mutations associated with severe malaria. 
Previous work had shown that parasite DNA can be retrieved from frozen patient whole 
blood samples, although the efficiency of human DNA depletion was variable and not 
as efficient as required in some samples (Pinheiro et al., 2015). Following optimisation 
steps, frozen patient whole blood was successfully leukocyte depleted using the 
Whatman-Plasmodipur method followed by parasite pellet washing to remove soluble 
hDNA. Although parasite DNA was not enriched in all clinical samples that were 
processed using the Whatman Plasmodipur method, those that did show enrichment for 
parasite DNA predominantly had minimal human DNA contamination. PkDNA was 
purified by the removal of hDNA in 13 of the 22 samples processed, producing 8 
samples with DNA concentrations suitable for whole genome sequencing. Other 




amplification was suggested as a last resort method to increase the overall DNA 
concentration. The purified samples contained low enough hDNA and high enough 
quantities of PkDNA to enable MinION long read sequencing. 
Genome sequence data was available from six recently sequenced P. knowlesi clinical 
isolates (Pinheiro et al., 2015). Of these, two sequences contained previously reported 
variation in the dimorphic invasion gene, Pknbpxa (cluster 2), shown to associate with 
high parasitaemia in P. knowlesi infections (Ahmed et al., 2014). Using the 6 available 
clinical genome sequences, alongside previously published haplotype analysis (Ahmed 
et al., 2014), the full length cluster 2 Pknbpxa sequences were codon optimised and 
synthesised. The Pknbpxa cluster 2 sequences were sequentially cloned into a P. 
knowlesi specific transfection vector. Single crossover homologous recombination 
(Moon et al., 2013) was used to replace the native Pknbpxa in the PkA1-H.1 clone 
producing a transgenic line expressing clinically relevant variation for use in studies 
associated with high parasitaemia. 
The effect of non-synonymous mutations on the binding of RBP proteins to erythrocyte 
receptors is not well characterised. As previously discussed a single residue substitution 
in PfRh5 resulted in an altered host tropism with merozoites capable of invading Aotus 
monkey erythrocytes (Hayton et al., 2008). Furthermore, research shows single 
mutations within the P. vivax Duffy binding protein (DBP) can change binding 
efficiency (Batchelor et al., 2014). Together this work highlights the impact of single 
amino acid mutations within essential parasite invasion proteins.  Like the PfRh5 and 
PvRBP proteins, the P. knowlesi NBPXa protein has an essential role in erythrocyte 
invasion. Therefore, non-synonymous mutations within this gene may have an impact 




In vitro work in P. knowlesi 
One commonly used method to analyse the effects of single amino acid mutations on 
protein function is to analyse the mutated parasite proteins in vitro. Presented here is 
one such method, allowing our clinically relevant mutations of interest to be analysed 
for their association with severe disease. As shown in this study, the P. knowlesi in vitro 
culture in human erythrocytes is capable of genetic manipulation involving the 
replacement of large genes. Our results suggest the size of the transfection construct 
may affect the transfection efficiencies. Replacement of large genes could be improved 
using CRISPR technologies opposed to single crossover homologous recombination 
(Ghorbal et al., 2014, Wagner et al., 2014, Zhang et al., 2014, Lu et al., 2016, Mogollon 
et al., 2016).  
An advantage of working with P. knowlesi experimental models is that studies can be 
applied to both in vitro and in vivo systems. This is because P. knowlesi is a zoonotic 
parasite and naturally infects macaques, now a widely employed animal model for 
human disease. The in vitro cultured P. knowlesi lines can be genetically manipulated 
and the H-strain, adapted to long term in vitro culture in Rhesus erythrocytes, is 
infective to non-human primates (Kocken et al., 2002, Moon et al., 2013). The H-strain 
in vivo and in vitro line is amenable to genetic manipulated, and retains the ability to 
produce gametogytes in vivo enabling transmission studies to be carried out (Murphy et 
al., 2014, Kocken et al., 2002). P. falciparum is the most widely used in vitro cultured 
species. P. falciparum can experimentally infect Aotus monkeys, but without 
sequestration in brain microvasculature, a key features of severe P. falciparum malaria 
seen in human disease (Voller et al., 1969). Additionally, there is no in vivo 




widely used as an in vivo model, and literature suggests that it can be maintained in 
vitro for short periods of time (Jambou et al., 2011). Recent controversy regarding the 
suitability of P. berghei in vivo studies has shown that it cannot model crucial human 
aspects of severe P. falciparum malaria, such as cytoadhesion (Craig et al., 2012). 
In vivo work in P. knowlesi 
As P. knowlesi is the only malaria species to naturally infect both macaques and 
humans, it also allows researchers a unique opportunity to monitor the effects of genetic 
manipulations within a non-human primate in vivo model. This information could reveal 
potential parasite invasion mechanisms in human severe disease. In particular, the lines 
generated from this work could be phenotyped in vivo to validate associations between 
Pknbpxa polymorphisms and high parasitaemia. Furthermore, P. knowlesi could be used 
to model aspects of P. falciparum malaria in vivo. For example, P. knowlesi expresses 
the SICA antigens, proposed to have a signification amount of common sequence with 
the P. falciparum erythrocyte membrane proteins (PfEMP1) when compared at the 
protein level (Korir and Galinski, 2006). Variants of PfEMP1 are linked to different 
aspects of severe malaria, such as cerebral sequestration, placental sequestration and 
iRBC rosetting (Pasternak and Dzikowski, 2009, Claessens et al., 2014, Rowe et al., 
1995). Importantly, as with P. falciparum, P. knowlesi has been shown to sequester in 
brain microvasculature, as identified in a fatal case of P. knowlesi infection, but 
importantly, does not produce coma (Cox-Singh et al., 2010). This suggests a common 
function between these two protein families, one which could be studied in vivo using 
P. knowlesi. The rodent malaria causing parasite P. berghei has been used to model 
cerebral malaria however, it does not express orthologues of the PfEMP1 or SICA 




that P. knowlesi would be a more suitable model for investigations into iRBC 
sequestration linked with P. falciparum malaria. 
Non-Human Primates and P. knowlesi 
A number of non-human primates, such as the Olive baboon, marmoset and Rhesus 
macaque, have been experimentally infected with P. knowlesi (Ozwara et al., 2003, 
Langhorne and Cohen, 1979, Coatney et al., 1971), although few of these have been 
fully assessed for clinical features of severe malaria. From these studies, it is apparent 
that a wide array of non-human primates are susceptible to P. knowlesi. One species 
which has been characterised for modelling severe malaria is the Olive baboon (Papio 
anubis). When Olive baboons were challenged with P. knowlesi, sequestration was 
observed in brain microvasculature and in the placenta of pregnant females (Ozwara et 
al., 2003, Onditi et al., 2015). This mirrored the sequestration present in brain 
microvasculature of both P. falciparum and P. knowlesi human infections (Cox-Singh et 
al., 2008, Miller et al., 2002). If specific parasite-host interactions are implicated in 
causing brain microvasculature and placenta sequestration in the olive baboons, this 
could have important implications for human disease.  
Concluding remarks 
In this project we have initiated a translational approach to test genetic associations with 
severe malaria in vitro. We have validated the use of the Whatman-Plasmodipur method 
for the enrichment of parasite DNA from frozen whole blood, producing quantities 
suitable for whole genome sequencing. This work has opened new avenues of 
investigation with the ability to obtain whole genome sequence data from archived 




with a clinically relevant copy were developed and would have led to in vitro testing, 
validating SNP associations with severe malaria. Furthermore, by using P. knowlesi the 
progression to in vivo modelling of associations with severe disease can be achieved. 











Appendix A:   Cytomix Transfection Buffer 
Buffer stocks, and dilutions for CytoMix Transfection reagent 
 
CytoMix 
Stock solution For 100 mL 
Reagent Grams Volume Concentration Added CytoMix conc 
KCl 4.47 g 50 mL 1.2 M 10 mL 120 mM 
CaCl2 83.2 mg 50 mL 0.15 M 0.1 mL 0.15 mM 
EGTA 0.76 g 10 mL 0.2 M 1 mL 2 mM 
MgCl2 825 mg 50 mL 0.5 M 1 mL 5 mM 
HEPES N/A N/A  1 M 2.5 mL 25 mM 
K2HPO4/ 
KH2PO4 
N/A N/A 1 M 1 mL 10 mM 
      
 
 
For 1 M K2HPO4/KH2PO4 
Stock solution  
Reagent Grams Volume Concentration Added  
K2HPO4  8.7g 50mL 1M 40.1 mL 
50 mL (1 M) 















Participant Information Sheet 
Project Title  
Parasite culture for malaria pathobiology study. 
What is the study about?  
We invite you to participate in a research project to understand pathobiology in malaria.   
For the study we need to culture malaria parasites in the laboratory. Malaria parasites 
grow inside red blood cells and therefore we need a supply of human red blood cells to 
maintain our parasite cultures. The blood will not be tested. 
This study is being conducted as part of a PhD project on malaria pathophysiology.  
Do I have to take Part? 
No your participation is completely voluntary.  
This information sheet has been written to help you decide if you would like to take part.   
It is up to you and you alone whether or not to take part.   If you do decide to take part 
you will be free to withdraw at any time without providing a reason.    
What would I be required to do? 
You will be required to donate 20mls of blood (approximately 1 - 2 table spoons 
equivalent). The blood will be washed and the red cell fraction will be used to culture 
malaria parasites under varying conditions to measure parasite growth.  
Exclusion - We will not be able to include you in the study if you have ever had malaria 
or if you have taken anti-malarials or antibiotics during the past 4 weeks.   
Will my participation be Anonymous and Confidential?  
Your participation will be anonymous - your participation will be coded as healthy 
donor, male or female and age.   
 
Only the researcher(s) and supervisor(s) will have access to your data which will be 




form for the data you provide, which will be anonymised, to be used for future scholarly 
purposes. 
Storage and Destruction of Data Collected 
Data gathered during this research project will be coded and kept confidentially by the researcher 
with only the researcher and supervisor having access.   It will be securely stored in an excel spread 
sheet for the duration  
of the study and kept for 15 years. Signed consent forms will be stored as hard copy in a secure 
filing cabinet for 15 years. . 
What will happen to the results of the research study? 
In vitro parasite culture will support various studies in malaria research.  
Reward  
N/A 
Are there any potential risks to taking part? 
No risk is anticipated.  The blood will be collected by a trained phlebotomist in an area 
designated for sample collection in the School of Medicine.  
Questions 
You will have the opportunity to ask any questions in relation to this project before 
giving completing a Consent Form. 
Consent and Approval 
What should I do if I have concerns about this study? 
A full outline of the procedures governed by the University Teaching and Research 
Ethical Committee is available at http://www.st-
andrews.ac.uk/utrec/Guidelines/complaints/ 
Contact Details  
Researcher:  
Name Scott  Millar (PhD student)  
School of Medicine,  
University of St Andrews,  
Medical and Biological Sciences Building,  
North Haugh,  
ST ANDREWS,  








Supervisors Na me  
Dr Janet Cox-Singh,  
School of Medicine,  
University of St Andrews,  
Medical and Biological Sciences Building,  
North Haugh,  
ST ANDREWS,  
Fife,  KY16 9TF 
Scotland 
Tel: 01334461896 

























Participant Consent Form 
Anonymous Data 
Project  Tit le: Malaria parasite pathobiology  
 
Researcher(s)  Name(s)   
Scott Millar (PhD student)  
School of Medicine,  
University of St Andrews,  
Medical and Biological Sciences Building,  
North Haugh,  
ST ANDREWS,  





Supervisors Na mes  
Dr Janet Cox-Singh,  
School of Medicine,  
University of St Andrews,  
Medical and Biological Sciences 
Building,  
North Haugh,  
ST ANDREWS,  
Fife,  KY16 9TF 
Scotland 
Tel: 01334461896 
email: jcs26@st.andrews.ac .uk 
 
 
The University of St Andrews attaches high priority to the ethical conduct of research.  We therefore 
ask you to consider the following points before signing this form. Your signature confirms that you 
are happy to participate in the study. 
 
What is Anonymous Data? 
 
THE TERM ‘ANONYMOUS DATA’ REFERS TO DATA COLLECTED BY A RESEARCHER 
THAT HAS NO IDENTIFIER MARKERS SO THAT EVEN THE RESEARCHER CANNOT 
IDENTIFY ANY PARTICIPANT.  CONSENT IS STILL REQUIRED BY THE RESEARCHER, 
HOWEVER NO LINK BETWEEN THE PARTICIPANT’S SIGNED CONSENT AND THE 




The purpose of this form is to ensure that you are willing to take part in this study and to let you 
understand what it entails.   Signing this form does not commit you to anything you do not wish to 
do. 
 
Material gathered during this research will be anonymous, so it is impossible to trace back to you.   
It will be securely stored. Data gathered during this research project will be coded, anonymised and 
kept confidentially by the researcher with only the researcher and supervisor having access.   The 
data will be securely stored in an excel spread -sheet and kept for 15 years. Signed consent forms 





The balance of the blood sample may be kept by the researcher and archived and used for further 
related research projects or by other bona fide researchers. 
Please answer each statement concerning the collection and use of the research data. 
 
I have read and understood the information sheet.  Yes   No 
I have been given the opportunity to ask questions about the study.  Yes  No 
I have had my questions answered satisfactorily.  Yes  No 
I understand that I can withdraw from the study without having to give 
an explanation. 
 Yes  No 
I understand that my data once processed will be anonymous and that 
only the researcher(s) (and supervisors) will have access to the raw data 
which will be kept confidentially. 
 Yes   No 
I understand that my data will be stored for a period of 15 years before 
being destroyed. 
 Yes  No 
I have been made fully aware of the potential risks associated with this 
research and am satisfied with the information provided. 
 Yes   No 
I agree to take part in the study  Yes   No 
   
Participation in this research is completely voluntary and your consent is required before you can 
participate in this research.   












Appendix C:   PkDNA retrieval vs Trophozoite 
percentage 
The percentage recovery of PkDNA was plotted against the percentage of Trophozoites 
(where available in patient data set) in each clinical sample processed. A negative 
correlation of - 0.56 was observed. However, all samples plotted that produced no 









































Appendix D:   Amino Acids Defining Cluster 2 Type 
Pknbpxa 
Amino acid locations and non-synonymous differences between cluster 1 type and 
cluster 2 type PkNBPXa protein. 
















12 * G A  1105 S G 
15 * V I  1109 V M 
67 * S F  1155 N S 
121 * F L  1156 Q E 
123 * R I  1174 M T 
125 * A G  1177 R K 
135 * L V  1184 Q K 
145 * N K  1199 L F 
146 * M V  1288 A S 
148 * D P  1298 E G 
150 * T V  1302 S I 
151 * I L  1374 A V 
153 * G N  1382 E A 
215 H Y  1430 E Q 
219 D A  1677 L R 
223 S A  1729 M K 
238 S P  1765 K N 
248 G R  1805 A E 
260 G D  1810 S N 
263 Q E  1821 Q K 
318 D A  1835 T A 
328 L I  1838 F Y 
332 N S  1923 S N 
335 S T  2248 F L 
338 L W  2279 N K 
369 M I  2282 D E 
410 P L  2289 K N 
571 N K  2329 R Q 
722 Q R  2597 A E 
1026 N D  2694 D G 
1035 T K  2695 A D 
1058 D E  2757 K R 




Appendix E:   Synthetic Pknbpxa generation and 























































Lane 2 uncut pMA-RQ_Pknbpxa_f1, lane 3 digestion with NotI, lane 4 pMA-
RQ_Pknbpxa_f1 digestion with XmaI, lane 5 double digest of pMA-RQ_Pknbpxa_f1 
using NotI and XmaI. The two single digests (lanes 3 and 4) linearised the 3 kb plasmid, 






pMA-RQ_Pknbpxa_f2 restriction digest with XmaI and SacII 
 



















Lane 2 uncut pMA-RQ_Pknbpxa_f2, lane 3 digestion with XmaI, lane 4 pMA-
RQ_Pknbpxa_f2 digestion with SacII, lane 5 double digest of pMA-RQ_Pknbpxa_f2 
using XmaI and SacII. The two single digests (lanes 3 and 4) linearised the 6 kb 








pMA-RQ_Pknbpxa_f3 restriction digest with SpeI and SacII 
 






















Lane 2 uncut pMA-RQ_Pknbpxa_f3, lane 3 digestion with SpeI, lane 4 pMA-
RQ_Pknbpxa_f3 digestion with SacII, lane 5 double digest of pMA-RQ_Pknbpxa_f3 
using SpeI and SacII. The two single digests (lanes 3 and 4) linearised the 6 kb plasmid, 





Appendix F:   Cloning validation, Restriction digests 
    and Sequencing results 
















Lane 2 uncut PkconGFP, lane 3 PkconGFP digestion with NotI, lane 4 PkconGFP digestion 
with XmaI, lane 5 double digest of PkconGFP using NotI and XmaI. The two single 
digests (lanes 3 and 4) linearised the 7.3 kb plasmid, the double digest excised the 
PkHSP70 promoter (lane5). The two single digests (lanes 3 and 4) linearised the 7.3 kb 
plasmid, the double digest excised the HSP70 promoter of 1.3 kb (lane5) 
 


















Lane 2 uncut PkconGFP_Pknbpxa_f1, lane 3 PkconGFP_Pknbpxa_f1 digestion with NotI, 
lane 4 PkconGFP_ Pknbpxa_f1  digestion with XmaI, lane 5 double digest of PkconGFP 
Pknbpxa_f1 using NotI and XmaI. The two single digests (lanes 3 and 4) linearised the 




Sequence confirmation of the NotI restriction site following ligation of the 
Pknbpxa_f2 fragment, F-NotI primer was used 
 
Alignment of Sequence_1:  [F-NotI] with Sequence_2: [PkconPknbpxa_f1-3]  
 
Similarity : 654/659 (99.24 %)NotI GCGGCCGC 
 
Seq_1  1     AGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAATTAATGTG  60 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  1     AGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAATTAATGTG  60 
 
Seq_1  61    AGTTAGCTCACTCATTAGGCACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTATGTTG  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  61    AGTTAGCTCACTCATTAGGCACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTATGTTG  120 
 
Seq_1  121   TGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAACAGCTATGACCATGATTACGCC  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  121   TGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAACAGCTATGACCATGATTACGCC  180 
 
Seq_1  181   AAGCTATTTAGGTGACACTATAGAATACTCAAGCTGCGGCCGCTCACGGCAGGTGTTTCA  240 
             ||||||||||||||||||||||||||||||     ||||||||||||||||||||||||| 
Seq_2  181   AAGCTATTTAGGTGACACTATAGAATACTC-----GCGGCCGCTCACGGCAGGTGTTTCA  235 
 
Seq_1  241   CTATTGAAGGATAATTTTAGGAAAGGTATAATGTATGGAATTGGTAAATCAGTTAAATAA  300 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  236   CTATTGAAGGATAATTTTAGGAAAGGTATAATGTATGGAATTGGTAAATCAGTTAAATAA  295 
 
Seq_1  301   TATATGTAACAAACCAGAAGTGCTTAAAAAGGGAGAAGTTTACAAAGAACCAGATTATAG  360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  296   TATATGTAACAAACCAGAAGTGCTTAAAAAGGGAGAAGTTTACAAAGAACCAGATTATAG  355 
 
Seq_1  361   GTGAAGGGGAAGAAGGAAAAAAAAAAAAAAAAAAAAAAGGAGCATAAGTGTAAAACTGCA  420 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  356   GTGAAGGGGAAGAAGGAAAAAAAAAAAAAAAAAAAAAAGGAGCATAAGTGTAAAACTGCA  415 
 
Seq_1  421   AACAGTAGTTTCATATATTTACAGCTTGTAAAATGAAGAAGAATGGATTGTGGGGAGCAT  480 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  416   AACAGTAGTTTCATATATTTACAGCTTGTAAAATGAAGAAGAATGGATTGTGGGGAGCAT  475 
 
Seq_1  481   CCTTCGGAGTTCTTATCCTTCTTATGGGTACAATTTCACAAAAGAGGGTAGAAGTGGATT  540 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  476   CCTTCGGAGTTCTTATCCTTCTTATGGGTACAATTTCACAAAAGAGGGTAGAAGTGGATT  535 
 
Seq_1  541   TTCATGCACACATGAATAGATGCGCAAATGTGCAGTTGTAATCGGTGACAAATGGGCAAA  600 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  536   TTCATGCACACATGAATAGATGCGCAAATGTGCAGTTGTAATCGGTGACAAATGGGCAAA  595 
 
Seq_1  601   TTCATGAACCCCAATTAGGGCTGATCTATATGGCATTATTATACATCCTATGCTAAACA  659 
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 









Sequence confirmation of the XmaI restriction site following ligation of the 
Pknbpxa_f2 fragment, R-XmaI was primer used. 
 
Alignment of Sequence_1:  [R-XmaI] with Sequence_2: [PkconPknbpxa_f1-3]  
 
Similarity : 860/860 (100.00 %) XmaI CCCGGG 
 
Seq_1  1     GCTAAACACCCCTTTATGTTAAACCTTCCACATTTGTTGTAGGTGCAAGCTGGGAACAAG  60 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  1     GCTAAACACCCCTTTATGTTAAACCTTCCACATTTGTTGTAGGTGCAAGCTGGGAACAAG  60 
 
Seq_1  61    TTATAAGCGAATCGAATAAGCAGCAGAAGGAAGAAACGAATTCTTCTGTTAATTATTATT  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  61    TTATAAGCGAATCGAATAAGCAGCAGAAGGAAGAAACGAATTCTTCTGTTAATTATTATT  120 
 
Seq_1  121   GGGGTGGTAGAAATGACTCAGGGTACCCTAGAAGGAAGAGGAAAAATTTGCAAAAACATA  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  121   GGGGTGGTAGAAATGACTCAGggtaccCTAGAAGGAAGAGGAAAAATTTGCAAAAACATA  180 
 
Seq_1  181   GTTTGTTCCCAGGAAAGGAGGAATATAGGAAGAGTAACACACCCAGCGGGAAAAGTGGAA  240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  181   GTTTGTTCCCAGGAAAGGAGGAATATAGGAAGAGTAACACACCCAGCGGGAAAAGTGGAA  240 
 
Seq_1  241   ATGAATCAGAGTTATATAGAAAGAATTCACTTATACATGTAGGAGATGGCACATTTGGAA  300 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  241   ATGAATCAGAGTTATATAGAAAGAATTCACTTATACATGTAGGAGATGGCACATTTGGAA  300 
 
Seq_1  301   GGAAGCCATCACGCTATGCGTATATTAAACGTAACAATGAAGACAATTTTTATAGAAATG  360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  301   GGAAGCCATCACGCTATGCGTATATTAAACGTAACAATGAAGACAATTTTTATAGAAATG  360 
 
Seq_1  361   CTAGTAGTACTAAGGATGCAAATAATAGGCTTAATGGAATAATCAGTTCCTTTTTACAAA  420 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  361   CTAGTAGTACTAAGGATGCAAATAATAGGCTTAATGGAATAATCAGTTCCTTTTTACAAA  420 
 
Seq_1  421   ATATGAAAGCTCCTACGATAGACAGAATTTTAGATTACTACGAAATAGTGAATAATAAAG  480 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  421   ATATGAAAGCTCCTACGATAGACAGAATTTTAGATTACTACGAAATAGTGAATAATAAAG  480 
 
Seq_1  481   GGGAGTTAGTCTTTTCCTTAGAATCATACTATGTGGACATATACACGTGCGAAGAAATTG  540 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  481   GGGAGTTAGTCTTTTCCTTAGAATCATACTATGTGGACATATACACGTGCGAAGAAATTG  540 
 
Seq_1  541   TGAATTCTATAAAGCGTAAGGGGTCAACGAATTCCCGGGATAATAGCGGTGATGATGATC  600 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  541   TGAATTCTATAAAGCGTAAGGGGTCAACGAATTCCCGGGATAATAGCGGTGATGATGATC  600 
 
Seq_1  601   CGGAAAAAAAAGGCGATAAAGACAACAACTATAACAGCGGTGCAAAAGAAGATGCCATGA  660 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  601   CGGAAAAAAAAGGCGATAAAGACAACAACTATAACAGCGGTGCAAAAGAAGATGCCATGA  660 
 
Seq_1  661   TCAAAAAACTGTATGATAACATGGAACTGCTGCGTATGCCGTGCTTTAGCATTAAAAGCG  720 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  661   TCAAAAAACTGTATGATAACATGGAACTGCTGCGTATGCCGTGCTTTAGCATTAAAAGCG  720 
 
Seq_1  721   AACTGCAGCGTAAAATCAACAGCCTGGAATATGCACAGACCGAAGATAATGAAGAAGTTA  780 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  721   AACTGCAGCGTAAAATCAACAGCCTGGAATATGCACAGACCGAAGATAATGAAGAAGTTA  780 
 
Seq_1  781   GCGGCACCAGCAATAGCAAAACCTATAAACTGATCGAGGATGAGTATGTGAACTGCCTGA  840 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 






Seq_1  841   AAAATAACAGCGAAAACGCC  860 
             |||||||||||||||||||| 


























Lane 2 uncut PkconPknbpxa_f1-2, lane 3 PkconPknbpxa_f1-2 digestion with XmaI, lane 4 
PkconPknbpxa_f1-2  digestion with SacII, lane 5 double digest of PkconPknbpxa_f1-2 
using XmaI and SacII. The two single digests (lanes 3 and 4) linearised the 10 kb 
plasmid, the double digest excised the Pknbpxa_f1 fragment of 4 kb (lane5). 
 
 
Sequence confirmation of the SpeI restriction site following ligation of the 
Pknbpxa_f3 fragment, F-SpeI primer used. 
 
 
Alignment of Sequence_1:  [F-SpeI] with  Sequence_2: [PkconPknbpxa_f1-3]  
 
Similarity : 735/735 (100.00 %) SpeI ACTAGT 
 
Seq_1  1     CAATCCAAAGAGTATCGGGATAACGCCAGCCTGTATTATCGTAATGCAAGCAGCCGTAAA  60 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  1     CAATCCAAAGAGTATCGGGATAACGCCAGCCTGTATTATCGTAATGCAAGCAGCCGTAAA  60 
 
Seq_1  61    AACAAACTGGAATATCTGAAAAAACGCGGTAAAGATGACATCGAGCAGATCGATATGGAT  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  61    AACAAACTGGAATATCTGAAAAAACGCGGTAAAGATGACATCGAGCAGATCGATATGGAT  120 
 
Seq_1  121   AAAGTTAATGCCAGCGTTGAACAGTGCATGACACTAGTAAACAAAGCAGCCGAAAGCGAA  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  121   AAAGTTAATGCCAGCGTTGAACAGTGCATGACACTAGTAAACAAAGCAGCCGAAAGCGAA  180 
 
Seq_1  181   GAGGTTATTCGTAAACATGGTGAACGCTATATGGAATACGAAGGCAAAATGAACAGCCTG  240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  181   GAGGTTATTCGTAAACATGGTGAACGCTATATGGAATACGAAGGCAAAATGAACAGCCTG  240 
 
Seq_1  241   ATTAACGAAATTAGCATTCTGCAGATTCGCACCATTTATGCCAAACGTAAAGATGAAGCC  300 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  241   ATTAACGAAATTAGCATTCTGCAGATTCGCACCATTTATGCCAAACGTAAAGATGAAGCC  300 
 
Seq_1  301   AGCAACATTATGGGTGAAATTCAGCAGCTGCATACCGATATGGAAAAAAAACTGAAAGAG  360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 







Seq_1  361   AGCGAAGAAAAACTGGCCAAATGTAAAAGCGAAAGCCCGATTGATGAAAAAGCCTATATT  420 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  361   AGCGAAGAAAAACTGGCCAAATGTAAAAGCGAAAGCCCGATTGATGAAAAAGCCTATATT  420 
 
Seq_1  421   CTGAACAACGAAAAAAGCAAAACCGCCTATATGAACGTGAAACTGAATCTGGAACTGGTG  480 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  421   CTGAACAACGAAAAAAGCAAAACCGCCTATATGAACGTGAAACTGAATCTGGAACTGGTG  480 
 
Seq_1  481   GAAAGCAATCTGCGTCAGATCGAAAATGTTAAAGAAAGCATGAACAACATCCTGGAAAAA  540 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  481   GAAAGCAATCTGCGTCAGATCGAAAATGTTAAAGAAAGCATGAACAACATCCTGGAAAAA  540 
 
Seq_1  541   TCCACCAATCTGAAAAACAGCATTCTGGGTGCAAGCATCATTGAAAATAACAATAGCGTG  600 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  541   TCCACCAATCTGAAAAACAGCATTCTGGGTGCAAGCATCATTGAAAATAACAATAGCGTG  600 
 
Seq_1  601   GATGTGCTGAAAAAAGAAGAGGTGCATTATATGCAGTACCTGAAAAATATCGAGAACGAG  660 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  601   GATGTGCTGAAAAAAGAAGAGGTGCATTATATGCAGTACCTGAAAAATATCGAGAACGAG  660 
 
Seq_1  661   AAAAAACGCATGATGGACGAAAAATCGAATGTGGATGTGATCCATGATAACGTCCTGAAA  720 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 











PkconPknbpxa_f1-3 restriction digest to validate removal of 16 bp link separating 














Lane 2 uncut PkconPknbpxa_f1-3, lane 3 PkconPknbpxa_f1-3 digestion with SpeI, lane 4 
PkconPknbpxa_f1-3  digestion with SacII, lane 5 double digest of PkconPknbpxa_f1-3 
using SpeI and SacII. The two single digests (lanes 3 and 4) linearised the 14 kb 
plasmid, the double digest excised the Pknbpxa_f3 fragment of 4 kb (lane5). 
 
 
Sequence confirmation of the SacII restriction site following ligation of the 
Pknbpxa_f3 fragment. F-SacII primer used 
 
 
Alignment of Sequence_1:  [F-SacII] with  Sequence_2: [PkconPknbpxa_f1-3]  
 
Similarity : 711/713 (99.72 %) SacII CCGCGG 
 
Seq_1  1     CGTGTTTACCTATAATAACGATGAAGTGGAAGAGGCCGATTTTGAACGTGATCGTGAATA  60 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  1     CGTGTTTACCTATAATAACGATGAAGTGGAAGAGGCCGATTTTGAACGTGATCGTGAATA  60 
 
Seq_1  61    TTTCGAGTACGACATCTATAGCAATAAACGCGACGAAGAGGAAATTATCGAAGTCACCTT  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  61    TTTCGAGTACGACATCTATAGCAATAAACGCGACGAAGAGGAAATTATCGAAGTCACCTT  120 
 
Seq_1  121   TGATGAAAGCAACGAGTATATCTACCCATACGATGTTCCAGATTACGCTTACCCATACGA  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  121   TGATGAAAGCAACGAGTATATCTACCCATACGATGTTCCAGATTACGCTTACCCATACGA  180 
 
Seq_1  181   TGTTCCAGATTACGCTTACCCATACGATGTTCCAGATTACGCTTGACCGCGGATATGGCA  240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  181   TGTTCCAGATTACGCTTACCCATACGATGTTCCAGATTACGCTTGAccgcggATATGGCA  240 
 
Seq_1  241   GCTTAATGTTCGTTTTTCTTATTTATATATTTATACCAATTGATTGTATTTATAACTGTA  300 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  241   GCTTAATGTTCGTTTTTCTTATTTATATATTTATACCAATTGATTGTATTTATAACTGTA  300 
 
Seq_1  301   AAAATGTGTATGTTGTGTGCATATTTTTTTTTGTGCATGCACATGCATGTAAATAGCTAA  360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 







Seq_1  361   AATTATGAACATTTTATTTTTTGTTCAGAAAAAAAAAACTTTACACACATAAAATGGCTA  420 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  361   AATTATGAACATTTTATTTTTTGTTCAGAAAAAAAAAACTTTACACACATAAAATGGCTA  420 
 
Seq_1  421   GTATGAATAGCCATATTTTATATAAATTAAATCCTATGAATTTATGACCATATTAAAAAT  480 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  421   GTATGAATAGCCATATTTTATATAAATTAAATCCTATGAATTTATGACCATATTAAAAAT  480 
 
Seq_1  481   TTAGATATTTATGGAACATAATATGTTTGAAACAATAAGACAAAATTATTATTATTATTA  540 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  481   TTAGATATTTATGGAACATAATATGTTTGAAACAATAAGACAAAATTATTATTATTATTA  540 
 
Seq_1  541   TTATTTTTACTGTTATAATTATGTTGTCT-CTTCAATGATTCATAAATAGTTGGACTTGA  599 
             |||||||||||||||||||||||| |||| |||||||||||||||||||||||||||||| 
Seq_2  541   TTATTTTTACTGTTATAATTATGT-GTCTCCTTCAATGATTCATAAATAGTTGGACTTGA  599 
 
Seq_1  600   TTTTTAAAATGTTTATAATATGATTAGCATAGTTAAATAAAAAAAGTTGAAAAATTAAAA  659 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  600   TTTTTAAAATGTTTATAATATGATTAGCATAGTTAAATAAAAAAAGTTGAAAAATTAAAA  659 
 
Seq_1  660   AAAAACATATAAACACAAATGATGTTTTTTCCTTCAATTTCGATATCATATAGC  713 
             |||||||||||||||||||||||| ||||||||||||||||||||||||||||| 































































































































Genome sequences, and 
Pknbpxa sequences obtained 







Appendix H:   Site Directed Mutagenesis Validation 
pMA-RQ_Pknbpxa_f1: ag382cc mutation, sequence alignment 
Alignment of Sequence_1:  [R-XmaI] with Sequence_2: [pMA-RQ_Pknbpxa_f2]  
 
Similarity : 581/583 (99.66 %)S200P ag382cc 
 
               G  R  N  R  Q  N  P  L  *  I  K  R  I  D  R  D  R  V  E  W 
Seq_1  1     TAGGCCGAAATCGGCAAAATCCCTTATAAATCAAAAGAATAGACCGAGATAGGGTTGAGT  60 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  1     TAGGCCGAAATCGGCAAAATCCCTTATAAATCAAAAGAATAGACCGAGATAGGGTTGAGT  60 
               G  R  N  R  Q  N  P  L  *  I  K  R  I  D  R  D  R  V  E  W 
 
               P  L  Q  G  A  P  I  R  H  S  G  C  A  T  V  G  K  G  V  S 
Seq_1  61    GGCCGCTACAGGGCGCTCCCATTCGCCATTCAGGCTGCGCAACTGTTGGGAAGGGCGTTT  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  61    GGCCGCTACAGGGCGCTCCCATTCGCCATTCAGGCTGCGCAACTGTTGGGAAGGGCGTTT  120 
               P  L  Q  G  A  P  I  R  H  S  G  C  A  T  V  G  K  G  V  S 
 
               V  R  A  S  S  L  L  R  Q  L  A  K  G  G  C  A  A  R  R  L 
Seq_1  121   CGGTGCGGGCCTCTTCGCTATTACGCCAGCTGGCGAAAGGGGGATGTGCTGCAAGGCGAT  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  121   CGGTGCGGGCCTCTTCGCTATTACGCCAGCTGGCGAAAGGGGGATGTGCTGCAAGGCGAT  180 
               V  R  A  S  S  L  L  R  Q  L  A  K  G  G  C  A  A  R  R  L 
 
               S  W  V  T  P  G  F  S  Q  S  R  R  C  K  T  T  A  S  E  R 
Seq_1  181   TAAGTTGGGTAACGCCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTGAGC  240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  181   TAAGTTGGGTAACGCCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTGAGC  240 
               S  W  V  T  P  G  F  S  Q  S  R  R  C  K  T  T  A  S  E  R 
 
               D  V  I  R  L  T  I  G  R  I  G  G  R  P  S  R  P  H  S  R 
Seq_1  241   GCGACGTAATACGACTCACTATAGGGCGAATTGGCGGAAGGCCGTCAAGGCCGCATTCCC  300 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  241   GCGACGTAATACGACTCACTATAGGGCGAATTGGCGGAAGGCCGTCAAGGCCGCATTCCC  300 
               D  V  I  R  L  T  I  G  R  I  G  G  R  P  S  R  P  H  S  R 
 
               D  N  P  G  D  D  D  P  E  K  K  G  D  K  D  N  N  Y  N  S 
Seq_1  301   GGGATAATCCCGGTGATGATGATCCGGAAAAAAAAGGCGATAAAGACAACAACTATAACA  360 
             ||||||||##|||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  301   GGGATAATAGCGGTGATGATGATCCGGAAAAAAAAGGCGATAAAGACAACAACTATAACA  360 
               D  N  S  G  D  D  D  P  E  K  K  G  D  K  D  N  N  Y  N  S 
 
               G  A  K  E  D  A  M  I  K  K  L  Y  D  N  M  E  L  L  R  M 
Seq_1  361   GCGGTGCAAAAGAAGATGCCATGATCAAAAAACTGTATGATAACATGGAACTGCTGCGTA  420 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  361   GCGGTGCAAAAGAAGATGCCATGATCAAAAAACTGTATGATAACATGGAACTGCTGCGTA  420 
               G  A  K  E  D  A  M  I  K  K  L  Y  D  N  M  E  L  L  R  M 
 
               P  C  F  S  I  K  S  E  L  Q  R  K  I  N  S  L  E  Y  A  Q 
Seq_1  421   TGCCGTGCTTTAGCATTAAAAGCGAACTGCAGCGTAAAATCAACAGCCTGGAATATGCAC  480 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  421   TGCCGTGCTTTAGCATTAAAAGCGAACTGCAGCGTAAAATCAACAGCCTGGAATATGCAC  480 
               P  C  F  S  I  K  S  E  L  Q  R  K  I  N  S  L  E  Y  A  Q 
 
               T  E  D  N  E  E  V  S  G  T  S  N  S  K  T  Y  K  L  I  E 
Seq_1  481   AGACCGAAGATAATGAAGAAGTTAGCGGCACCAGCAATAGCAAAACCTATAAACTGATCG  540 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  481   AGACCGAAGATAATGAAGAAGTTAGCGGCACCAGCAATAGCAAAACCTATAAACTGATCG  540 






               D  E  Y  V  N  C  L  K  N  N  S  E  N  X   
Seq_1  541   AGGATGAGTATGTGAACTGCCTGAAAAATAACAGCGAAAACGC  583 
             ||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  541   AGGATGAGTATGTGAACTGCCTGAAAAATAACAGCGAAAACGC  583 



























Site Directed Mutagenesis of the pMA-RQ_Pknbpxa_f2-1043ag plasmid. The PCR reaction was 
carried out using GC buffer compatible with the Phusion polymerase. A temperature gradient was used to 
identify the optimal temperature allowing primer binding. GC denotes a control pcr reaction using primers 
specific for a 10 Kb Lambda DNA amplicon. F2+ denotes 100 ng of neat pMA-RQ_Pknbpxa_f2 plasmid 
used as template for the PCR reaction digested with DpnI. F2- denotes 100 ng of neat pMA-RQ_Pknbpxa-
f2 used as template for the PCR. Molecular weight marker was Hyperladder 1 Kb, and agarose gels were 
stained with SYBR Safe. 
 
pMA-RQ_Pknbpxa_f1: gt1043ag mutation, sequence alignment  
 
Alignment of Sequence_1:  [F-SDM_XA_gt1043ag] with  Sequence_2: [pMA-
RQ_Pknbpxa_f2] G420E gt1043ag 
 
Similarity : 1151/1153 (99.83 %) 
 
               I  L  S  S  I  K  F  L  Q  N  E  I  S  N  I  I  N  N  Y  N 
Seq_1  1     ATATCCTGAGCAGCATCAAATTTCTGCAAAACGAAATCAGCAACATCATCAACAACTACA  60 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  1     ATATCCTGAGCAGCATCAAATTTCTGCAAAACGAAATCAGCAACATCATCAACAACTACA  60 
               I  L  S  S  I  K  F  L  Q  N  E  I  S  N  I  I  N  N  Y  N 
 
               Y  H  F  E  N  I  K  K  A  I  S  N  I  K  K  H  E  N  Y  D 
Seq_1  61    ACTACCACTTCGAGAACATCAAAAAAGCCATTAGCAATATCAAAAAACACGAGAACTACG  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  61    ACTACCACTTCGAGAACATCAAAAAAGCCATTAGCAATATCAAAAAACACGAGAACTACG  120 
               Y  H  F  E  N  I  K  K  A  I  S  N  I  K  K  H  E  N  Y  D 
 
               K  L  S  N  L  D  K  K  T  L  V  E  K  S  L  D  L  A  K  N 
Seq_1  121   ATAAACTGAGCAACCTGGACAAAAAAACCCTGGTTGAGAAAAGCCTGGATCTGGCCAAAA  180 
             ||||||||||||||||||||||||||||||||||||##|||||||||||||||||||||| 
Seq_2  121   ATAAACTGAGCAACCTGGACAAAAAAACCCTGGTTGGTAAAAGCCTGGATCTGGCCAAAA  180 
               K  L  S  N  L  D  K  K  T  L  V  G  K  S  L  D  L  A  K  N 
 
               M  S  L  Y  K  F  N  N  E  M  F  K  K  M  K  E  L  Y  D  F 
Seq_1  181   ATATGAGCCTGTATAAATTCAACAACGAGATGTTCAAAAAAATGAAAGAGCTGTACGATT  240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  181   ATATGAGCCTGTATAAATTCAACAACGAGATGTTCAAAAAAATGAAAGAGCTGTACGATT  240 







               K  S  N  K  F  K  R  I  F  T  F  L  A  D  A  L  K  D  K  I 
Seq_1  241   TCAAAAGCAACAAATTCAAACGCATCTTCACCTTTCTGGCAGATGCACTGAAAGACAAAA  300 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  241   TCAAAAGCAACAAATTCAAACGCATCTTCACCTTTCTGGCAGATGCACTGAAAGACAAAA  300 
               K  S  N  K  F  K  R  I  F  T  F  L  A  D  A  L  K  D  K  I 
 
               N  L  F  T  E  S  M  I  Y  E  E  K  Y  N  S  I  M  V  D  W 
Seq_1  301   TTAACCTGTTTACCGAGAGCATGATCTATGAAGAGAAATACAACAGCATCATGGTGGACT  360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  301   TTAACCTGTTTACCGAGAGCATGATCTATGAAGAGAAATACAACAGCATCATGGTGGACT  360 
               N  L  F  T  E  S  M  I  Y  E  E  K  Y  N  S  I  M  V  D  W 
 
               K  V  I  W  E  Y  V  V  G  E  Y  N  K  N  L  N  A  I  Q  S 
Seq_1  361   GGAAAGTGATTTGGGAATATGTTGTGGGCGAGTACAATAAAAACCTGAATGCAATTCAGA  420 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  361   GGAAAGTGATTTGGGAATATGTTGTGGGCGAGTACAATAAAAACCTGAATGCAATTCAGA  420 
               K  V  I  W  E  Y  V  V  G  E  Y  N  K  N  L  N  A  I  Q  S 
 
               Y  E  G  N  E  N  V  E  V  I  I  V  R  N  K  V  K  E  K  L 
Seq_1  421   GCTATGAGGGCAATGAAAACGTGGAAGTTATTATCGTGCGCAACAAAGTGAAAGAAAAAC  480 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  421   GCTATGAGGGCAATGAAAACGTGGAAGTTATTATCGTGCGCAACAAAGTGAAAGAAAAAC  480 
               Y  E  G  N  E  N  V  E  V  I  I  V  R  N  K  V  K  E  K  L 
 
               G  T  F  K  S  M  A  D  E  L  Q  G  L  F  N  I  I  E  L  K 
Seq_1  481   TGGGCACCTTTAAAAGCATGGCCGATGAACTGCAGGGTCTGTTTAATATCATCGAGCTGA  540 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 






pMA-RQ_Pknbpxa_f1: g1982a mutation generation 
 
     
Site Directed Mutagenesis of the pMA-RQ_Pknbpxa_f2-1982a plasmid. The PCR reaction was carried 
out with the GC buffer compatible with the Phusion polymerase. A temperature gradient from 67ºC to 63ºC 
was used to allowing primer binding. F2 denotes 100 ng of neat pMA-RQ_Pknbpxa_f2 plasmid used as 
template for the PCR reaction. Molecular weight marker was Hyperladder 1 Kb, and agarose gels were 
stained with SYBR Safe. 
pMA-RQ_Pknbpxa_f1: g1982a mutation, sequence alignment 
 
Alignment of Sequence_1:  [F-SDM_XA_g1982a] with Sequence_2: [pMA-
RQ_Pknbpxa_f2] S733N g1982a 
 
Similarity : 1103/1104 (99.91 %) 
 
              N  I  K  M  I  I  K  D  I  Y  K  D  D  L  K  K  F  V  Q  E  
Seq_1  1     CAACATCAAAATGATTATCAAAGACATCTATAAAGATGATCTGAAAAAATTCGTGCAAGA  60 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  1     CAACATCAAAATGATTATCAAAGACATCTATAAAGATGATCTGAAAAAATTCGTGCAAGA  60 
              N  I  K  M  I  I  K  D  I  Y  K  D  D  L  K  K  F  V  Q  E  
 
              I  S  R  N  M  E  K  Y  T  D  S  I  D  N  S  S  S  A  D  E  
Seq_1  61    AATCAGCCGCAACATGGAAAAATACACCGATAGCATTGATAACAGCAGCAGCGCAGATGA  120 
             |||||||||||||||||||||||||||||||||||||||||#|||||||||||||||||| 
Seq_2  61    AATCAGCCGCAACATGGAAAAATACACCGATAGCATTGATAGCAGCAGCAGCGCAGATGA  120 
              I  S  R  N  M  E  K  Y  T  D  S  I  D  S  S  S  S  A  D  E  
 
              L  D  D  V  L  K  G  I  K  V  D  Y  E  K  I  K  S  M  K  Y  
Seq_1  121   ACTGGATGATGTACTGAAAGGTATCAAAGTGGACTATGAGAAAATCAAAAGCATGAAATA  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  121   ACTGGATGATGTACTGAAAGGTATCAAAGTGGACTATGAGAAAATCAAAAGCATGAAATA  180 
              L  D  D  V  L  K  G  I  K  V  D  Y  E  K  I  K  S  M  K  Y  
 
              D  D  I  A  E  S  V  E  N  I  T  N  M  L  K  I  I  S  D  A  
Seq_1  181   CGACGACATTGCCGAAAGCGTTGAAAATATCACCAACATGCTGAAAATTATCTCCGATGC  240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  181   CGACGACATTGCCGAAAGCGTTGAAAATATCACCAACATGCTGAAAATTATCTCCGATGC  240 
              D  D  I  A  E  S  V  E  N  I  T  N  M  L  K  I  I  S  D  A  
 
              R  E  E  I  L  K  I  K  F  G  E  T  N  K  K  L  T  N  S  L  
Seq_1  241   CCGTGAGGAAATCCTGAAAATCAAATTTGGTGAAACCAACAAAAAACTGACCAATAGCCT  300 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  241   CCGTGAGGAAATCCTGAAAATCAAATTTGGTGAAACCAACAAAAAACTGACCAATAGCCT  300 
              R  E  E  I  L  K  I  K  F  G  E  T  N  K  K  L  T  N  S  L  
 
              E  Q  L  K  S  V  Y  D  K  L  K  V  S  I  A  E  Y  T  A  E  
Seq_1  301   GGAACAGCTGAAAAGCGTTTATGACAAACTGAAAGTTAGCATTGCCGAATACACCGCAGA  360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  301   GGAACAGCTGAAAAGCGTTTATGACAAACTGAAAGTTAGCATTGCCGAATACACCGCAGA  360 




              K  R  K  I  E  E  D  R  A  V  I  L  K  R  E  E  E  F  F  G  
Seq_1  361   AAAACGTAAAATTGAAGAAGATCGCGCAGTTATCCTGAAACGCGAAGAAGAATTTTTCGG  420 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  361   AAAACGTAAAATTGAAGAAGATCGCGCAGTTATCCTGAAACGCGAAGAAGAATTTTTCGG  420 
              K  R  K  I  E  E  D  R  A  V  I  L  K  R  E  E  E  F  F  G  
 
              K  V  Y  D  K  D  D  D  M  L  D  V  K  D  A  Y  T  N  F  L  
Seq_1  421   CAAAGTGTATGACAAAGATGATGATATGCTGGATGTGAAAGATGCGTATACCAACTTCCT  480 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  421   CAAAGTGTATGACAAAGATGATGATATGCTGGATGTGAAAGATGCGTATACCAACTTCCT  480 
              K  V  Y  D  K  D  D  D  M  L  D  V  K  D  A  Y  T  N  F  L  
 
              K  H  K  D  N  F  F  K  N  R  N  N  V  F  E  E  F  H  T  T  
Seq_1  481   GAAACATAAAGATAACTTTTTCAAAAACCGCAACAACGTGTTCGAAGAATTTCACACCAC  540 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  481   GAAACATAAAGATAACTTTTTCAAAAACCGCAACAACGTGTTCGAAGAATTTCACACCAC  540 
              K  H  K  D  N  F  F  K  N  R  N  N  V  F  E  E  F  H  T  T  
 
              K  E  A  L  K  V  V  R  I  N  F  L  Y  Y  I  S  M  P  E  K  
Seq_1  541   CAAAGAAGCGCTGAAAGTTGTTCGTATTAACTTTCTGTACTACATCAGCATGCCGGAAAA  600 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  541   CAAAGAAGCGCTGAAAGTTGTTCGTATTAACTTTCTGTACTACATCAGCATGCCGGAAAA  600 
              K  E  A  L  K  V  V  R  I  N  F  L  Y  Y  I  S  M  P  E  K  
 
              Y  N  I  I  Y  Q  K  E  N  E  N  Y  K  E  L  I  K  E  I  I  
Seq_1  601   ATACAACATCATCTATCAGAAAGAGAACGAGAATTACAAAGAACTGATCAAAGAGATCAT  660 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  601   ATACAACATCATCTATCAGAAAGAGAACGAGAATTACAAAGAACTGATCAAAGAGATCAT  660 
              Y  N  I  I  Y  Q  K  E  N  E  N  Y  K  E  L  I  K  E  I  I  
 
              D  K  H  I  D  M  K  L  D  E  Y  E  S  D  F  K  R  N  N  K  
Seq_1  661   CGATAAACACATCGACATGAAACTGGACGAATATGAGAGCGATTTCAAACGGAATAACAA  720 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  661   CGATAAACACATCGACATGAAACTGGACGAATATGAGAGCGATTTCAAACGGAATAACAA  720 










Appendix I:   Growth Monitoring of Tf11.4 
PkconPknbpxa_f1-3 
Monitoring of the Tf11.4 Transfection following LD MACs synchronisation 
 
 
Live cell immunofluorescence of Tf11.5 (Pkconp230pGFP control) prior to loss of the 
culture. Cells were stained with Hoechst 33342 (1 µg/mL). Slides were imaged on a 




Appendix J:  Uncropped Integration PCR gel images 
 
Uncropped gel image of Figure 4.14 
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Ahmed, A. M., et al. (2014). "Disease progression in Plasmodium knowlesi malaria is 
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Millar, S. B. and J. Cox-Singh (2015). "Human infections with Plasmodium knowlesi--
zoonotic malaria." Clin Microbiol Infect 21(7): 640-648. 
  
Pinheiro, M. M., et al. (2015). "Plasmodium knowlesi genome sequences from clinical 
isolates reveal extensive genomic dimorphism." PLoS One 10(4): e0121303. 
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